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General introduction, aims and outline 
1.1 Renal physiology and pathology 
 Normal kidney function 
The kidneys are a pair of bean-shaped organs located in the retroperitoneal space of the 
abdominal cavity. Their main function is to excrete (i) metabolic end-products, like urea 
(protein metabolism) and uric acid (nucleic acid metabolism) and (ii) inorganic compounds 
from dietary intake (water, Na+, PO4
2-
, Ca2+, acids, bases, …). The kidneys also have an 
endocrine function producing 1,25-dihydroxyvitamin D (i.e. the active form of vitamin D), 
renin, an enzyme involved in blood pressure regulation and erythropoietin (EPO), a protein 
stimulating the bone marrow to generate erythrocytes.  
The smallest functional unit of a kidney is the nephron, which is composed of a glomerulus, 
Bowman’s capsule, proximal tubule, Henle’s loop and distal tubule (Figure 1-1). Each kidney 
contains approximately 1 – 1.3 106 nephrons and one collecting duct drains multiple nephrons. 
Blood purification is the result of two processes: glomerular filtration and tubular secretion. An 
afferent arteriole delivers blood to the glomerulus. Glomerular filtration forms the primary 
urine, by the process of ultrafiltration, which is collected in the Bowman’s space. This primary 
urine has a similar composition than plasma, but mainly contains compounds with a molecular 
weight (MW) < 60 – 65 kDa. Subsequently, many of the filtered electrolytes (Na+, K+, Ca2+, 
HCO3-, PO4
2-




takes place at the proximal tubule, Henle’s loop and distal tubule via peritubular capillaries 
which are supplied by the efferent arteriole, containing blood that previously left the 
glomerulus. Amongst others, this unfiltered blood transports compounds which cannot be 
(totally) excreted by glomerular filtration, but only (also) by tubular secretion. This process 
takes place at the peritubular capillaries and is mostly the result of active transport. 
Approximately 1 % of the primary urine will reach the bladder via the ureters. Finally, the 
bladder is voided via the urethra during urination. 
In healthy young individuals, the glomerular filtration rate (GFR) is about 125 mL/min/1.73 m² 
and declines gradually from the age of 35 – 40 years on (about 0.5 – 1 mL/min/1.73 m² per 
year) [1,2]. 
Figure 1-1 Schematic representation of the kidney’s functional unit: the nephron [3]. 
 
 Chronic kidney disease 
1.1.2.1 Definition 
In 2002, the Kidney Disease Outcomes Quality Index (KDOQI) guidelines from the United 
States National Kidney Foundation defined chronic kidney disease (CKD) as either kidney 
damage (i.e. pathologic abnormalities in blood or urine tests or in imaging studies) or a 
GFR < 60 mL/min/1.73 m² over a period of at least three months [4]. CKD was classified into 
5 stages, based on the GFR only. The prevalence of CKD in the worldwide population is 
estimated to be 5 – 18 %, as based on the GFR < 60 mL/min/1.73 m² criterion [5–9]. Next to 
GFR, albuminuria (i.e. abnormal albumin loss in the urine) was found to be associated with the 
progression of kidney disease. For this reason, an update of CKD classification was published 
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in 2011 by the Kidney Disease: Improving Global Outcomes (KDIGO) in which albuminuria 
stages and a renal diagnosis category were added next to GFR stages (Figure 1-2) [10]. Patients 
with CKD stage 5 (GFR < 15 mL/min/1.73 m²) may need renal replacement therapy such as 
kidney transplantation or dialysis in order to survive when their GFR further declines. This 
stage is also referred as end-stage kidney disease (ESKD).  
Figure 1-2 Prognosis of chronic kidney disease (CKD) by glomerular filtration rate (GFR) and 
albuminuria categories. 
Prognosis of CKD by GFR 
and Albuminuria Categories: 
KDIGO 2012 
Persistent albuminuria categories 
(mg/g) 
Description and range 














































G1 Normal or high ≥ 90    
G2 Mildly decreased 60 – 89    
G3a 
Mildly to  
moderately decreased 
45 – 59    
G3b 
Moderately to  
severely decreased 
30 – 44    
G4 Severely decreased 15 – 29    
G5 Kidney failure < 15    
 
Green: low risk (if no other markers of kidney disease, no CKD); yellow: moderately increased risk;  
orange: high risk; red: very high risk. Adapted from [11]. 
1.1.2.2 GFR determination 
The GFR can be measured by urinary or plasma clearance of exogenous (i.e. administered) 
filtration markers, which can be radio-isotopically labeled. Ideally, these markers are inert, not 
bound to proteins and only cleared by glomerular filtration. Examples of exogenous markers 
include inulin, 51Cr-ethylenediaminetetraacetic acid (EDTA), 125I-iothalamate and 
99Tc-dietylenediaminepentaacetic acid (DTPA) [12,13].  
These methods are however costly and labor intensive. Therefore, GFR is in practice estimated 
(eGFR) by measuring endogenous filtration markers and using their concentrations in eGFR 
formulae. Creatinine is the most widely used endogenous filtration marker and has a relatively 
constant within-subject production. Renal excretion of creatinine occurs mainly via glomerular 
filtration without tubular reabsorption. However, a small fraction of creatinine is also cleared 
by tubular secretion, accounting for 5 – 10 % of the urinary content and is different among 




important with lower GFR. Nevertheless, due to the cheap and easily accessible analysis of 
serum creatinine in routine laboratories, creatinine-based formulae are the most commonly used 
in the clinical setting. The Cockcroft-Gault (Eq. 1-1) equation [14], which estimates the 
creatinine clearance, was the first formula that was used in practice. Nowadays, eGFR is usually 
estimated by the Modified Diet in Renal Disease (MDRD, Eq. 1-2) [15,16] or the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI, Eq. 1-3) [17] formulae. 
Creatinine clearance = 
(140-age) BW
72 Screa
 (0.85 if F)   (Eq. 1-1) 
eGFR  = 186 Screa
-1.154
age-0.203 (0.742 if F) (1.21 if B)   (Eq. 1-2) 










(0.993)age (1.018 if F) (1.159 if B)    (Eq. 1-3) 
Where creatinine clearance and eGFR are expressed in mL/min and mL/min/1.73 m², 
respectively, age in years and bodyweight (BW) in kg. Screa is serum creatinine concentration 
(in mg/dL), F is female, B is black, κ is 0.7 (female) or 0.9 (male) and α is -0.329 (female) 
or -0.411 (male). 
It should however be stressed that the renal elimination of waste products and/or metabolites is 
not only controlled by glomerular filtration, but also by tubular secretion. Therefore, in some 
cases eGFR might only partially reflect renal elimination of specific metabolites. 
1.2 Renal replacement therapy 
At end-stage kidney disease (ESKD), i.e. a GFR < 15 mL/min/1.73 m², patients may need renal 
replacement therapy in order to purify the blood from (accumulated) waste products and 
metabolites. 
 Kidney transplantation 
Transplantation is, in general, the preferred renal replacement therapy. However, because of the 
lack of donor kidneys or transplant rejections/fails as well as the possibility that patients are not 
eligible for transplantation (e.g. due to comorbidity, infection or cancer), a significant portion 
of ESKD patients are treated with dialysis. 
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 Peritoneal dialysis 
In peritoneal dialysis (PD), the peritoneum is used as a semi-permeable membrane and allows 
the transport of small solutes, water and electrolytes (Figure 1-3). Via a permanent peritoneal 
catheter, placed in the lower part of the abdomen, the peritoneal cavity is filled with dialysis 
fluid. Small solutes move across the peritoneal membrane from blood side to dialysis fluid 
compartment, or vice versa, via diffusion, depending on the concentration gradient. Water 
removal takes place by osmosis as well, due to the addition of an osmotic agent (e.g. glucose, 
icodextrin, amino acids) to the dialysis fluid. In continuous ambulatory peritoneal dialysis 
(CAPD), the fluid is drained at regular intervals (typically 4 – 6 hours) and replaced by means 
of gravity, with a long dwell time overnight. In automated peritoneal dialysis (APD), several 
fluid changes are performed overnight, with a long dwell time during the day. 
Figure 1-3 Schematic representation of peritoneal dialysis [18]. 
 
PD might be the first choice of treatment for several reasons. The continuous character of this 
treatment is less stressful for the heart and results in an improved well-being of the patient 
compared to hemodialysis (HD), where the treatment is intermittent and waste products 
accumulate between each dialysis session. Furthermore, PD is characterized by a lower cost for 






In hemodialysis, blood flows through an artificial kidney (i.e. the hemodialyzer) in an 
extracorporeal circuit (Figure 1-4). A typical dialyzer contains about 10000 hollow fibers, 
having an internal diameter in the range of 180 – 225 µm and a wall thickness of 15 – 50 µm, 
depending on the brand [19–21]. Blood flows in the lumen of these hollow fibers, while dialysis 
fluid (i.e. pure water containing electrolytes) flows around them, in the opposite direction. 
These fibers act as a semi-permeable membrane and allow the transport of small compounds 
and water through the many pores via different transport mechanisms (see 1.2.3.3 Removal 
processes in hemodialysis). Typical blood flow rates are in the range of 250 – 350 mL/min, 
whereas dialysis fluid flow rate is preferably 1.5 – 2 times the blood flow. As vascular access, 
an arteriovenous fistula or graft can be used as well as a central venous catheter. Next to the 
removal of waste products and metabolites, hemodialysis can also correct for electrolyte 
imbalance and acidosis by choosing the optimal dialysis fluid composition.  
Figure 1-4 Schematic representation of hemodialysis [22]. 
 
Typically, patients come to the hospital three times a week for a dialysis session of four hours. 
Not only night dialysis in the hospital can be an alternative, but also self-care or home dialysis 
treatment might be an option, especially for patients that go to work during the day. In between 
the different dialysis sessions, the plasma concentration of solutes increases due to 
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re-equilibration in the body immediately after dialysis (i.e. the so-called rebound) and due to 
generation after liquid and food intake, both depending on the residual renal function. 
1.2.3.2 Dialyzer membranes 
Low-flux hemodialysis treatment uses membranes with small pores (i.e. low flux), enabling 
removal of mainly small compounds, such as urea (60 Da) or creatinine (113 Da). The more 
efficient removal of larger solutes, such as β2-microglobulin (β2M, 12 kDa), can be established 
by using membranes with larger pores (i.e. high flux). The sieving coefficient describes the 
permeability of a hemodialyzer membrane for a solute and varies between 0 (not permeable) 
and 1 (fully permeable). In Figure 1-5, the sieving coefficient for a low and high flux membrane 
is presented as a function of solute molecular weight. More recently, membranes having larger 
pore sizes with a more uniform distribution (medium and high cut-off) became available. This 
results in an even higher permeability for high molecular weight solutes and steeper curves in 
Figure 1-5, respectively [23].  
Figure 1-5 Sieving coefficient as a function of molecular weight for different hemodialysis membrane 
types, based on the pore size. 
  
MCO: medium cut-off; HCO: high cut-off; β2M: β2-microglobulin, κflc: κ free light chains; TNFα: tumor 
necrosis factor α; λflc: λ free light chains (see 1.3.2 Middle molecules). Adapted from [23]. 
Next to the variation in membrane thickness, and pore size, dialyzer membranes also differ in 
chemical composition. Most common synthetic dialyzer membranes are nowadays made of 
polysulfone, polyamide, polyethersulfone, polyacrylonitrile or a copolymer of 
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To avoid blood clotting in the dialyzer, anticoagulants like low molecular weight heparin are 
usually administered at the start of the dialysis session. 
1.2.3.3 Removal processes in hemodialysis 
In the dialyzer, blood purification is the result of four physical processes, i.e. diffusion, 
convection, osmosis and adsorption. Diffusion is the result of solute concentration gradient 
between blood and dialysate across the semi-permeable membrane. Applying a countercurrent 
blood – dialysate flow, increases the removal of solutes due to an established concentration 
gradient over the entire length of the dialyzer. Convective transport of solutes and fluid removal 
are achieved by ultrafiltration induced by a transmembrane pressure gradient. This convective 
transport is, however, counteracted by osmosis due to the presence of proteins in blood. In the 
clinically used adsorptive hemodialysis techniques, solutes are removed from the blood by the 
adsorption to a resin in a separate column; i.e. hemodialysis with HFR Evolution (Bellco-
Medtronic, Italy) [24] and liver dialysis with fractionated plasma separation and adsorption 
(FPSA) as with the Prometheus (Fresenius Medical Care, Germany) [25,26]. In addition, 
in vitro data showed that when adding sorbent to the dialysate side [27], using a monolithic 
sorbent [28] or combining hemodialysis with adsorption on one membrane (i.e. the mixed 
matrix membrane) [29] might be promising alternatives. 
1.2.3.4 Different dialysis modes 
When using large membrane pores, one is able to choose between different dialysis modes. In 
hemodialysis (HD), the main transport is diffusion and results in the clearance of mainly small 
solutes. A small portion of convective transport, either only forward filtration or both forward 
and backfiltration (i.e. internal filtration), takes place when correcting for the patient’s dry 
bodyweight [30]. In hemofiltration (HF), there is only convection, removing substantial 
quantities of body fluid (i.e. plasma water), while substituted by buffered saline in pre- or post-
dilution, i.e. at the arterial or venous blood line, respectively. Hemodiafiltration (HDF) 
combines both removal modes, i.e. diffusion and convection, resulting in a good removal of 
both small and larger compounds [31]. 
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1.3 Uremic toxins 
CKD is characterized by the retention of a large number of compounds that are normally 
excreted by the healthy kidneys. Many of these uremic retention solutes have a negative impact 
on biological functions of the body and are therefore called uremic toxins. Three groups of 
uremic toxins were proposed by the European Uremic Toxin (EUTox) Workgroup as based on 
their physicochemical properties, i.e. the small water-soluble solutes, middle molecules, and 
protein-bound uremic toxins [32,33]. 
 Small water-soluble solutes 
Small water-soluble solutes have a MW < 500 Da and are not bound to proteins. The prototype 
within this group is urea (60 Da). Uric acid (UA, 168 Da) and guanidine compounds such as 
creatinine (Crea, 113 Da), asymmetric dimethylarginine (ADMA, 202 Da) and symmetric 
dimethylarginine (SDMA, 202 Da) are also commonly studied [32–34]. Several small 
water-soluble solutes have been associated to cardiovascular disease, inflammation and 
metabolic function, as illustrated in Figure 1-6 [35].  
Figure 1-6 Relative amount of toxins within each group of uremic toxins affecting specific biological 
systems.  
 
CVD: cardio-vascular disease; CKD-MBD: chronic kidney disease-metabolic bone disease; PEW: protein 
energy wasting. Adapted from [35]. 
Small water-soluble solutes



































 Middle molecules 
Middle molecules are retention solutes in the large molecular weight range, i.e. > 500 Da, with 
β2-microglobulin (β2M, 11 kDa) as prototype. Amongst others, interleukin-6 (IL-6, 24.5 kDa), 
tumor necrosis factor α (TNFα, 26 kDa), immunoglobulin κ and λ free light chains (κflc and λflc, 
22.5 kDa and 45 kDa respectively) are included in this class [32–34]. Many of these middle 
molecules have been linked to cardiovascular disease, inflammation and fibrosis (Figure 1-6) 
[35]. 
 Protein-bound uremic toxins 
The protein-bound uremic toxins (PBUTs) are a group of compounds with predominantly a 
MW < 500 Da, where a certain fraction of their concentration is bound to plasma proteins. 
Prototypes of this group are phenols (e.g. p-cresyl sulfate) and indoles (e.g. indoxyl sulfate) 
[32–34]. In analogy with compounds from the other two classes, also a large number of PBUTs 
are associated to inflammation, metabolic function, cardiovascular disease and fibrosis, as 
indicated in Figure 1-6. 
1.4 Kinetics of protein-bound uremic toxins 
In this thesis, only a selected panel of PBUTs was studied, including p-cresyl glucuronide 
(pCG, 284 Da, pKa = 3.30), hippuric acid (HA, 179 Da, pKa = 3.59), indole-3-acetic acid 
(IAA, 175 Da, pKa = 4.66), indoxyl sulfate (IS, 213 Da, pKa = -1.80) and p-cresyl sulfate 
(pCS, 188 Da, pKa = -2.00) and their chemical structures are presented in Figure 1-7. All five 
listed PBUTs are organic acids and ionized for > 99.9% at physiologic pH (i.e. pH = 7.4), as 
calculated from their pKa – values (Eq. 1-4).  
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Figure 1-7 Chemical structures of p-cresyl glucuronide (pCG), hippuric acid (HA), indole-3-acetic acid 
(IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS). 
 
 Generation and secretion 
Phenolic and indolic compounds are predominantly generated by gut microbiota which takes 
place in the distal part of the colon [36,37]. Proteins, mostly originating from diet, enter the 
large intestine and are depolymerized into small oligopeptides and amino acids. The amino 
acids tyrosine and phenylalanine are further converted into phenolic compounds such as phenol 
and 4-methyl phenol, which is also known as p-cresol. Subsequently, p-cresol is conjugated by 
sulfotransferase and glucuronlytransferase in the mucosa of the colon and in the liver into pCS 
and, to a lesser extent, to pCG [38]. Indolic compounds, such as IAA and IS, are generated from 
the amino acid tryptophan by bacteria in the colon generating indole which is further 
metabolized in the liver into IS [39,40]. While the role of gut microbiota in the generation of 
pCG, IAA, IS and pCS in humans is well-documented, this is not the case for HA. It has been 
shown that benzoic acid, the precursor of HA, originating from plant polyphenols or from added 
food preservatives, is metabolized into HA. In animal studies, gut microbiota were found to be 
involved in this process [41,42] and human data presented by Aronov et al. suggested that the 
place of action in humans is in the small intestine rather than in the colon [30]. Besides benzoic 
acid, quinic acid, a sugar compound in plants, is believed to be metabolized into HA as well, 
after dietary intake [43].  
All above described compounds bind to plasma proteins when entering the circulating system 
[44]. In normal conditions, the free (i.e. unbound) fraction of these PBUTs is cleared by 
glomerular filtration, whereas organic anion and cation transporters expressed on proximal 






 Protein binding 
The binding of PBUTs to plasma proteins is not covalently, but a result of intermolecular 
interactions between both. These interactions may include hydrophobic Van der Waals 
interactions, hydrogen bonds and/or electrostatic interactions with ionized residues, present on 
the toxin and plasma protein. Consequently, this binding is reversible and there is an 
equilibrium between bound and free fraction in plasma. The percentage that is bound to plasma 
proteins is expressed as the percentage protein binding (%PB) and ranges from almost 0 % to 
even 100 % [44]. Previous studies demonstrated that albumin, the most abundant protein in 
plasma (> 50 % of total protein), is the major binding protein for these PBUTs [46]. Next to 
albumin, these PBUTs can, in theory, also be bound to other plasma proteins, such as α1-acid 
glycoprotein (AAG). However, to the best of our knowledge, no proof for binding to AAG or 
other plasma proteins has been published for PBUTs so far. 
The free drug hypothesis states that for most drugs the free (i.e. unbound) concentration at the 
site of action exerts pharmacological activity [47]. Accordingly, it could be hypothesized that 
the toxicity of PBUTs is exerted by the free fraction rather than the total amount. In literature, 
it is often postulated that the %PB of uremic toxins might be decreased in patients with CKD 
as compared to healthy subjects, because of the possible saturation of plasma proteins as a 
consequence of the elevated uremic toxin concentrations in patients with CKD [48]. 
Additionally, it has been suggested that the %PB of PBUTs might be influenced by competition 
between different PBUTs bound to the same binding site on albumin [49–51], as well as 
between PBUTs and drugs like antibiotics [49,52–60]. If the %PB of PBUTs in patients with 
CKD would indeed be decreased due to protein saturation or binding competition, this may also 
have biological implications as a decrease from e.g. %PB = 95 % to 90 % means a doubling in 
free fraction and potentially a doubling in toxic effect. In clinical pharmacology, it has however 
been matter of debate whether alterations in %PB of drugs are clinically relevant and it is now 
believed that this is only the case for drugs with a narrow therapeutic window that are 
administered intravenously, having a high clearance and high %PB (i.e. > 70 %) [61]. 
 Kinetics during dialysis 
For many years, urea clearance (K) multiplied by time (t) and normalized for urea distribution 
volume (Vd) was the parameter to evaluate dialysis adequacy: [Kt/Vd]urea. The choice for urea 
as a marker was, however, based on practical rather than on pathophysiologic considerations. 
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It should therefore be stressed that [Kt/Vd]urea
 only estimates the kinetics of urea, which is a 
small water-soluble compound that is easily removed by diffusion during dialysis and has a 
distribution volume close to the patient’s total body water. Previous studies reported that this 
parameter does not adequately describe the removal of some other small water-soluble 
compounds [62–66] and certainly not of larger middle molecules and PBUTs, which are 
removed by different transport mechanisms and may have a different distribution volume as 
compared to urea [67–71].  
It is therefore of great interest to study the kinetics of middle molecules and PBUTs during 
dialysis and finally find (a) representative compound(s) for each group of uremic toxins. For 
PBUTs, finding a representative compound might be more difficult than first thought, because 
the range of protein binding is large and only the free fraction can pass the pores of the dialyzer 
membrane. 
1.5 Aims and outline  
Because of the protein binding, removal efficiency of protein-bound uremic toxins (PBUTs) 
during hemodialysis (HD) is much lower as compared to small water-soluble solutes, especially 
for those with a high %PB. Since many of the PBUTs have an impact on the cardiovascular 
system and contribute to the increased propensity for cardiovascular events and mortality in 
patients with chronic kidney disease (CKD), it is of great interest to improve their removal 
during HD. For this, we need to understand the full picture of PBUT kinetics in the patient and 
the extracorporeal circuit.   
The general aim of this thesis was therefore to obtain more insight into the kinetics of PBUTs 
and protein-bound antibiotics in patients with CKD. These kinetics were explored either in vivo 
and/or in different in vitro settings after development and/or optimization of analytical 
techniques. 
The basic principles of the most important analytical methods used during the thesis are 
described in Chapter 2, while other techniques are described in the chapter of the corresponding 
study.  
In Chapter 3, the in house developed ultra-high performance liquid chromatography method 
with ultraviolet and fluorescence detection (UHPLC-UV/FLD) for PBUT quantification was 




cycle on the %PB of PBUTs, using blood from HD patients. Furthermore, a novel ultra-high 
performance liquid chromatography – high resolution mass spectrometry (UHPLC-HRMS) 
assay was developed and validated for the quantification of the antibiotic teicoplanin. 
In an in vivo study, provided in Chapter 4, PBUT %PB data was collected in 95 patients with 
different stages of CKD and 10 patients on hemodialysis. In these HD patients, kinetics with 
changes in %PB of PBUTs were evaluated by blood sampling at different time points during 
an HD session from the arterial as well as venous blood line.  
The binding characteristics of PBUTs and their related competition are described in Chapter 5. 
These were explored in vitro in serum from healthy subjects as well as from HD patients, to 
include possible differences in albumin and binding characteristics. In addition, the %PB of the 
two antibiotics vancomycin and teicoplanin was compared in vitro in plasma from healthy 
subjects as well as from HD patients and the possible competition with PBUTs was checked.  
In Chapter 6, PBUT distribution in a direct accessible extra-plasmatic compartment, i.e. the 
erythrocytes, is illustrated in blood from stable HD patients. Information on their transport 
across the erythrocyte membrane is provided as well and was obtained by loading and unloading 
experiments of erythrocytes from healthy subjects and HD patients, respectively. 
This thesis is closed (Chapter 7) with a general summary and critical interpretation of the 
findings as well as the broader relevance of the work and future perspectives.  
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Analytical methods for the quantification of protein-bound uremic 
toxins and antibiotics 
2.1 Introduction 
In this thesis, free and total concentrations of protein-bound uremic toxins (PBUTs) and the 
protein-bound antibiotic agent vancomycin were determined by different validated analytical 
methods [1–4]. The method to quantify free and total teicoplanin concentrations has been 
further developed and validated during the course of the present thesis. 
PBUT quantifications were performed by three different reversed-phase (ultra-)high 
performance liquid chromatography methods in which the compounds were detected either by 
ultraviolet or fluorescence detection [(U)HPLC – UV/FLD] [1,2] or by tandem mass 
spectrometry (UHPLC – MS/MS) [3]. Vancomycin was determined by a chemiluminescent 
microparticle immunoassay (CMIA) [4], whereas teicoplanin was quantified by reversed-phase 
UHPLC coupled to high resolution mass spectrometry (UHPLC-HRMS).  




2.2 Reversed-phase (ultra-)high performance liquid chromatography 
 Principle 
(U)HPLC is a technique to separate, identify and quantify analytes in solution. In brief, 
degassed solvent (i.e. mobile phase) is continuously pumped through a (U)HPLC column, 
which can be temperature-controlled, under (ultra-)high pressure (typical < 400 bar in HPLC 
and 300 – 1200 bar in UHPLC). Typical flow rates in HPLC and UHPLC are 1 – 3 mL/min and 
0.3 – 0.6 mL /min, respectively. In reversed-phase (U)HPLC, the mobile phase is mainly 
hydrophilic and can be constant (i.e. isocratic) or varied (i.e. gradient) in composition during 
the analysis. A reversed-phase column is packed with silica particles of which silanol groups 
are partly substituted by alkyl chains, where octadecylsilane (C-18, ODS), octylsilane (C-8) 
and phenyl(hexyl)silane are the most common ones.  
 Sample preparation 
In general, most samples need to be pretreated prior to (U)HPLC analysis. Amongst others, 
sample preparation might be necessary to concentrate, purify, extract or derivatize the analytes 
to enhance the sensitivity or for column lifetime issues. In this thesis, serum and plasma samples 
were analyzed and needed a pretreatment step to precipitate serum or plasma proteins to prevent 
column clogging. Proteins can e.g. be precipitated by heating the sample, or by adding organic 
solvents such as methanol or acetonitrile. 
During the sample preparation, preferably at the start, a known amount of internal standard can 
be added to both the samples and calibrators (see 2.2.4.4 Quantification). In this way, it is 
possible to correct for analyte losses during sample preparation or for a variation in instrument 
injection. Ideally, the internal standard is a compound that is not present in the native samples, 
stable during sample preparation, well-resolved during the analysis and very similar in 
molecular structure as compared to the analyte. In some methods, more than one internal 
standard can be added. This is especially the case when the analytes are detected by mass 
spectrometry. Here, the deuterated form of preferably each analyte is added to the sample, when 
available and affordable. These deuterated forms behave similarly as their non-deuterated forms 
but are detected at a different mass-to-charge ratio (see 2.2.4.3 Mass spectrometry) and are 
therefore the ideal internal standards. 
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In most of the presented work, both total and free (i.e. unbound) serum or plasma analyte 
concentrations were determined. Free concentrations were obtained either indirectly by using 
equilibrium dialysis or directly by means of ultrafiltration. 
Equilibrium dialysis (ED) is the most widely used method to obtain free analyte fractions and 
is often seen as the gold standard [5,6]. This method is based on the equilibration of free 
fractions over two chambers which are separated by a semi-permeable membrane (Figure 2-1 
left). At the start, one chamber is filled with serum or plasma while (ideally) an equal volume 
of buffer is added to the other chamber. Subsequently, free analytes equilibrate over the total 
(i.e. plasma + buffer) volume and cause the release of bound fraction. After several hours, 
typically 5 – 6 hours, a new equilibrium is established and analytes can be quantified in both 
serum/plasma and buffer chambers. Finally, the free analyte fractions are obtained by dividing 
the analyte concentrations on the buffer side by the analyte concentrations on the serum/plasma 
side. The original free analyte concentrations in the sample are subsequently obtained by 
multiplying the free fractions by the original total analyte concentrations in the sample. The 
time needed for equilibration can be determined in a pilot experiment in which samples are 
taken at different time points.  
These chambers need to be sealed during dialysis to prevent shifts in pH, as this might induce 
a shift in free fraction [7–9]. Furthermore, due to serum or plasma oncotic pressure, free 
fractions may be higher than in the original sample [5,6,10,11]. The Donnan effect may arise 
due to the impermeability of the membrane for large charged plasma proteins, and can result in 
the shift of charged free compounds towards the buffer chamber [5]. However, shifts in free 
fractions due to oncotic pressure or the Donnan effect can be reduced to a minimum by using 
isotonic buffers, such as 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) or 
phosphate buffered saline (PBS) [5]. Moreover, non-specific binding to the ED device and 
membrane needs to be studied when recovery is important [5,9].  
Ultrafiltration (UF) is an alternative for ED and is characterized by a much higher analysis 
speed, which is typically 10 – 30 minutes. In UF, serum or plasma containing protein-bound 
analytes is ultrafiltered during centrifugation through the pores of a semi-permeable membrane. 
This process results in fluid containing free analytes (i.e. ultrafiltrate) at the other side of the 
membrane (Figure 2-1 right). Finally, the free concentration can be directly determined in the 
ultrafiltrate. Also here, non-specific binding and the Donnan effect may result in inaccurate free 




centrifugation can cause a shift in free fraction and consequently result in inaccurate free 
concentrations as well [5,6]. 
Figure 2-1 Left: Principle of equilibrium dialysis for an analyte with a free fraction of 50 %. Right: 
Principle of ultrafiltration, based on the use of Merck Amicon filters [12]. 
 
 
In this thesis, both ED and UF were used to obtain free analyte concentrations. In ED, PBS 
buffer and ultrafiltrate obtained from healthy serum were used. A small volume shift due to 
oncotic pressure was observed and concentrations were corrected for this shift. In addition, the 
possible non-specific binding to ED or UF membranes was studied as well. Both will be 
discussed further in this thesis. 
 From injection to detection 
After sample preparation, samples are transferred into autosampler vials and placed in a sample 
tray, which can be temperature-controlled (Figure 2-2). When the sample is injected (typically 
30 – 50 µL in HPLC and 1 – 30 µL in UHPLC), analytes travel with the mobile phase through 
the column and interact with the hydrophobic stationary phase (e.g. C18, C8). The more 
hydrophilic analytes show no or only a small affinity for the stationary phase and are not or 
minimally retained by the column. Hence, these more hydrophilic analytes will elute first and 
will be subsequently detected first. Depending on the analytes present in the injected sample, 
different interactions between analytes and stationary phase will result in different elution 
orders. As already mentioned before, the composition of the mobile phase can be modified 
during a run. This is typically performed to ensure that very hydrophobic analytes elute as well. 
For example, the mobile phase can consist of 95 % aqueous buffer (solvent A) and 5 % organic 
solvent (solvent B, e.g. methanol, acetonitrile) at the start of the analysis and change to 10 % 
buffer and 90 % organic solvent at the end. From the column, every eluted analyte travels with 
the mobile phase towards the detector.  
Serum/
Plasma






1. Fill 3. Collect
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UHPLC differs from HPLC by its shorter columns (typical 50 – 100 mm in UHPLC versus 
100 – 300 mm in HPLC), smaller column internal diameters (typical 2.1 mm in UHPLC versus 
4.6 mm in HPLC) and smaller particles (typical 1.7 – 2.6 µm in UHPLC versus 3.5 – 5 µm in 
HPLC). This results in a better resolution, higher sensitivity, faster analyses and less solvent 
consumption in UHPLC as compared to HPLC [13,14]. 
Figure 2-2 Simplified schematic representation of an (U)HPLC system. 
 
 Detection mechanisms 
Analytes eluting from the column are further transported by the mobile phase towards the 
detector. Only detector systems used during the thesis will be discussed in this section. 
2.2.4.1 Diode array detector 
In a traditional ultraviolet (UV) or UV – visible light (UV – VIS) detector, a deuterium 
(λ = 190 – 380 nm) or tungsten (λ = 380 – 900 nm) lamp is used as light source, respectively. 
Subsequently, the emitted light is diffracted and dispersed, and one specific wavelength is 
guided to the flow cell (Figure 2-3 left). The mobile phase flows continuously through this cell 
and a difference in absorption is observed when an eluted analyte passes through the cell. Only 
one specific wavelength can be registered in a traditional UV detector.  
In a diode array detector (DAD), also known as photodiode array detector (PDA), light emitted 
from the lamp is guided directly to the flow cell and is diffracted and dispersed after passing 
through the cell (Figure 2-3 right). Because of the multiple diode arrays in this detector, multiple 














Figure 2-3 Simplified schematic illustration of a traditional UV(-VIS) detector (left) and  
a diode array detector (right).  
  
D: deuterium lamp; W: tungsten lamp. Adapted from [15]. 
2.2.4.2 Fluorescence detector 
Some compounds have the characteristic to emit light at one specific wavelength (λem) after 
being excited by another specific wavelength (λex), where λex < λem. This process is called 
fluorescence and is, besides UV detection, also commonly used in (U)HPLC analyses. In 
fluorescence detection, a xenon lamp can be used as light source and the emitted light is 
diffracted and dispersed to a specific excitation wavelength (Figure 2-4). This light travels 
through the flow cell and a passing analyte can be excited, followed by its relaxation by the 
emission of light with a lower energy. This emitted light is then, orthogonal to the exciting light, 
guided towards the detector. 
Figure 2-4 Simplified schematic illustration of a fluorescence detector. 
 
Xe: xenon lamp. Adapted from [16]. 
2.2.4.3 Mass spectrometry 
Mass spectrometry (MS) is a technique in which gaseous ions are separated based on their 
mass-to-charge (m/z) ratio. Besides providing information on molecular weight, mass 
spectrometers are also able to elucidate the molecular structure of an analyte. In general, a mass 
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compounds eluting from the column are ionized and transferred into the gaseous phase and 
subsequently guided to the mass analyzer, which operates under high vacuum. Here, the ions 
are separated based on their m/z ratio by applying a magnetic and/or electric field. Finally, the 
ion beam is transferred into a signal in the detector. Various types of ion sources and mass 
analyzers are available but only those used during the thesis will be discussed in this paragraph. 
(Heated) electrospray ionization (ESI) is a soft ionization technique, which means that the 
ionization results in only a limited amount of fragmentation. The mobile phase containing 
analytes is guided into a (heated) metal capillary with a fine tip, under a high positive or 
negative voltage (typically 2.5 – 6.0 kV). A nitrogen flow is applied to nebulize the flow of 
mobile phase and relatively large charged droplets are formed (Figure 2-5 left). Depending on 
the polarity of the applied voltage, these droplets can be positively or negatively charged. In 
positive mode (ESI+), predominantly protonated compounds are formed which results in peaks 
at [MW+n]n+. In negative mode (ESI-), predominantly deprotonated compounds are formed 
which results in peaks at [MW-n]n-. Usually, n equals 1 in both positive and negative modes. 
Due to an excess of droplets having the same charge, these droplets are repulsed resulting in a 
so-called conical electrospray (Figure 2-5 left). Subsequently, the mobile phase is evaporated. 
This process is enhanced by applying a drying gas, such as nitrogen, in an opposite direction. 
As a result, the droplet size decreases and at a certain moment, the electrostatic repulsion 
between ions with the same charge becomes higher than the surface tension of the droplet, 
i.e. the Rayleigh limit. At this moment, the droplets explode (i.e. Coulomb explosion) into 
smaller droplets with a lower surface charge density. The process of decreasing in size and 
exploding into smaller droplets is repeated and finally, single analyte ions in the gaseous phase 
are formed (right). These ions are then guided from the ESI source, which operates at 
atmospheric pressure, towards the mass analyzer which operates at high vacuum [17]. 
Figure 2-5 Principle of electrospray ionization. 
  





























Two different mass analyzers were used in this thesis, i.e. a tandem mass spectrometer 
(MS/MS) and a high resolution mass spectrometer (HRMS).  
A tandem quadrupole mass spectrometer is typically composed of three quadrupole mass 
analyzers, positioned in a linear way and is therefore often called ‘triple quadrupole’. 
In general, a quadrupole mass analyzer consists of four parallel metal rods and each opposing 
rod is connected together electrically (Figure 2-6). A specific electrical field is formed by 
applying a radiofrequency (RF) and direct current (DC) voltage to these rods. Analyte ions 
travel through the quadrupole and only those with a specific m/z ratio have a stable trajectory 
at the selected electrical field and are guided to the detector. All other ions have unstable 
trajectories and are removed. Changing the electrical field allows ions with other m/z ratios to 
travel through the quadrupole followed by their detection.  
Figure 2-6 Simplified schematic illustration of a quadrupole mass analyzer. 
 
Adapted from [19]. 
Analyte ions which are formed by (H)ESI show a low degree of fragmentation and the resulting 
spectra mainly contain the molecular ions. In some cases it might be desirable to create 
fragments of the analyte ions, e.g. in molecular structure elucidation or when ions with the same 
m/z ratio interfere with the analyte ion of interest. This fragmentation can be achieved by using 
a triple quadrupole system (Figure 2-7). The analyte ion of interest is selected in the first 
quadrupole (Q1) and allowed to collide with a collision gas (typical argon) to form fragments. 
This fragmentation occurs in a collision cell which is usually an RF-only quadrupole (Q2) or 
hexapole. In the third quadrupole (Q3), specific fragments can be selected to travel towards the 
detector. In this thesis, a photomultiplier was used to detect ions that were selected in Q3 
[20,21]. In this type of detector, an ion hits a conversion dynode and results in the emission of 
electrons. These electrons are accelerated towards a scintillation substance which on its turn 
emits photons after the electrons collide to this substance. The emitted photons collide to a 
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photoelectric effect. On their way to the anode, these ejected electrons are multiplied and 
finally, the large number of electrons reaching the anode produce an electric signal. 
Accordingly, it is possible to e.g. select an analyte ion of interest in Q1 and select a specific 
fragment of that analyte in Q3. In this way, two or more ions with the same m/z ratio that 
co-elute from the (U)HPLC column can be separated, resulting in a much higher sensitivity. 
This mode is called multiple reaction monitoring (MRM) and is commonly used in MS/MS 
analyses. 
Figure 2-7 Schematic representation of the tandem mass spectrometer used  
in this thesis (Xevo TQS, Waters). 
 
ESI: electrospray ionization. Adapted from [20]. 
In a quadrupole, ions are selected based on their nominal mass. Consequently, different ions 
with the same nominal mass and charge, but a different exact mass, have the same m/z ratio 
and cannot be separated by a single quadrupole. Therefore, a triple quadrupole can be used for 
the detection of only e.g. fragment ions of the specific analyte of interest. Alternatively, a high 
resolution mass spectrometer (HRMS) is capable to resolve ions with the same nominal mass, 
but a different exact mass. This type of mass spectrometer is characterized by its high resolution 
and high mass accuracy.  
In the HRMS method used in this research, analyte ions are formed by heated ESI followed by 
the introduction into the mass spectrometer (Figure 2-8). These ions are further focused by a 
stacked ring ion guide (S-lens) and residual neutrals are removed using the bent flatapole. In a 
next step, ions with a specific nominal m/z ratio can be selected via the quadrupole prior to be 
accumulated in the C-trap. Subsequently, analyte ions are injected into the orbitrap in which 
ions with different exact masses are separated. The orbitrap is composed of a central electrode 
surrounded by two outer electrodes, which enable it to function as both a mass analyzer and 
detector. When a packet of analyte ions is injected from the C-trap into the orbitrap, they 
Quadrupole 1 Detector
HESI







oscillate around the central electrode and in between the two outer electrodes. Finally, analyte 
ions with different exact masses are separated because of their different axial and spatial 
oscillation frequencies.  
The frequencies of the axial oscillations are measured on the outer electrodes by the process of 
image current detection. Optionally, analyte ions can be fragmented in the high energy collision 
dissociation cell (HCD cell), before being trapped in the C-trap and injected into the orbitrap 
[22,23]. 
Figure 2-8 Schematic representation of the high resolution mass spectrometer used in this thesis  
(Q-Exactive Plus, Thermo Fisher Scientific). 
  
HESI: heated electrospray ionization; HCD: high energy collision dissociation. Adapted from [23]. 
2.2.4.4 Quantification 
In (U)HPLC analyses, analytes can be quantified by external calibration. In this calibration 
method, a series of calibrator standards are prepared, containing an increasing known amount 
of the analytes of interest. These calibrator standards may contain the same amount of internal 
standard as the samples and a calibration curve is obtained by plotting the analyte-to-internal 
standard area ratios to their amount ratios in the different calibrator levels. This calibration 
curve can be linear, quadratic or exponential, with different weightings, e.g. equal weighting, 
1/x and 1/x². Quantification of the unknown analytes is performed by relating their 
analyte-to-internal standard area ratio to the calibration curve. 
 Detailed summary of used (U)HPLC methods 
Depending on the date of analysis and/or the collaboration with other laboratories, different 
(U)HPLC methods were used for the quantification of PBUTs. In the in vivo study as described 
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used: one for the separation of hippuric acid, indole-3-acetic acid and indoxyl sulfate [1] and 
one for the separation of p-cresylglucuronide and p-cresyl sulfate [2]. More recent studies 
included the analysis of PBUTs by UHPLC-UV/FLD (Chapters 3, 5 and 6) or UHPLC tandem 
MS [3] (Chapter 5), both using a single column for the separation of the above listed 
compounds.  
Teicoplanin (i.e. compounds A3-1, A2-1, A2-2 & A2-3 and A2-4 & A2-5) was quantified by 
UHPLC-HRMS (Chapters 3 and 6). The used chromatographic settings are summarized in 
Table 2-1 and the used UV/FLD and mass spectrometer settings in Table 2-2 and Table 2-3, 
respectively.   
2.3 Chemiluminescent microparticle immunoassay 
For the quantification of free and total vancomycin, a chemiluminescent microparticle 
immunoassay (CMIA) method was used [4]. This technique is based on the detection of light, 
which is emitted following a chemical reaction.  
This CMIA method mixes sample containing vancomycin, anti-vancomycin paramagnetic 
microparticles and vancomycin acridinium-labeled conjugates (Figure 2-9). The 
anti-vancomycin coated microparticles bind to vancomycin present in the sample and to the 
vancomycin acridinium-labeled conjugates. Subsequently, a magnet attracts the paramagnetic 
microparticles to the wall and a washing step with PBS removes all compounds that are not 
bound to the microparticles. After a second washing step, a so-called pre-trigger (1.32 w/v % 
H2O2) is added and the background signal is recorded. The created acid milieu pre-activates the 
acridinium. In a next step, a trigger solution (0.35 M NaOH) is added and an oxidative 
chemiluminescent reaction leads to the formation of N-methylacridone. Emitted photons travel 
towards the detector, which is a photomultiplier, and strike the photocathode. Electrons are 
ejected from the surface of the photocathode, multiplied and finally generate an electrical 
signal, which is expressed as relative light units (RLUs). These RLUs are inversely correlated 
to the amount of vancomycin present in the sample. 
The main benefit of this method is that sample preparation is not required. Hence, an 
autosampler vial can directly be filled with serum or plasma, making this method suitable for 
high-throughput routine analyses. Free vancomycin analysis, however, involves the separation 




























Table 2-1 Summary of used liquid chromatography settings for the analysis of protein-bound uremic toxins and teicoplanin. 
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pCG: p-cresyl glucuronide; HA: hippuric acid; IAA: indole-3-acetic acid; IS: indoxyl sulfate; pCS: p-cresyl sulfate;  





Table 2-2 Summary of used UV and FLD settings for the analysis of protein-bound uremic toxins and teicoplanin. 
Analytes Lab Instrument Detector 


















λex: 280, λem: 340 













λex: 265, λem: 290 



















λex: 280, λem: 350 
λex: 280, λem: 376 
λex: 264, λem: 290 
 HA: hippuric acid; IAA: indole-3-acetic acid; IS: indoxyl sulfate; pCS: p-cresyl sulfate; (U)HPLC: (ultra-)high performance liquid chromatography;  
UV: ultraviolet; FLD: fluorescence detection. 
 
 
Table 2-3 Summary of used mass spectrometry settings for the analysis of protein-bound uremic toxins and teicoplanin.  
Analytes Lab Instrument Ionization Tandem MS Orbitrap 

































A2-2 & A2-3 




















HA: hippuric acid; IAA: indole-3-acetic acid; IS: indoxyl sulfate; pCS: p-cresyl sulfate; UHPLC: ultra-high performance liquid chromatography; MS/MS: tandem mass 
spectrometry; HRMS: high resolution mass spectrometry; HESI + or -: heated electrospray ionization positive or negative mode, respectively;  
underlined ion m/z values are for total teicoplanin analysis whereas the sum of five ion m/z values was made for free teicoplanin analysis. 
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Development and optimization of analytical methods for the 
quantification of protein-bound uremic toxins and antibiotics 
3.1 Introduction 
Prior to analysis, serum and plasma samples need to be pretreated and an important step in this 
sample preparation is the separation of the free fraction. Equilibrium dialysis (ED) and 
ultrafiltration (UF) are the two most commonly used methods for this purpose. During ED and 
UF there are experimental parameters possibly affecting the percentage protein binding (%PB) 
of protein-bound uremic toxins (PBUTs).  
In addition to previously validated methods for PBUT quantification, a new analytical method 
was developed and validated to quantify the total and free concentration of the antibiotic 
teicoplanin by ultra-high performance liquid chromatography – high resolution mass 
spectrometry (UHPLC-HRMS). 
In this chapter, the possible effect of non-specific adsorption (NSA) of PBUTs to ED and UF 
membranes is discussed as well as the comparison of ED and UF to measure free PBUT 
concentrations. Furthermore, the possible effect of sample temperature, pH and matrix on the 
%PB of PBUTs is described. In a last section, the development and validation (including NSA 
testing and ED/UF comparison) of the analytical method to quantify total and free teicoplanin 




3.2 Non-specific adsorption of protein-bound uremic toxins to equilibrium 
dialysis or ultrafiltration membranes 
 Introduction 
In both ED and UF, a semi-permeable membrane is used to separate the free from the 
protein-bound fraction in serum and plasma samples. Typically, these membranes are made of 
regenerated cellulose and have a specific molecular weight cut-off (MWCO) ranging from 
3.5 kDa to 100 kDa [1]. Analytes of interest may, however, be adsorbed to these membranes 
and can consequently lead to an underestimation of the free analyte fraction, and thus an 
overestimation of the %PB [2,3]. The influence of this NSA to ED and UF membranes on the 
%PB is even more pronounced for highly protein-bound analytes.  
Therefore, the extent of NSA to ED and UF membranes should be studied prior to use the 
particular ED or UF method. When NSA is present, either a mathematical correction can be 
used or calibration standards can be dialyzed or filtered, together with the unknown samples. 
A small experiment was conducted to check whether the studied PBUTs show NSA to the ED 
and UF membranes used during this thesis. 
 Materials and methods 
3.2.2.1 Chemicals 
Hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and phosphate buffered 
saline (PBS) tablets were purchased from Sigma-Aldrich (St. Louis, MO, USA) and p-cresyl 
sulfate (pCS) was obtained from TCI Chemicals (Zwijndrecht, Belgium). Water (HPLC grade) 
was purchased from Acros Organics (Thermo Scientific, Geel, Belgium). The chemical 
structures of HA, IAA, IS and pCS are presented in Figure 3-1. 
Figure 3-1 Chemical structures of the measured protein-bound uremic toxins. 
 
Hippuric Acid Indole-3-Acetic Acid Indoxyl Sulfate p-Cresyl Sulfate




3.2.2.2 Equilibrium dialysis and ultrafiltration 
Equilibrium dialysis (n = 3). An HTDialysis 96b system (HTDialysis, Connecticut, USA) 
system was used. The dialysis membranes, consisting of regenerated cellulose with a MWCO 
of 12-14 kDa, were used according to the manufacturer’s guidelines. A mixed stock solution 
with theoretical concentrations of 14 (HA), 1.4 (IAA), 5.2 (IS) and 7 (pCS) mg/L was prepared 
in PBS buffer and 150 µL was transferred into an ED chamber. The stock solution was dialyzed 
against PBS buffer (150 µL, pH = 7.4) for 5 h at room temperature (RT) on a reciprocating 
shaker. The wells were sealed with an adhesive film until equilibrium between the two 
chambers was established, i.e. after 5 h (determined in a pilot experiment, data not shown). 
Subsequently, the mixture of 4 PBUTs was removed from each chamber and transferred into 
1.5 mL Eppendorf tubes (Eppendorf, Hamburg, Germany).  
Ultrafiltration (n = 3). Two different UF devices were used, i.e. Amicon Ultra 0.5 mL 
Centrifugal filters and Centrifree Ultrafiltration filters (Merck, Darmstadt, Germany). The 
membranes of these filters consisted of regenerated cellulose, having a MWCO of 30 kDa. A 
mixed stock solution with theoretical concentrations of 7 (HA), 0.7 (IAA), 2.6 (IS) and 
3.5 (pCS) mg/L was prepared in PBS buffer and 260 and 150 µL were transferred into the 
Amicon and Centrifree filters, respectively. Subsequently, Amicon filters were spun at 4520 g 
during 20 min at RT whereas Centrifree filters were spun at 1885 g during 30 min at RT 
(Beckman Coulter X-15R), as based on Stove et al. [4]. Next, ultrafiltrate was transferred into 
1.5 mL Eppendorf tubes (Eppendorf, Hamburg, Germany). 
Control samples. For each stock solution, a control sample was analyzed without ED or UF to 
determine the NSA, by calculating the recovery after ED or UF. These stock solutions were 
prepared accordingly in order to exclude possible differences due to sample preparation. 
Finally, 100 µL of each sample (i.e. plasma, buffer and ultrafiltrate samples) was treated in the 
same way. First, the sample was diluted with 260 µL HPLC water, heated at 95 °C (30 min) to 
precipitate the proteins, cooled down on ice (10 min) and centrifuged (7379g, 10 min) [5]. 
 Results and discussion 
The recovery of IAA, IS and pCS were in the range of 99.9 – 104.7 % in ED experiments. A 




± 15 % is accepted in validation guidelines [6,7]. In UF experiments, the recovery of all 4 
PBUTs was in the range of 100.9 – 104.1 % for both types of filters (Table 3-1). 
Table 3-1 Recovery (%) of 4 protein-bound uremic toxins [hippuric acid (HA), indole-3-acetic acid (IAA), 
indoxyl sulfate (IS) and p-cresyl sulfate (pCS)] as determined in a stock solution after equilibrium dialysis 
(ED) and ultrafiltration (UF), using two different UF filters. 
 ED UF (Amicon) UF (Centrifree) 
HA 88.5 ± 4.7 100.9 ± 3.9 104.1 ± 4.3 
IAA 99.9 ± 5.8 103.3 ± 6.4 103.8 ± 2.0 
IS 100.8 ± 5.8 102.4 ± 6.3 103.0 ± 2.1 
pCS 104.7 ± 6.0 101.5 ± 6.1 103.0 ± 1.9 
Values are expressed as mean ± standard deviation. 
 Conclusion 
From this experiment, it was concluded that the investigated PBUTs show no NSA to the used 
ED and UF membranes.  




3.3 Comparison of equilibrium dialysis and ultrafiltration to obtain free 
protein-bound uremic toxin concentrations 
 Introduction 
ED is often regarded as the reference method to obtain free fractions of a protein-bound analyte. 
A major drawback, however, is the time needed for equilibration, i.e. 5 – 6 hours for small 
compounds or even 24 hours for large compounds. Because of its shorter analysis time, which 
is typically 20 – 30 min, UF has gained more interest [2,3,8]. 
Different UF settings, such as centrifugation time and g-force, can affect the %PB of an analyte 
and final settings should be chosen in such a way that obtained free concentrations (and thus 
%PB) are comparable to those obtained by ED [9]. 
In this thesis, both ED and UF were used to determine free PBUT concentrations. Therefore, a 
small experiment was conducted on the comparison of both methods to obtain free PBUT 
concentrations. 
 Materials and methods 
3.3.2.1 Sample Collection 
Pre-dialysis blood samples from hemodialysis patients (n = 6) were collected in Vacutainer 
K2EDTA tubes (Becton Dickinson Company, New Jersey, USA). Subsequently, blood was 
centrifuged for 10 min at 2095g at RT (Beckman Coulter X-15R centrifuge - VWR, Leuven, 
Belgium) and the obtained plasma was stored  at -80 °C. 
This experiment was conducted according to the Declarations of Helsinki, was approved by the 
Ethical Committee of Ghent University Hospital (2017/0162) and all participants gave their 
written informed consent. 
3.3.2.2 Chemicals 
PBS tablets were purchased from Sigma-Aldrich (St. Louis, MO, USA) and water (HPLC 




3.3.2.3 Equilibrium dialysis and ultrafiltration 
Equilibrium dialysis (n = 6). An HTDialysis 96b system (HTDialysis, Connecticut, USA) 
system was used. The dialysis membranes, consisting of regenerated cellulose with a MWCO 
of 12-14 kDa, were used according to the manufacturer’s guidelines. Plasma samples (150 µL) 
were dialyzed against PBS buffer (150 µL, pH = 7.4) for 5 h at 37 °C on a reciprocating shaker. 
Subsequently, the plasma and PBS samples from each chamber were transferred into 1.5 mL 
Eppendorf tubes (Eppendorf, Hamburg, Germany). Total PBUT concentrations were measured 
in native plasma samples, whereas free concentrations were determined by multiplying free 
fractions and total concentrations. As described in 2.2.2 Sample preparation, these free fractions 
were calculated from the concentrations measured in the samples at both sides of the ED 
membrane. 
Ultrafiltration (n = 6). Amicon Ultra 0.5 mL Centrifugal filters (Merck, Darmstadt, Germany) 
with a membrane MWCO of 30 kDa were filled with plasma (260 µL) and spun at 4520 g 
during 20 min at 37 °C. Subsequently, ultrafiltrate was transferred into 1.5 mL Eppendorf tubes 
(Eppendorf, Hamburg, Germany). Total and free concentrations were measured in the native 
plasma and the ultrafiltrate, respectively. 
Finally, 100 µL of each sample (i.e. plasma, buffer and ultrafiltrate samples) was treated in the 
same way. First, the sample was diluted with 260 µL HPLC water, heated at 95 °C (30 min) to 
precipitate the proteins, cooled down on ice (10 min) and centrifuged (7379g, 10 min) [5]. 
3.3.2.4 Calculations 
The %PB was calculated from the measured free (CF) and total (CT) concentration:  
%PB = (1 - 
CF
CT
)  x 100 %     (Eq. 3-1) 
Statistical evaluation was performed with GraphPad Prism 4.00 for Windows (GraphPad 
Software, La Jolla, California USA). Data were checked for normality by a Shapiro-Wilk test 
and Wilcoxon signed-rank tests were used to compare the CF and %PB as obtained by ED and 
UF. P < 0.05 was considered significant. 




 Results and discussion 
Total PBUT concentrations measured in the native plasma samples, free PBUT concentrations 
determined after separation by ED and UF as well as the calculated %PB are tabulated in Table 
3-2. The total PBUT concentrations reflect the large inter-patient variability, especially for HA. 
For all PBUTs, the free concentrations obtained by ED and UF were comparable, resulting in 
comparable %PB values between ED and UF. 
Table 3-2 Total (CT) and free (CF) concentrations as well as the percentage protein binding (%PB) of 4 
protein-bound uremic toxins [hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and 
p-cresyl sulfate (pCS)] as determined in plasma from 6 hemodialysis patients either immediately (CT) or 
after equilibrium dialysis (ED) and ultrafiltration (UF) for CF. 
 CT (mg/dL) CF (mg/dL) %PB (%) 
  ED UF ED UF 
HA 3.23[2.55;5.20] 1.47[1.24;2.57] 1.38[1.07;2.76] 53.3[48.6;51.5] 54.2[50.2;55.5] 
IAA 0.16[0.15;0.19] 0.041[0.037;0.044] 0.044[0.040;0.055] 75.6[71.9;78.5] 74.1[72.8;75.5] 
IS 1.86[0.96;2.44] 0.13[0.09;0.24] 0.09[0.05;0.17] 90.6[88.8;91.4] 93.7[93.3;94.5] 
pCS 3.00[1.91;4.18] 0.26[0.14;0.33] 0.25[0.18;0.36] 92.5[89.2;93.4] 93.4[87.8;94.0] 
Values are expressed as median [25th percentile (pct); 75th pct]; For IS n = 5 due to a visual outlier. 
 Conclusion 
From this experiment, it was concluded that both ED and UF, at the tested settings, gave 




3.4 Effect of sample temperature, pH and matrix on the percentage protein 
binding of protein-bound uremic toxins 
Based on: Deltombe O, Dhondt A, Van Biesen W, Glorieux G, Eloot S (2017) Effect of sample temperature, pH, 
and matrix on the percentage protein binding of protein-bound uraemic toxins. Anal Methods 9:1935–1940. doi: 
10.1039/C7AY00054E. 
 Abstract 
While studying and trying to optimize dialysis clearances of protein-bound uremic toxins 
(PBUTs), the percentage protein binding (%PB) might be an important parameter and can be 
calculated from measured free and total concentrations. Since different parameters may alter 
this %PB, we investigated whether the ultrafiltration temperature, sample pH and sample matrix 
(i.e. serum or plasma) affect the %PB of PBUTs. Pre-dialysis serum and plasma samples were 
obtained from 10 stable hemodialysis patients. Ultrafiltration was performed at 37 °C for fresh 
samples and at 4 °C, room temperature and 37 °C for thawed samples and sample pH was 
determined (all n = 10). Total and free serum/plasma concentrations of hippuric acid, indole-3-
acetic acid, indoxyl sulfate and p-cresyl sulfate were simultaneously measured by 
high-performance liquid chromatography with ultraviolet and fluorescence detection. No 
differences in %PB were found between fresh and thawed samples at 37 °C or between serum 
and plasma samples prepared at the same temperature despite a difference in pH. However, in 
both serum and plasma samples, the free concentration increased with increasing ultrafiltration 
temperatures and resulted in a decrease in %PB from 4 °C to 37 °C. In conclusion, the %PB of 
PBUTs can be determined in both thawed serum and plasma samples and ultrafiltration should 
be performed at 37 °C. 
 Introduction 
A myriad of compounds are retained in patients suffering from chronic kidney disease (CKD). 
Amongst these compounds, some interact negatively with biological functions and are called 
uremic toxins. Based on their physico-chemical properties, three classes of uremic toxins can 
be distinguished: (i) the free small water-soluble compounds [molecular weight 
(MW) < 500 Da], (ii) the middle molecules (MW > 500 Da) and (iii) the protein-bound solutes 
[10,11]. Many of these protein-bound solutes contribute to the increased inflammation and 
cardiovascular morbidity and mortality in CKD patients [12–19]. Furthermore, the removal of 




these protein-bound uremic toxins (PBUTs) is hampered during dialysis, especially for those 
uremic toxins with high protein binding, e.g. indoxyl sulfate or p-cresyl sulfate [20–22]. Due to 
the importance of their toxic effects and the hampered removal during dialysis, research on 
these PBUTs is timely and relevant. 
Recently, Arund et al. developed a method for the online measurement of fluorophores, like 
tryptophan and indoxyl sulfate, in spent dialysate during hemodialysis by coupling a 
spectrofluorometer to the drain outlet of the dialysis machine [23]. Besides this indirect method, 
no other methods are currently available to analyze uremic toxins and the percentage of protein 
binding (%PB) in-vivo. In order to measure these toxin concentrations, blood sampling is 
required; serum or plasma tubes are most often centrifuged and aliquots of the supernatant are 
usually stored at -80 °C until batch analysis. Over the years, several methods have been 
developed to analyze PBUTs, including gas and liquid chromatography, either using an 
ultraviolet, fluorescence or mass spectrometer as detector [24–28]. Since no techniques are 
currently available to directly estimate the %PB, an extra step during sample preparation needs 
to be introduced. In this step, equilibrium dialysis (ED) or ultrafiltration (UF) is used to separate 
the free and the protein-bound fractions. The %PB can then be calculated from the measured 
free and total concentrations.  
The binding of solutes to proteins is considered to be a dynamic equilibrium between the free 
and bound fractions, and is reported to vary from 10 % (e.g. p-cresyl glucuronide) to nearly 
100 % (e.g. p-cresyl sulfate) for PBUTs. This equilibrium is known to be influenced by the pH 
of the serum or plasma samples and has been studied for a large number of drugs [3,9,29,30]. 
An increase in pH is caused by diffusion of CO2 out of the serum or plasma and may occur 
when these samples are unsealed or undergo one or multiple freeze/thaw cycles [31].  
The percentage of protein binding is also influenced by the temperature. Consequently, 
temperature control might be important during the processing of samples by UF (duration 
20-30 min) or even more in ED (duration 4-6 h) to avoid bias. In previous studies, several 
temperature conditions during ED or UF have been compared for various drug compounds, and 
37 °C is typically selected as a standard since it best reflects the physiological condition 
[3,4,9,32]. 
Parameters that may alter the %PB of PBUTs should be known when studying these solutes. 
However, to the best of our knowledge, only a few studies to date investigated whether pH and 




influence on the %PB of PBUTs [33–35], and whether these findings can also be extrapolated 
to uremic patients, as it can be postulated that there is a different interaction with uremic 
proteins. Therefore, in this study, we compared the following in samples of uremic patients: 
(i) the impact of pH on %PB in fresh and thawed serum and plasma samples; (ii) the %PB when 
UF was performed at 37 °C, room temperature (RT) and 4 °C; and (iii) the pH and %PB between 
serum and plasma samples, prepared at the same temperatures. 
 Materials and methods 
3.4.3.1 Sample collection and preparation 
Blood samples were collected from 10 stable hemodialysis patients in Venosafe serum (Terumo 
Europe, Leuven, Belgium) or Vacutainer K2EDTA (Becton Dickinson Company, New Jersey, 
USA) tubes. Serum tubes were allowed to clot, whereas plasma tubes were put on ice 
immediately after collection. These tubes were centrifuged (2095g, 10 min) and aliquots of 
500 µL were immediately used or frozen at -80 °C until further sample preparation. This study 
was performed according to the Declarations of Helsinki, approved by the Ethical Committee 
of Ghent University Hospital (EC 2015/0932) and all patients gave their written informed 
consent. 
The effect of pH, temperature and sample matrix (i.e. serum or plasma) on the %PB of PBUTs 
was investigated using the following protocol. Immediately after collection (fresh 37 °C) or 
thawing (37 °C, RT or 4 °C) at 4 °C, serum (n = 10)/plasma (n = 10) samples and Amicon Ultra 
0.5 mL Filters (molecular weight cut-off 30 kDa, Merck KGaA, Darmstadt, Germany) were 
both adjusted to the right temperature for 30 min at either 37 °C, RT or 4 °C, followed by pH 
measurement of each sample with a WTW pH 330 instrument (Weilheim, Germany). 
Subsequently, 260 µL of sample was filtered (4520 g, 20 min) through the Amicon filters at 
either 37 °C, RT or 4 °C. The ultrafiltrate (100 µL) containing the free fraction was further 
diluted with 260 µL HPLC water and heated at 95 °C during 30 min, cooled down on ice 
(10 min) and centrifuged (15588 g, 10 min). In this way, all steps were equal to those for total 
toxin concentration determination. 
Untreated serum/plasma samples (100 µL) were first diluted with 260 µL HPLC water, 
followed by a protein denaturation step (95 °C, 30 min) to determine the total concentration. 




After heating, the samples were cooled down on ice for 10 min. Subsequently, the samples were 
centrifuged (15588 g, 10 min) and filtered (4520 g, 20 min) through the Amicon filters.  
Finally, each sample (225 µL) was transferred into an autosampler vial and frozen at -80 °C 
until batch analysis. Prior to analysis, the samples were thawed, 25 µL of internal standard 
(fluorescein, 50 mg/L) was added in order to correct for instrument performance variations and 
the mixture was vortexed. All samples were kept at 4 °C in the autosampler and 18 µL was 
injected onto the column. 
3.4.3.2 Chemicals 
Hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and fluorescein were 
purchased from Sigma-Aldrich (St. Louis, MO, USA) and p-cresyl sulfate (pCS) from TCI 
Chemicals (Zwijndrecht, Belgium). Water and methanol, both HPLC grade, were purchased 
from Acros Organics (Thermo Scientific, Geel, Belgium), formic acid from VWR (Leuven, 
Belgium), and ammonia from Merck (Merck KGaA, Darmstadt, Germany). The chemical 
structures of HA, IAA, IS and pCS are presented in Figure 3-1. 
3.4.3.3 Calibration standards 
Stock solutions (100 mg/dL) of all compounds were prepared in HPLC water and kept at -80 °C. 
Seven calibration standards were prepared by spiking 100 µL blank serum with 100 µL stock 
solution and 160 µL HPLC water, followed by the sample preparation for total concentration. 
Blank serum was obtained as described by de Loor et al. [28].  
3.4.3.4 Instrumentation 
Concentrations of PBUTs were determined on an ultra-high performance liquid 
chromatography instrument with ultraviolet and fluorescence detection (UPLC-UV/FLD). An 
Agilent 1290 Infinity device was used and chromatographic separation was performed at 26 °C 
on a Waters Acquity UPLC BEH C18 column (1.7 µm, 2.1 x 100 mm) with a Waters Acquity 
UPLC BEH C18 Van Guard column (1.7 µm, 2.1 x 5 mm). A linear gradient elution was used 
to separate the compounds at a flow rate of 0.3 mL/min, and started at 98 % ammonium formate 
buffer (50 mM, pH 3, mobile phase A), followed by a composition change of 90 % A in 7 min. 




held for 3 min. Finally, a re-equilibration step was performed. HA was detected with an Agilent 
G4212A diode array detector at 245 nm. IS (λex: 280 nm, λem: 376 nm), pCS (λex: 264 nm, 
λem: 290 nm), IAA (λex: 280 nm, λem: 350 nm) and fluorescein (λex: 443 nm, λem: 512 nm) were 
detected by an Agilent G1316C fluorescence detector. A representative chromatogram for total 
concentration of HA (top), IAA, IS, and pCS (bottom) in a serum sample prepared at 37 °C is 
depicted in Figure 3-2. 
The within-run and between-run precisions were determined by using an EDTA uremic plasma 
pool. From this pool, 6 samples were individually prepared and analyzed in a single run 
(i.e. within-run, n = 6) as well as in different runs performed on 3 different days 
(i.e. between run, n = 6). Subsequently, the relative standard deviation on the measured 
concentration was calculated, resulting in a within-run and between-run precision of 1.99 % 
and 3.24 % for HA, 2.56 % and 6.34 % for IAA, 2.58 % and 4.84 % for IS, and 2.52 % and 
5.95 % for pCS respectively. 
Figure 3-2 Representative chromatogram for total concentration of hippuric acid (HA, top, UV detection) 
and indoxyl sulfate (IS), p-cresyl sulfate (pCS) and indole-3-acetic acid (IAA) (bottom, fluorescence 
detection) in a serum sample prepared at 37 °C. 
 
Int. Std.: internal standard. 
3.4.3.5 Calculations 
The %PB was calculated from the measured free (CF) and total (CT) concentration:  
%PB = (1 - 
CF
CT
)  x 100 %     (Eq. 3-1) 
Statistical evaluation was performed with GraphPad Prism 4.00 for Windows (GraphPad 






















Kolmogorov Smirnov test and paired t-tests were used to compare the concentrations (both total 
and free), pH and %PB between each group. P < 0.05 was considered significant. 
 Results 
The total and free concentrations of the measured PBUTs are presented in Table 3-3 and Table 
3-4, respectively. Serum and plasma samples prepared at different temperatures, as well as 
serum and plasma samples prepared at the same temperature, were compared. For IS, a small 
decrease in total concentration was observed when prepared at 4 °C, compared to the total 
concentrations when prepared at RT and 37 °C. No differences in total PBUT concentrations 
were found between the other temperatures and between the different sample matrices at the 
same temperature. The free concentrations of HA, IAA and IS slightly decreased from 37 °C to 
RT and were found to be the lowest at 4 °C. 
Table 3-3 Total concentration (mg/dL) of four protein-bound uremic toxins in serum and plasma: 
hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS); freshly 
prepared (fresh 37 °C) or after 1 freeze/thaw cycle (37 °C, RT and 4 °C). 





1.76 ± 1.48 
1.72 ± 1.51 
1.71 ± 1.54 
1.68 ± 1.38 
1.67 ± 1.45 
1.65 ± 1.42 
1.74 ± 1.57 





0.25 ± 0.23 
0.23 ± 0.23 
0.23 ± 0.24 
0.23 ± 0.21 
0.23 ± 0.22 
0.21 ± 0.20 
0.21 ± 0.21 





1.22 ± 0.51 
1.13 ± 0.45 
1.14 ± 0.46 
1.13 ± 0.48 
1.12 ± 0.44 
1.07 ± 0.45 
0.96 ± 0.41a,b,c 





3.44 ± 1.85 
3.25 ± 1.64 
3.12 ± 1.36 
3.23 ± 1.71 
3.12 ± 1.48 
3.02 ± 1.39 
2.92 ± 1.30a 
2.91 ± 1.37 
 a p < 0.05 versus fresh 37 °C. b p < 0.05 versus 37 °C. c p < 0.05 versus RT.  
Values are expressed as mean ± standard deviation. 
Table 3-4 Free concentration (mg/dL) of four protein-bound uremic toxins in serum and plasma: hippuric 
acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS); freshly prepared 
(fresh 37 °C) or after 1 freeze/thaw cycle (37 °C, RT and 4 °C). 





1.15 ± 1.02 
1.04 ± 1.00 
1.07 ± 1.01 
1.01 ± 0.97 
1.00 ± 0.93a,b 
1.04 ± 1.06 
0.89 ± 0.86a,b,c 





0.08 ± 0.09 
0.08 ± 0.09 
0.08 ± 0.09 
0.08 ± 0.08 
0.07 ± 0.08a 
0.08 ± 0.08 
0.06 ± 0.06a 





0.13 ± 0.09 
0.11 ± 0.07 
0.13 ± 0.09 
0.11 ± 0.07 
0.09 ± 0.07a,b 
0.08 ± 0.06a,b 
0.05 ± 0.04a,b,c 





0.31 ± 0.20 
0.28 ± 0.17 
0.36 ± 0.25 
0.26 ± 0.14 
0.25 ± 0.14 
0.26 ± 0.16 
0.24 ± 0.22a 
0.20 ± 0.18b 
a p < 0.05 versus fresh 37 °C. b p < 0.05 versus 37 °C. c p < 0.05 versus RT. 
Values are expressed as mean ± standard deviation. 
The effect of sample matrix and preparation temperature on the sample pH is illustrated in 




pH (7.35-7.45) compared to the pH of the serum samples. The lowest and most physiologic pH 
was observed in the plasma samples prepared at 37 °C. A small decrease in pH was found in 
thawed samples (37 °C) as compared to fresh samples (fresh 37 °C) in both serum (borderline 
significant with p = 0.059) and plasma (p < 0.001) samples. 
Figure 3-3 Measured pH of serum and plasma samples, prepared fresh (fresh 37 °C) or  
after 1 freeze/thaw cycle (37 °C, RT, and 4 °C).  
 
* p < 0.001, (*) p = 0.059. 
Table 3-5 summarizes the observed %PB of the four PBUTs in serum and plasma samples, 
when prepared freshly (fresh 37 °C) or after one freeze/thaw cycle (37 °C, RT and 4 °C). The 
increase in %PB with decreasing sample preparation temperature was more pronounced in the 
serum samples, especially for HA, IS, and pCS, while in the plasma samples this increase in 
%PB was only significant for HA and IS at 4 °C. 
Table 3-5 Percentage protein binding (%PB) of four protein-bound uremic toxins in serum and plasma: 
hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS); freshly 
prepared (fresh 37 °C) or after 1 freeze/thaw cycle (37 °C, RT and 4 °C). 





39.4 ± 9.7 
45.5 ± 7.2 
42.2 ± 7.2 
46.3 ± 11.2 
45.3 ± 6.2a,b 
45.3 ± 10.5 
49.4 ± 13.8a,b,c 





63.7 ± 13.5 
64.6 ± 11.9 
63.5 ± 11.6 
64.9 ± 13.0 
66.3 ± 10.1b 
64.2 ± 14.1 
70.1 ± 11.1 





88.7 ± 6.3 
89.9 ± 5.5 
88.0 ± 6.4 
89.7 ± 6.0 
91.2 ± 4.7a,b 
92.0 ± 4.5a,b 
95.0 ± 3.0a,b,c 





90.5 ± 4.1 
91.2 ± 3.4 
89.2 ± 4.2 
91.3 ± 3.7 
91.6 ± 3.4a,b 
91.4 ± 3.8 
92.3 ± 4.3b 
93.6 ± 3.7 
a p < 0.05 versus fresh 37 °C. b p < 0.05 versus 37 °C. c p < 0.05 versus RT. 
Values are expressed as mean ± standard deviation. 





















































































































































No significant differences in %PB were found in serum or plasma samples when prepared fresh 
(fresh 37 °C) or thawed (37 °C); similarly, the %PB between serum and plasma samples 
prepared at the same temperature did not differ significantly (Table 3-5). 
 Discussion 
Establishing the correct %PB of PBUTs is important: (i) to be able to estimate the biological 
activity of uremic toxins, since the free fraction is considered to be the biologically active one 
and (ii) in view of their removal during dialysis, because the removal is hampered by the protein 
binding. Therefore, it is interesting to know to what extent parameters known to influence the 
%PB of various drug compounds also affect the %PB of PBUTs during sample preparation. To 
the best of our knowledge, the present study is the first to present the effect of pH, temperature 
and matrix on the determination of total and free concentrations of PBUTs including HA, IAA, 
IS and pCS. In literature, the use of a variety of sample preparation temperatures (i.e. 4 °C, 
25 °C, RT and 37 °C) can be found [20,26,35]. Furthermore, the matrix in which the 
protein-bound uremic toxins are determined differs from the method used [24–28]. Therefore, 
this work focused on parameters that, in the field of protein-bound drugs, are known to have an 
influence on the %PB [3,4,9,29,30,32,36].  
The present study reveals that total concentrations in serum and plasma did not differ, except 
for IS at 4 °C, where a significantly lower concentration was observed. Although we have no 
explanation for this observation, we suggest that this is only specific for IS at 4 °C, since the 
total concentration did not decrease for HA, IAA and pCS at 4 °C.  
The  small, but significant difference in pH between the freshly prepared (fresh 37 °C) and 
thawed samples at 37 °C did not affect the %PB. Consequently, serum or plasma samples can 
be frozen and thawed for at least once, without a change in %PB. This is an important 
observation, since most research groups store their samples at -80 °C to perform batch analysis 
to avoid the introduction of bias caused by differences between batches. 
Notwithstanding the larger difference in pH between serum and plasma samples, no differences 
in %PB were observed. This implicates that both serum and plasma samples can be used to 
determine the %PB for these compounds. Sakai et al. reported that even larger differences in 
pH (i.e. 6.5, 7.4 and 8.5 at 25 °C) have only a slight effect on the binding affinity constant (and 
thus the %PB) for IS to human serum albumin (HSA) in solution [34]. For IAA, Bertuzzi et al. 




[33]. Except for pH 7.4, the pH conditions described by Sakai et al. and Bertuzzi et al. are 
physiologically irrelevant and are too extreme. In the present work, pH 8.5 was never reached 
because at least one factor that affects the pH, i.e. exposure to the air, was minimized by keeping 
the tubes sealed. Additionally, it was shown that the %PB was not influenced in the range of 
pH 7.4 – 8.0. 
The free concentration increased with increasing ultrafiltration temperatures (Table 3-4), 
resulting in a lower %PB at 37 °C. This is in accordance with Viaene et al. for IS and pCS [35], 
although the %PB of pCS was not found to be significantly decreased in our work. For IAA, 
no decrease in %PB was found with increasing temperatures. However, 37 °C should be the 
temperature of choice when analyzing PBUTs in general because this best reflects the 
physiological condition. Nevertheless, the difference in %PB at RT and 37 °C was rather small, 
and performance of UF at RT when no temperature-controlled centrifuge is available might be 
justifiable. 
The chromatographic method used in this study does not allow to correct for variations during 
the sample preparation step. The internal standard used (fluorescein) was added just before the 
chromatographic analysis, because the molecule binds to proteins and adsorbs to the Amicon 
filters (data not shown). Ideally, each analyte should have an internal standard to correct for 
and the standard should be added at the start of the sample preparation. If the lower total IS 
concentration at 4 °C was caused by loss of IS during the sample preparation, this could possibly 
be corrected by addition of an internal standard at the start. To date, no alternative internal 
standard for the current method is available. However, both the total concentration range and 
%PB measured by our method are in line with values found in literature, in which deuterated 
internal standards for HA, IAA, IS and pCS were added at the start of the sample preparation 
and samples were analyzed with mass spectrometry [26,28]. 
 Conclusion 
In this study, we investigated whether the pH, temperature, or the type of sample matrix affects 
the determination of total and free concentrations, and thus the %PB, of four PBUTs including 
HA IAA, IS and pCS. Our findings revealed that the %PB of PBUTs can be determined in both 
thawed serum and plasma samples, but UF should be performed at 37 °C. 
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3.5 Development and validation of an UHPLC – high resolution 
MS method for the quantification of total and free teicoplanin 
in human plasma  
In preparation: Deltombe O, Mertens T, Eloot S and Verstraete A G, Development and validation of an UHPLC – 
high resolution MS method for the quantification of total and free teicoplanin in human plasma. 
 Abstract 
The antibiotic teicoplanin, used for the treatment of infections caused by Gram-positive 
bacteria, is highly bound to plasma proteins (percentage protein binding, %PB, around 90 %) 
and therapeutic plasma levels of total teicoplanin are 10 – 100 mg/L. Because of the low free 
concentrations (i.e. < 1 – 10 mg/L), current immunoassays are not able to quantify free 
teicoplanin concentrations, although it might be more relevant in therapeutic drug monitoring 
than total concentrations. 
In this study, an ultra-high performance liquid chromatography – high resolution mass 
spectrometry (UHPLC-HRMS) method for the quantification of total and free teicoplanin in 
K2EDTA plasma samples was developed and validated. Furthermore, %PB obtained by 
ultrafiltration was compared with that obtained by equilibrium dialysis using spiked samples 
from healthy subjects. 
Analytes were separated using a phenylhexyl column, gradient mobile phase analysis was used, 
total run time was 4.5 min and teicoplanin was detected by orbitrap MS. The precision and 
accuracy were below 15 % and within ± 15 %, respectively and teicoplanin was found to be 
stable for at least 14 days in plasma at 4 °C. The %PB of teicoplanin in spiked plasma from 
healthy subjects as obtained by ultrafiltration (94.1 ± 1.3 %) was in good agreement with that 
obtained by equilibrium dialysis (93.6 ± 0.4 %), whereas mean %PB of teicoplanin in samples 
from infected patient who received the antibiotic was 87.7 ± 4.2 % (range: 79.6 – 95.4 %). 
A novel highly sensitive UHPLC-HRMS method was developed and validated for the 
quantification of total and free teicoplanin in human K2EDTA plasma samples. Amongst others, 
this method is suitable for therapeutic drug monitoring. 





It is considered that only the free drug fraction is biologically active because only this fraction 
can travel through cell membranes, by e.g. passive diffusion, towards the site of action [37]. 
Alterations in free fractions can be of clinical relevance, especially for drug compounds with a 
high level of protein binding having a narrow therapeutic range or when drug resistance is 
possible. A change in percentage protein binding (%PB) from e.g. 95 % to 90 % implicates a 
doubling in free fraction and may have an impact on the pharmacokinetics (PK) and 
pharmacodynamics (PD) of that drug. Therefore, knowledge of the free drug concentrations 
may be more relevant than total concentrations to fully understand PK/PD as for instance with 
therapeutic drug monitoring (TDM) [38–40]. 
The most widely used methods to separate free fractions are equilibrium dialysis (ED) and 
ultrafiltration (UF) [2, 3, 8]. Although ED is considered to be the reference, its major drawback 
is the long equilibration time (i.e. equilibration of the free fraction between the serum/plasma 
and buffer chamber), which is 5 – 6 hours for small compounds or even 24 hours for large 
compounds. In addition, equilibration time also depends on the molecular weight cut-off of the 
membrane. Conversely, UF is a more rapid method and separates the free fraction in only 
20 – 30 min by centrifugation, which forces water and free drugs through the filter membrane. 
It should however be mentioned that both ED and UF sometimes suffer from non-specific 
adsorption (NSA) to the used membrane. In ED, this can be solved by measuring the 
concentration in both the buffer and serum/plasma chamber, whereas in UF, correction for NSA 
can be readily performed by filtering the calibration standards, together with the unknown 
samples.  
Besides vancomycin, the glycopeptide antibiotic teicoplanin can also be used for the treatment 
of infections caused by Gram-positive bacteria such as methicillin-resistant Staphylococcus 
aureus (MRSA) [41–44]. Teicoplanin is composed of a mixture of compounds which only 
differ in the alkyl side chain (see Figure 3-4), including 5 major (A2-1 to 5) compounds 
accounting for 90 – 95 % of the total product, a more polar compound (A3-1) and 4 minor 
(RS-1 to 4) compounds [41, 45] binds to plasma proteins, with a %PB reported to range from 
around 70 to 99 % [38, 46, 47] and is less toxic than vancomycin, particularly in terms of 
nephrotoxicity [48,49]. Therapeutic levels of total teicoplanin in plasma range from 10 to 
100 mg/L [50–52] and hence, theoretical free teicoplanin concentrations range from below 1 




concentrations to clinical outcome are limited and even absent for free teicoplanin [53,54]. 
Nevertheless, TDM is important to ensure its therapeutic effectiveness [47,52]. However, since 
the free drug fraction is responsible for therapeutic effects and the inter-patient variability is 
large [38, 39], free concentration monitoring might be more relevant than total concentration. 
Despite this theoretical importance of monitoring free teicoplanin concentrations, no clinical 
studies have confirmed this so far. 
Figure 3-4 Chemical structures of the 5 different major teicoplanin compounds, A2-1 to A2-5, and the 
more polar compound A3-1, which only differ in the alkyl side chain on the core group. 
 
Throughout the years, different analytical methods have been developed for the quantification 
of total teicoplanin in serum or plasma samples, including fluorescence polarization (FPIA) 
[46,55–57] and homogeneous particle-enhanced turbidimetric [58] immunoassays as well as 
high performance liquid chromatography techniques in which teicoplanin was quantified by 
ultraviolet detection [38] or mass spectrometry [59–61]. In the small number of papers 
discussing the quantification of free teicoplanin, there was no evidence for the accuracy of the 
obtained free fractions (e.g. by comparison with ED) or these free fractions were obtained at 
physiologically irrelevant temperatures (4 °C) [38,46,56]. 
Therefore, we developed and validated a sensitive method for the quantification of total and 
free teicoplanin in plasma samples by ultra-high performance liquid chromatography – high 




resolution mass spectrometry (UHPLC-HRMS). In our method, free fractions were obtained by 
UF at 37 °C and the used UF settings were compared with the reference method ED. 
 Materials and methods 
3.5.3.1 Chemicals 
Acetone, acetonitrile, methanol and formic acid (all LC-MS grade) were purchased from 
Biosolve BV (Valkenswaard, The Netherlands). Teicoplanin European pharmacopoeia 
reference standard (CRS 50), ammonium formate and trimipramine-D3 100 mg/L in methanol 
were obtained from Sigma Aldrich (Saint-Louis, MO, USA). The teicoplanin reference 
standard consisted of 5 major compounds (with different relative abundances), including 
teicoplanin A2-1 (6.2%), isomers A2-2 & A2-3 (67.5%) and isomers A2-4 & A2-5 (21.1%) as 
well as the more polar compound A3-1 (5.2%) (Figure 3-4). Ultrapure water (conductivity 
< 1 µS and filtered through a 45 µm filter) was used for all dilutions and prepared using an Elga 
Medica R7 instrument (Veolia water solutions & Technologies, Ede, The Netherlands). 
3.5.3.2 Sample Collection 
Blood samples from healthy subjects (n = 6) and infected patients (n = 41) to whom teicoplanin 
was administered were collected in K2EDTA and lithium heparin plasma tubes as well as in 
serum separating tubes (SST) (all Becton Dickinson Company, New Jersey, USA). 
Subsequently, blood was centrifuged for 10 min at 2095 g at room temperature (RT) (Beckman 
Coulter X-15R centrifuge - VWR, Leuven, Belgium) and the obtained plasma and serum was 
stored at -80 °C. The method described here was developed and validated using K2EDTA 
plasma only. Lithium heparin plasma and serum were only used to study the effect of blood 
tube type on the quantification of teicoplanin, for method comparison and to determine the %PB 
of teicoplanin in patient samples. 
This study was conducted according to the Declarations of Helsinki, was approved by the Ethics 
Committee of Ghent University Hospital (2017/0162 for healthy volunteers and 2015/004 for 




3.5.3.3 Teicoplanin standards 
A stock solution of teicoplanin European pharmacopoeia reference standard with a theoretical 
concentration of 1400 mg/L was prepared and used for both total and free teicoplanin analyses. 
A pool of K2EDTA plasma from healthy volunteers (i.e. blank plasma) was used to prepare 
calibration curves. 
For the determination of total teicoplanin, 8 calibrator stock solutions (10x the final 
concentration) were prepared and for each calibrator level, 100 µL was added to 900 µL blank 
plasma. For free teicoplanin, 7 calibrator stock solutions (10x solution of the final 
concentration) were prepared and 100 µL was added to 900 µL ultrafiltrate, which was obtained 
by ultrafiltration of blank plasma using Centrifree Ultrafiltration filters (Merck, Darmstadt, 
Germany; 30 min, 1885 g, RT – Beckman Coulter X-15R centrifuge). Subsequently, these 
calibrator levels in ultrafiltrate were filtered under the same conditions in order to account for 
NSA to the UF membrane (see further). 
For each calibrator level, aliquots of 50 µL were transferred into 1.5 mL Eppendorf tubes 
(Hamburg, Germany) and stored at -80 °C until analysis. 
3.5.3.4 Sample preparation 
The internal standard trimipramine-D3 (50 µL, 0.5 mg/L in acetone) was added to either 50 µL 
calibrator prepared in blank plasma (for calibration) or unknown plasma samples for total 
teicoplanin analysis or to 50 µL calibrator prepared in blank plasma ultrafiltrate (for calibration) 
or ultrafiltrate samples (obtained by Centrifree filters, 30 min, 1885 g, 37 °C – Beckman Coulter 
X-15R centrifuge) for free teicoplanin analysis, followed by thorough mixing. Subsequently, 
200 µL of a cold (4 °C) solution containing methanol and acetonitrile (50/50 v/v %) was added 
to precipitate the proteins and the samples were mixed again. After cooling down 
(30 min, -20 °C), each sample was mixed, placed in a Thermomixer for 5 min at 1400 rpm and 
at 10 °C (Eppendorf, Hamburg, Germany) and centrifuged (5 min, 16162 g, RT – Beckman 
Coulter Microfuge 16). Finally, 100 µL supernatant was transferred into an autosampler vial 
and placed in the autosampler at 10 °C.  




3.5.3.5 UHPLC-HRMS analysis 
The chromatographic system consisted of a Dionex Thermo Scientific UltiMate 3000 system 
(Waltham, Massachusetts, USA) equipped with a binary pump and autosampler with 
thermostat, which was set at 10 °C. The injection volume was 1 µL and 2 µL for total and free 
teicoplanin, respectively. Chromatographic separation was performed at 40 °C using an 
Accucore phenylhexyl column  (100 x 2.1 mm, 2.6 µm particle size) (Thermo Scientific, 
Waltham, Massachusetts, USA). A linear gradient elution was used at 0.4 mL/min and started 
at 75% of mobile phase A (2 mM ammonium formate and 0.1% formic acid in water) and 25% 
of mobile phase B (2 mM ammonium formate, 0.1% formic acid, and 1% water in 50/50 v/v% 
methanol/acetonitrile). Subsequently, the composition of the mobile phase was changed to 
80% B during the first 2.5 minutes and was maintained for one minute. Finally, a composition 
change to 90 % B was achieved in 0.25 min and maintained for 0.75 min, followed by 
re-equilibration of the column at 75 % A during 0.5 min. The total run time was 4.5 min. 
Analytes were detected using a Q-Exactive Hybrid quadrupole orbitrap mass spectrometer 
(Thermo Scientific, Waltham, Massachusetts, USA). Heated electrospray ionization was used 
in positive mode at a sheath gas (N2) flow of 45 (arbitrary units, a.u.), a temperature of 300 °C 
and a spray voltage of 3.5 kV. Auxiliary gas (N2) flow and temperature were 15 a.u. and 350 °C, 
respectively. Full scan analysis (m/z 200 – 2000) was applied for total teicoplanin whereas three 
scan segments were introduced (Table 3-6) for free teicoplanin to increase sensitivity. 
Automatic gain control (AGC) targets were 1 106 and 2 10
5 for total and free teicoplanin, 
respectively. For both teicoplanin analyses, the resolution was set at 70000. Possible shifts in 
the mass spectrum were corrected by lock mass at m/z 391.284. Teicoplanin compounds A2-2 
& A2-3 and teicoplanin compounds A2-4 & A2-5 are both pairs of isomers and were therefore 
detected simultaneously, whereas compounds A2-1 and A3-1 were detected separately, as 
summarized in Table 3-6. Teicoplanin compounds A2-1 to 5 and A3-1 were summed up for 
calibration as well as for unknowns. Minor compounds (RS1 – 4) were not included. Data 
acquisition and processing were performed using TraceFinder (Thermo Scientific, Waltham, 







Table 3-6 Retention times (tR) and instrument settings. For each teicoplanin compound, z = 2. 
 tR (min) m/z 1 m/z 2 m/z 3 m/z 4 m/z 5 
Scan segment 1: 0.0 – 1.4 min (m/z 780 – 788) 
A3-1 0.83 782.183 782.685 783.183 783.683 784.184 
Scan segment 1: 1.4 – 2.1 min (m/z 936 – 951) 
A2-1 1.72 938.778 939.280 939.779 940.280 940.780 
A2-2 & A2-3 1.72 939.786 940.287 940.786 941.286 941.786 
A2-4 & A2-5 1.87 946.793 947.295 947.794 948.295 948.794 
Scan segment 1: 2.1 – 4.5 min (m/z 290 – 300) 
Internal standard 2.35 298.236 n.a. n.a. n.a. n.a. 
m/z: mass-to-charge ratio; total teicoplanin: only underlined m/z values;  
free teicoplanin: scan segments and m/z 1 to 5; 
n.a.: not applicable. 
3.5.3.6 Equilibrium dialysis versus ultrafiltration 
Free fractions of spiked healthy plasma were obtained by both ED and UF. For ED, an 
HTDialysis 96b system (HTDialysis, Connecticut, USA) was used with membranes of 
regenerated cellulose (molecular weight cut-off of 12-14 kDa). These membranes were 
hydrated and used according to the manufacturer’s guidelines. Dialysis was performed against 
blank plasma ultrafiltrate during 24 h at 37 °C (equilibration time was determined in a pilot 
experiment, data not shown). An adhesive film was used to seal the ED wells to avoid water 
losses through evaporation and shifts in pH. 
Two different UF devices were checked for NSA, i.e. Amicon Ultra – 0.5 mL Centrifugal filters 
and Centrifree Ultrafiltration filters (both Merck, Darmstadt, Germany). Amicon filters were 
spun at 4520 g during 20 min at RT (based on [5]) whereas Centrifree filters were spun at 1885 g 
during 30 min at RT or 37 °C (Beckman Coulter X-15R), as previously described to obtain free 
vancomycin [4]. 
Non-specific adsorption of teicoplanin to both the ED device and membrane and to both UF 
membranes was checked by determining the recovery after ED or UF at RT, using calibrator 
level 6 for free teicoplanin quantification (i.e. 14 mg/L) which was prepared in blank plasma 
ultrafiltrate (all n = 3).  
Free (CF) teicoplanin concentrations in spiked plasma samples obtained by ED (37 °C) and UF 
(RT and 37 °C, Centrifree filters only) were compared. Additionally, the %PB was calculated 
from the measured total (CT) and CF concentrations: %PB = [1 – (CF/CT)] x 100%. For this 
experiment, blank plasma samples from 6 healthy volunteers were individually spiked with 
teicoplanin to reach final concentrations of either 7 (low), 70 (medium) or 140 (high) mg/L, 
with each level in duplicate. 




3.5.3.7 %PB in patient samples 
%PB of teicoplanin was also determined in anonymized left-over plasma (K2EDTA and lithium 
heparin) and serum samples (n = 41) from patients who received teicoplanin, which were 
collected in the core laboratory of Ghent University Hospital.  
3.5.3.8 Quality control samples 
In house quality control (QC) samples (low, medium and high concentration) were prepared in 
a pool of blank plasma (total teicoplanin) or in blank plasma ultrafiltrate (free teicoplanin). For 
total teicoplanin, theoretical concentrations were 7 mg/L (QCLT), 70 mg/L (QCMT) and 140 
mg/L (QCHT) whereas for free teicoplanin, theoretical concentrations were 0.93 mg/L (QCLF), 
5.6 mg/L (QCMF) and 12.6 mg/L (QCHF). 
3.5.3.9 Assay validation 
Both total and free teicoplanin assays were validated according to the European Medicines 
Agency (EMA) guidelines for selectivity, carry-over, limit of quantification (LOQ), calibration 
curves, accuracy (within-run and between-run), precision (within-run and between-run), matrix 
effect, storage and freeze/thaw stability [6]. 
Selectivity for both teicoplanin and internal standard was demonstrated by using 6 individual 
blank K2EDTA plasma samples and QC samples, respectively. For both selectivity validations, 
50 µL internal standard was replaced by 50 µL ultrapure water. In addition, selectivity was 
tested in patient samples collected in different blood tubes types, i.e. K2EDTA, lithium heparin 
and serum separating tubes (SST). Absence of interfering compounds was accepted when the 
response was < 20 % of LOQ for teicoplanin and < 5 % for the internal standard. 
For carry-over effects, six individual blank plasma samples were injected after the highest 
calibrator. Carry-over was assumed to be negligible when the response was < 20 % of LOQ for 
teicoplanin and < 5 % for the internal standard. 
The LOQ was considered to be the lowest calibration standard and was run 3 times. The LOQ 
was accepted if the response was at least 5 times the signal of a blank sample. 
Calibration curves were evaluated when prepared in blank plasma and blank plasma ultrafiltrate 




calibration curve was constructed for each teicoplanin compound (i.e. teicoplanin A3-1, A2-1, 
A2-2 & A2-3 and A2-4 & A2-5) and data shown here are the sum of these compounds. Results 
were expressed as coefficients of variation (CV%) and the bias (%) to the theoretical value was 
calculated. The calibration curves were accepted when the back calculated concentrations of 
the calibrator levels were within ± 15 % of the theoretical value, except for the LOQ for which 
± 20 % was accepted. The reproducibility was accepted when ≤ 15 % for all levels and ≤ 20 % 
for the LOQ. 
Precision and accuracy were assessed using in house made QC samples for both total and free 
teicoplanin. For within-run precision and accuracy, LOQT&F, QCLT&F, QCMT&F and QCHT&F 
were prepared and analyzed in one batch. Between-run precision and accuracy were determined 
by preparing LOQT&F, QCLT&F, QCMT&F and QCHT&F after 1, 4, 7 and 14 days storage 
at -80 °C. Also here, results were expressed as CV% and the bias (%) to the theoretical value 
was calculated. The assays were assumed to be precise and accurate when the CV% and bias 
were ≤ 15 % for QCLT&F, QCMT&F and QCHT&F and ≤ 20% for LOQT&F and within ± 15 % for 
QCLT&F, QCMT&F and QCHT&F and ± 20% for LOQT&F, respectively. 
Matrix effects were investigated using six blank plasma samples from healthy volunteers. For 
both total and free teicoplanin, plasma samples and ultrapure water were prepared for analysis 
but after extraction, 180 µL supernatant was spiked with 20 µL of low and high concentration 
calibrator stock solution. Matrix effects were evaluated by calculating the matrix factor (MF), 
which is the ratio of the peak area of teicoplanin or internal standard measured in plasma to the 
peak area of teicoplanin (MFteico) or internal standard (MFIS) measured in water. Matrix effects 
were assumed to be negligible when MFteico/MFIS was within ±15 % for both low and high 
concentration sets. For calculations, the mean of the obtained peak areas was used. 
Storage and freeze/thaw stability was studied using QCLT, QCMT and QCHT samples. For 
storage stability, these QC samples were stored at 4 °C for 1, 4, 7 and 14 days and the obtained 
total and free concentrations were compared to the same samples which were stored at -80 °C. 
Freeze/thaw stability was evaluated by comparing obtained total and free concentrations of 
QCLT, QCMT and QCHT after three freeze/thaw cycles (at -80 °C) with those which were stored 
at -80 °C. Stability was assumed when total and free concentrations were within ± 15 % of the 
concentrations found for QC samples which were stored at -80 °C. 




3.5.3.10 Effect of blood collection tube type: spiked plasma samples 
Plasma (K2EDTA and lithium heparin) and serum (SST) from healthy volunteers (all n = 6) 
were collected to study the possible effect of different blood tube types on total and free 
teicoplanin concentrations as well as on the %PB. These plasma and serum samples were spiked 
after thawing with either a low (final concentration: 11.2 mg/L) or high (final concentration: 
56 mg/L) concentration of teicoplanin. Subsequently, these samples were incubated for 30 min 
at RT prior to sample preparation. Concentrations were determined using a calibration curve in 
a pool of blank K2EDTA plasma (total teicoplanin) or blank K2EDTA plasma ultrafiltrate (free 
teicoplanin) only. 
3.5.3.11 Method comparison: patient and spiked samples 
For method comparison, the same left-over plasma (K2EDTA and lithium heparin) and serum 
samples (n = 41) from patients who received teicoplanin were used. K2EDTA plasma samples 
(n = 7) from healthy subjects which were spiked with teicoplanin were included as well. Each 
sample was stored at -80 °C immediately after collection until batch analysis was performed. 
Total teicoplanin concentrations were assayed by a validated homogeneous particle-enhanced 
turbidimetric (i.e. quantitative microsphere system, QMS® teicoplanin) immunoassay [58,60] 
on an Architect c4000 instrument (Abott, IL, USA) as well as by the UHPLC-HRMS method 
described here. Plasma and serum samples were quantified using a calibration curve prepared 
in the corresponding matrix. Subsequently, the obtained concentrations were compared by 




The described UHPLC-HRMS method was used to separate teicoplanin compounds A3-1, 
A2-1, A2-2 & A2-3 (pair of isomers) and A2-4 & A2-5 (pair of isomers) for the quantification 
of total and free teicoplanin. For both assays (i.e. total and free), the same separation procedure 
was used and the total run times were 4.5 min. The retention time of each teicoplanin compound 




values in Table 3-6) in full scan whereas for free teicoplanin, three scan segments were 
introduced and 5 mass isotopes (m/z 1 to 5 in Table 3-6) were monitored to enhance sensitivity. 
A representative chromatogram for each compound is shown in Figure 3-5. 
Figure 3-5 Representative chromatograms obtained from the highest calibrator standard for total and 
free teicoplanin compounds (A3-1, A2-1, A2-2 & A2-3 and A2-4 & A2-5), as well as for  
the internal standard (int. std.). 
 
3.5.4.2 Equilibrium dialysis versus ultrafiltration 
Teicoplanin recovery was 112.3 ± 12.1 % in ED analyses, and 23.1 ± 2.7 % and 79.5 ± 8.0 % 
in UF analyses using Amicon and Centrifree filters, respectively. Total (CT) and free (CF) 
teicoplanin concentrations as obtained by ED (37 °C) and UF (RT and 37 °C, Centrifree filters 
only) in individually spiked plasma samples were used to calculate the %PB of teicoplanin in 
each sample (Table 3-7). The overall mean value of CT, CF and %PB is also given in Table 3-7. 
The overall mean %PB was 93.6 ± 0.4 %, 94.1 ± 1.3 % and 95.8 ± 1.1 % as obtained by ED 
(37 °C), UF (37 °C) and UF (RT), respectively. 
3.5.4.3 %PB in patient samples 
The mean total and free teicoplanin concentrations as determined in 41 patient samples were 
23.9 mg/L (range 6.5 to 53.3 mg/L) and 2.7 mg/L (range 0.2 to 6.7 mg/L), respectively. The 
mean %PB of teicoplanin as determined in 41 patients was 87.7 % and ranged from 79.6 to 
95.4 %. 
A3-1 (0.83 min) A2-1 (1.72 min) A2-2/3 (1.72 min) A2-4/5 (1.87 min) Int. std. (2.35 min)
Total
Free




Table 3-7 Total (CT) and free (CF) teicoplanin concentrations and the corresponding percentage protein 
binding (%PB) as obtained by equilibrium dialysis at 37 °C and ultrafiltration at 37 °C and room 
temperature (RT) in blank plasma samples, which were spiked with a low, medium or high concentration 
of teicoplanin. 
 CT (mg/L) CF (mg/L) %PB (%) 
  ED (37 °C) UF (37 °C) UF (RT) ED (37 °C) UF (37 °C) UF (RT) 
Low 7a       
Sample 1 7.5 0.5 0.5 0.4 93.1 93.0 94.4 
Sample 2 6.7 0.4 0.5 0.4 93.9 92.2 94.4 
Medium 70a       
Sample 3 76.5 4.7 4.3 3.0 93.9 94.3 96.1 
Sample 4 73.7 5.1 3.3 2.6 94.1 95.6 96.5 
High 140a       
Sample 5 124.8 8.6 6.8 4.3 93.1 94.6 96.6 
Sample 6 149.7 9.8 7.3 4.5 93.5 95.1 97.0 
Overall     93.6 ± 0.4 94.1 ± 1.3 95.8 ± 1.1 
a Theoretical values. Values are expressed as mean ± standard deviation. 
3.5.4.4 Assay validation 
Selectivity. No detectable interferences were found in the individual blank EDTA plasma 
samples for teicoplanin. The QC samples showed no interference with the internal standard and 
in both types of analyses, a small peak was detected at the m/z ratio of the internal standard but 
its response was < 5%. However, in a number of patient samples which were collected in 
different blood tubes, an interfering peak for A2-4 & A2-5 detection was observed at 
m/z = 946.793. Therefore, we selected m/z = 948.295 for interference-free A2-4 & A2-5 
detection (Table 3-6). Thus, the method was selective for all teicoplanin compounds and the 
internal standard at these settings. 
Carry-over. No detectable peaks were found in individual blank plasma samples which were 
analyzed after the highest calibrator standard. 
LOQ. No peaks were detected in blank samples and the LOQ was 1.4 and 0.3 mg/L for total 
and free teicoplanin, respectively. 
Calibration curves. Appropriate calibration regressions and weightings were selected based on 
a recently described mathematical model [62,63]. For total teicoplanin, a quadratic curve was 
used with weighting factor x-² (R² = 0.99 ± 0.004; n = 5), whereas for free teicoplanin, a linear 
curve was used with weighting factor x-2 (R² = 0.99 ± 0.008; n = 5). Table 3-8 summarizes the 
precision of the back calculated concentrations and the accuracy to their corresponding 
theoretical value. Except for a high bias for calibrator standard 3 of free teicoplanin (15.4 %), 
all other calibrator standards had a precision < 15 % and a bias within ± 15 % of the nominal 




Precision and accuracy. Data on both within-run and between-run precision and accuracy are 
tabulated Table 3-9. The within-run precision was 5.2 % and 4.4 % at LOQ level and ranged 
from 6.3 to 12.9 % and from 3.1 to 6.6 % at QC levels, for total and free teicoplanin, 
respectively. The between-run precision was 1.7 and 15.4 % at LOQ level and ranged from 1.8 
to 7.6 % and from 4.8 to 11.5 % at QC levels, for total and free teicoplanin, respectively. 
Within-run accuracy values ranged from -10.4 to 9.6 %. Between-run accuracy ranged 
from -10.5 to 11.7 %. 
Table 3-8 Calibration curve information. 








Total teicoplanin     
Cal 1 1.4 1.4 ± 0.1 5.5 0.7 
Cal 2 2.8 2.8 ± 0.2 8.0 -1.3 
Cal 3 7.0 6.9 ± 1.0 14.7 -1.7 
Cal 4 28.0 30.5 ± 2.9 9.4 8.8 
Cal 5 70.0 62.5 ± 5.6 9.0 -10.7 
Cal 6 105.0 108.5 ± 10.0 9.2 3.1 
Cal 7 140.0 141.1 ± 16.3 11.6 0.8 
Free teicoplanin     
Cal 1 0.3 0.3 ± 0.01 4.4 -4.9 
Cal 2 1.4 1.6 ± 0.2 12.5 13.0 
Cal 3 2.8 2.4 ± 0.2 7.2 -15.4 
Cal 4 7.0 7.4 ± 0.3 4.0 6.3 
Cal 5 10.5 10.1 ± 0.8 7.6 3.7 
Cal 6 14.0 14.1 ± 0.8 5.5 1.0 
Calculated values are expressed as mean ± standard deviation; CV%: coefficient of variation;  
n = 5 for both total and free teicoplanin. 
Matrix effects. Peak areas of total and free teicoplanin as obtained in spiked extracts of blank 
plasma, blank plasma ultrafiltrate and ultrapure water with a low and a high concentration are 
provided in Table 3-10, together with peak areas of the internal standard. Except for low total 
teicoplanin, MFTeico/MFIS was within ± 15 % for each concentration set. 
Storage and freeze/thaw stability. Each QC sample was stable over a period of 14 consecutive 
days when stored at 4 °C as compared to those which were stored at -80 °C, for both total and 
free teicoplanin (all within ± 15 %). In addition, three freeze/thaw cycles of each QC sample 
had no effect on the stability of teicoplanin (all within ± 15 %). 
.





Table 3-9 Assay precision and accuracy. 
  Within-run Between-run 














Total teicoplanin        
LLOQT 1.4 1.4 ± 0.1 5.4 1.2 1.4 ± 0.04 2.8 1.9 
QCLT 7.0 7.4 ± 0.9 12.6 6.0 7.6 ± 0.4 5.1 7.9 
QCMT 70.0 77.7 ± 4.8 6.2 10.9 77.5 ± 7.5 9.7 10.7 
QCHT 140.0 131.8 ± 9.3 7.1 -5.9 155.5 ± 9.4 6.0 11.1 
Free teicoplanin        
LLOQF 0.3 0.3 ± 0.01 4.4 -4.9 0.3 ± 0.04 15.4 -10.5 
QCLF 0.9 0.9 ± 0.04 4.1 -3.6 0.9 ± 0.04 4.8 -3.7 
QCMF 5.6 5.0 ± 0.2 3.1 -10.4 5.0 ± 0.3 5.3 -9.9 
QCHF 12.6 11.9 ± 0.8 6.6 -5.7 12.3 ± 1.4 11.5 -2.4 
Calculated values are expressed as mean ± standard deviation; CV%: coefficient of variation; n = 5 (within-run) or n = 4 (between-run: after 1, 4, 7 and 14 days) for both total 




Table 3-10 Peak areas of teicoplanin (Teico) and internal standard (Int. std.) as measured in plasma and water, to study the matrix effect. 
 Plasma Water MFTeico or MFIS MFTeico/MFIS 
Total teicoplanin     
Teico (L) 3781232 ± 427582 3400519 ± 243514 1.11 
1.25 
Int. std. (L) 64898049 ± 3951204 72712426 ± 6139386 0.89 
Teico (H) 65404115 ± 12736450 63246396 ± 8181394 1.03 
1.13 
Int. std. (H) 66193315 ± 3720803 72488916 ± 2533207 0.91 
Free teicoplanin     
Teico (L) 7453429 ± 936331 7424363 ± 1197619 1.00 
1.02 
Int. std. (L) 123306400 ± 73059824 125210396 ± 10686508 0.98 
Teico (H) 89200239 ± 5338651 104190165 ± 24525044 0.86 
0.92 
Int. std. (H) 124503213 ± 12100533 133167832 ± 43036386 0.93 




3.5.4.5 Effect of blood collection tubes: spiked plasma samples 
Total and free teicoplanin concentrations as determined in spiked plasma (K2EDTA and lithium 
heparin) and serum (SST) samples from healthy donors are summarized in Table 3-11. For both 
low and high concentration sets in K2EDTA plasma, total teicoplanin concentrations 
corresponded to their nominal values. Because of the limited number of repetitions (n = 3), 
values were not statistically compared, but a trend of higher total concentrations when 
determined in lithium heparin plasma and in serum samples was observed as compared to those 
in K2EDTA plasma. This is due to a higher peak area of teicoplanin and not to a lower peak 
area of the internal standard (data not shown). However, no clear difference was found in free 
teicoplanin concentration amongst the different matrices. Consequently, a small increase in 
%PB was calculated in lithium heparin and serum samples as compared to in K2EDTA samples. 
Table 3-11 Effect of blood tube type on the total (CT) and free (CF) teicoplanin concentration and the 







Low 11.2a   
K2EDTA plasma 11.3 ± 1.1 1.0 ± 0.1 91.5 ± 0.5 
Lithium heparin plasma 15.5 ± 1.4 1.2 ± 0.1 92.3 ± 0.6 
SST serum 21.2 ± 3.5 1.1 ± 0.1 94.7 ± 1.1 
High 56.0a   
K2EDTA plasma 54.8 ± 4.4 4.9 ± 1.4 90.8 ± 3.3 
Lithium heparin plasma 67.0 ± 8.9 4.7 ± 0.3 92.9 ± 1.1 
SST serum 81.6 ± 10.1 4.3 ± 0.9 94.7 ± 0.7 
a Theoretical values; calculated values are expressed as mean ± standard deviation; n = 3 for both low and high 
concentrations of teicoplanin. 
3.5.4.6 Method comparison: patient and spiked samples 
Total teicoplanin concentrations determined by QMS® teicoplanin analysis and the 
UHPLC-HRMS method described here were compared by Passing-Bablok regression and a 
Bland-Altman plot, provided in Figure 3-6 and Figure 3-7 respectively. For Passing-Bablok 
regression, the correlation coefficient between both methods was 0.82 (95 % confidence 
interval: 0.70 – 0.90). Total teicoplanin concentrations were slightly higher when measured 
with the newly developed UHPLC-HRMS method as compared to the QMS® method. 
Bland-Altman analysis revealed a mean bias of 3.2 % between both methods and therefore, the 
here described UHPLC-HRMS method was accepted. 
 




Figure 3-6 Passing-Bablok regression for method comparison of total teicoplanin between the QMS® 
teicoplanin assay and the newly developed UHPLC-HRMS method. 
 
Figure 3-7 Bland-Altman plot for method comparison of total teicoplanin between the QMS® teicoplanin 
assay and the newly developed UHPLC-HRMS method. 
 
 Discussion 
A novel UHPLC-HRMS method for the quantification of total and free teicoplanin in K2EDTA 
plasma samples was developed and validated according to EMA guidelines. The here described 
method requires only 200 µL of plasma to quantify both the total and free teicoplanin 
concentration, which is much lower as compared to methods described elsewhere (700 µL in 
[38] and > 1 mL in [46]), and covers the complete therapeutic window of teicoplanin: ranging 
from 1.4 – 140 and 0.3 – 14 mg/L for total and free teicoplanin, respectively. In literature, only 
a limited number of papers discussed the analysis of both total and free teicoplanin [38,46,56]. 








































y = 1.154x - 3.105 
CI slope: 0.92 – 1.36



















































A2-1,  A2-2 & A2-3 and A2-4 & A2-5) using the same HRMS instrument [60]. However, in 
our method, four teicoplanin compounds (i.e. A3-1, A2-1,  A2-2 & A2-3 and A2-4 & A2-5) 
were separated by UHPLC resulting in a total run time of only 4.5 min, which is half the time 
as presented by Mueller et al. where HPLC was used [60].  
This method was selective for both teicoplanin and the internal standard in K2EDTA samples. 
The precision and accuracy of the total and free assay were within the requirements of the EMA 
guidelines, for both within-run and between-run analyses. In house prepared QC samples were 
all stable over a period of 14 consecutive days and three freeze/thaw cycles.  
A signal increase of teicoplanin was observed in spiked lithium heparin samples and in spiked 
serum samples as compared to spiked K2EDTA plasma samples. This effect could possibly be 
explained by a difference in ionization efficiency of the teicoplanin compounds between the 
different tested sample types, as previously found for other drug substances [64,65]. In a 
number of patient samples, an unknown interfering compound was present for A2-4 & A2-5 
detection at m/z = 946.793. Therefore, we selected a less abundant isotope at m/z = 948.295 for 
interference-free A2-4 & A2-5 detection. In this study, we were not able to elucidate the origin 
of this interfering compound and to the best of our knowledge, this is the first time that the 
presence of an interfering compound for teicoplanin A2-4 & A2-5 is reported. Therefore, we 
can only formulate a number of hypotheses which should be studied in future research, 
including the presence of concomitantly administered drugs, heparins as anticoagulant in 
lithium heparin blood tubes or compounds migrating from the separator gel in serum blood 
tubes (probably others than those used here in spiking experiments), as previously reported for 
other compounds [66,67].  
It should also be mentioned that no deuterated teicoplanin was used as internal standard. 
Consequently, there was no compound-specific correction for sample loss during sample 
preparation, sample injection or sample ionization. However, the method described here 
showed an acceptable precision and the obtained results were accurate. Therefore, the usage of 
expensive deuterated teicoplanin seemed to be unnecessary in our method, as well as in other 
mass spectrometry based teicoplanin assays [59–61]. 
Free teicoplanin concentrations were obtained by ultrafiltration at 37 °C and were close to the 
values obtained by equilibrium dialysis, which was also performed at 37 °C to mimic the human 
body’s temperature. Ultrafiltration at room temperature should be avoided since this leads to a 
small decrease (not statistically tested because n = 3) in free teicoplanin concentrations, 




resulting in a slightly higher %PB. Furthermore, ultrafiltration should not be carried out at 4 °C 
because of the apparent higher %PB of teicoplanin [46]. The use of Amicon filters is not 
recommended either because of their low recovery for teicoplanin. Calibrator levels for free 
teicoplanin calibration were also ultrafiltered after dilutions in ultrafiltrate to correct for the 
NSA to the Centrifree filters, which was around 20 %. The %PB (90 – 95 %) reported here for 
teicoplanin in spiked plasma samples was in good agreement with in vivo values reported in the 
literature where ultrafiltration was performed at 37 °C, but where no evidence for the accuracy 
of the obtained free fractions (e.g. by comparison with ED) was presented [38, 39]. In addition, 
the %PB of teicoplanin was found constant in the studied physiological concentration range, 
i.e. from 7 to 140 mg/L. The in vivo %PB values as obtained in patient samples was 87.7 % 
(range: 79.6 – 95.4 %), pointing out the large inter-patient variability, which was also reported 
in [38, 39]. 
In routine analyses, the QMS® teicoplanin assay is often used for quantification of total 
teicoplanin because of its short turn-around time as no sample preparation is required. This 
QMS® teicoplanin assay may, however, suffer from non-specific interferences since it is 
hypothesized that the used antibodies can also interact with compounds other than teicoplanin 
[60]. Furthermore, the LOQ of this QMS® teicoplanin assay is 10 mg/L, which is assumed to 
be the minimum for total teicoplanin through concentrations [50,51]. Consequently, free 
teicoplanin, i.e. the biologically active form, is usually < 10 mg/L and cannot be detected in a 
reliable way. Therefore, the major advantages of the present method, as compared to the QMS® 
teicoplanin assay, are its higher selectivity and sensitivity as well as its higher precision [68]. 
The correlation (r = 0.82) between the newly developed UHPLC-HRMS method and the QMS® 
teicoplanin assay was moderate, but in line with the correlation reported by Mueller et al. who 
used the same MS instrument, but only for total teicoplanin analysis purposes [60]. Not only 
K2EDTA plasma samples, but also serum en lithium heparin samples were used for method 
comparison. Hence, our UHPLC-HRMS method was developed and validated using K2EDTA 
plasma samples, but is also applicable for analysis of serum samples and even lithium heparin 
samples, but then, calibration curves should be constructed in the corresponding matrix.  
This new UHPLC-HRMS method can be useful in TDM. Although there is no consensus on 
the therapeutic value for free teicoplanin so far, it would be of additional value since the free 
fraction is biologically active and thus of therapeutic relevance. Nowadays, this free fraction is 
often estimated by a general percentage of around 10 %, despite the large inter-patient 




of free teicoplanin can be determined in a more reliable way as compared to the estimation of 
10%. 
 Conclusion 
In conclusion, a novel highly sensitive and fast UHPLC-HRMS method was developed and 
validated according to EMA guidelines for the quantification of total and free teicoplanin in 
human K2EDTA plasma samples. Furthermore, our method is applicable for interference-free 
total and free teicoplanin analysis in serum and lithium heparin samples. Amongst others, this 
method can be useful in therapeutic drug monitoring, especially when knowledge of the free 
teicoplanin concentration is important. 
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Protein binding of uremic toxins in patients with chronic kidney disease 
4.1 Introduction 
In addition to small water-soluble solutes (MW < 500 Da) and middle molecules (MW > 500 
Da), protein-bound uremic toxins (PBUTs, mostly MW < 500 Da) are accumulated in patients 
with chronic kidney disease [1,2]. Different PBUTs are known to contribute to the increased 
inflammatory and cardiovascular morbidity in patients with CKD [3–11]. In addition, in 
patients on hemodialysis (HD), removal of these PBUTs is hampered because of their binding 
to plasma proteins, such that only the free fraction is able to be transported in a passive way 
through the pores of the dialyzer membrane [12–14]. 
Both aspects, i.e. the toxicity of PBUTs and their hampered removal during HD, have been 
studied for almost three decennia, but are still the topic of ongoing research. One problem here 
is that most of the performed studies only focused on the total PBUT concentration while, in 
analogy to the pharmacokinetics of drug compounds, the free fraction of PBUTs is assumed to 
be biologically active. Hence, the percentage protein binding (%PB) might be an important 
parameter to study in uremia.   
Therefore, in this section, the protein binding of a selected panel of PBUTs is described in 





4.2 Exploring protein binding of uremic toxins in patients with different 
stages of chronic kidney disease and during hemodialysis 
Based on: Deltombe O, Van Biesen W, Glorieux G, Massy Z, Dhondt A, Eloot S (2015) Exploring Protein Binding 
of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis. Toxins 
(Basel) 7:3933–3946. doi: 10.3390/toxins7103933 
 Abstract 
As protein binding of uremic toxins is not well understood, neither in chronic kidney disease 
(CKD) progression, nor during a hemodialysis (HD) session, we studied protein binding in two 
cross-sectional studies. Ninety-five CKD 2 to 5 patients and ten stable hemodialysis patients 
were included. Blood samples were taken either during the routine ambulatory visit (CKD 
patients) or from blood inlet and outlet line during dialysis (HD patients). Total (CT) and free 
concentrations were determined of p-cresyl glucuronide (pCG), hippuric acid (HA), indole-3-
acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS), and their percentage protein 
binding (%PB) was calculated. In CKD patients, %PB/CT resulted in a positive correlation (all 
p < 0.001) with creatinine clearance for all five uremic toxins. In HD patients, %PB was 
increased after 120 min of dialysis for HA and at the dialysis end for the stronger (IAA) and 
the highly-bound (IS and pCS) solutes. During one passage through the dialyzer at 120 min, 
%PB was increased for HA (borderline), IAA, IS and pCS. These findings explain why protein-
bound solutes are difficult to remove by dialysis: a combination of the fact that (i) only the free 
fraction can pass the filter and (ii) the equilibrium, as it was pre-dialysis, cannot be maintained 
during the dialysis session, as it is continuously disturbed. 
 Introduction 
Uremic syndrome is characterized by the retention of a large number of compounds, which in 
healthy persons are excreted by the kidneys. Some of those retention solutes interact negatively 
with biological functions and are called uremic toxins. These toxins are classified into three 
groups: the free small water-soluble solutes (molecular weight (MW) < 500 Da), the middle 
molecules (MW > 500 Da) and the protein-bound solutes [1,2]. The latter solutes have a protein 
binding ranging from around 10 % (e.g., p-cresyl glucuronide) to near 100 % (e.g., p-cresyl 
sulfate). Many of these protein-bound substances are known to exert toxicity in a direct or 




indirect way [8,10,15]. However, in our current understanding, toxicity is only exerted by the 
free concentration and not by the protein-bound concentration. 
Since the extent of protein binding depends on the solute concentration, the protein 
concentration, the protein-solute affinity constant and the presence or absence of competing 
solutes [16], each protein-bound uremic toxin binds to the specific proteins to a variable degree. 
Structural changes of proteins can also alter the extent of protein binding, and therefore, it can 
be hypothesized that the degree of protein binding also changes in individual patients with the 
progression of their chronic kidney disease (CKD), as post-translational modifications 
(oxidation, carbamylation and glycosylation as the most relevant processes) of proteins increase 
as CKD progresses [17]. During hemodialysis (HD), only the free fraction can be removed, 
such that the overall dialyzer clearance depends, apart from blood and dialysate flow and 
dialyzer characteristics, on the free toxin concentration and on the speed of equilibration 
between bound and free fractions. Free fractions, and with it dialyzer clearance, can be 
increased, for example, by the presence of competing ligands in the serum, like sodium 
octanoate [18,19], or by infusing hypertonic saline at the dialyzer inlet [20–22]. The 
mechanisms of protein binding are, however, not well understood.  
In this study, we evaluated the percentage protein binding at different stages of CKD (i.e. Stages 2 
to 5), during a hemodialysis session in dialysis patients and in healthy controls. This information 
might be useful in the development of new removal strategies aiming at the optimization of 
dialysis. 
 Materials and methods 
To calculate the percentage protein binding in CKD patients, data were taken from a cross-
sectional study including 95 patients with confirmed diagnosis of CKD Stages 2 to 5. To unravel 
changes in protein binding in the hemodialyzer, as well as during the course of a hemodialysis 
session, data were taken from a second cross-sectional study including 10 stable HD patients. 
Data from 10 healthy controls with normal renal function were also collected to cover the range 





4.2.3.1 Patients and sampling protocol 
CKD patients: 95 CKD patients (CKD Stages 2 to 5) were included from Amiens University 
Hospital (France), in whom concentrations of uremic retention solutes were evaluated for their 
relation to clinical outcomes [5,7,23]. These patients were older than 40 years and had a 
confirmed diagnosis of CKD (creatinine clearance below 90 mL/min, calculated in the 
aforementioned study according to the Cockcroft-Gault formula [24]). Exclusion criteria were 
the presence of chronic inflammatory disease, atrial fibrillation, complete heart block, 
abdominal aorta aneurysm, aortic and/or femoral artery prosthesis, primary hyperparathyroidism, 
kidney transplantation, treated with dialysis and any acute cardiovascular event in the 3 months 
before screening for inclusion. Blood samples were taken in the morning on the occasion of a 
visit at the outpatient clinic.  
HD patients: 10 stable hemodialysis patients were included from Ghent University Hospital. 
Exclusion criteria were active infection, pregnancy, unstable condition, vascular access 
problems and age below 18 years. During the experimental session at midweek, conventional 
two needle/lumen HD was performed for 240 min using high-flux dialyzers: FX800 (n = 6) 
(Fresenius Medical Care, Bad Homburg, Germany), Evodial (n = 1) (Gambro, Lund, Sweden), 
Xenium 210 (n = 1) (Baxter, Dearfield, IL, USA), Phylter HF17G (n = 1) and Phylter HF17SD 
(n = 1) (Bellco, Mirandola, Italy) in a diffusive mode. Blood and dialysate flows were set at 
300 and 700 mL/min, respectively, while ultrafiltration rates were set according to the needs of 
the patients. Nine patients had a well-functioning fistula and one patient a Bard Optiflow central 
venous catheter (Bard, Covengton, GA, USA) as vascular access. Residual renal function was 
calculated as the arithmetic mean of the creatinine and urea clearance, calculated from the 
interdialytic urine collection (volume and concentration) and blood concentrations at the start and 
end of the interdialytic period [25]. During the experimental session, blood samples were 
collected at the start of the session from the vascular access and from the inlet blood line after 
60 and 120 min, and immediately after discontinuation of the dialysis session (at 240 min). 
Blood samples were also collected from the outlet blood line after 120 min since the start of the 
dialysis session. 
Both studies were approved by the local ethical committees (Comité de protection des 
Personnes Nord-Ouest II, CHU Amiens, Amiens, France, 06H3 for CKD patients, and Ghent 
University Hospital, Ghent, Belgium, UZG 2008/128 for healthy controls and 2008/081 for HD 




patients), performed in accordance with the principles of the Declaration of Helsinki, and all 
patients gave their written informed consent. 
Healthy Controls: Data from 10 healthy volunteers with normal renal function were collected 
at Ghent University Hospital. Subjects who were smoking, had an infection, were pregnant or 
on medication were excluded. 
4.2.3.2 Laboratory 
All blood samples were immediately centrifuged after sampling and serum was stored at -80 °C 
until batch analysis. 
Concentrations of protein-bound uremic toxins were determined by reversed-phase high 
performance liquid chromatography (RP-HPLC), as described earlier [26,27]. The solutes 
analyzed were p-cresyl glucuronide (pCG, MW: 284.3 Da), hippuric acid (HA, MW: 179.2 Da), 
indole-3-acetic acid (IAA, MW: 174.2 Da), indoxyl sulfate (IS, MW: 212.2 Da) and p-cresyl 
sulfate (pCS, MW: 187.2 Da). To determine the total concentration, serum samples were first 
deproteinized by heat denaturation prior to HPLC analysis [12]. HA was analyzed by UV 
detection at 254 nm, whereas pCG and pCS (λexc. = 265 nm, λem = 290 nm) and IAA and IS 
(λexc. = 280 nm, λem = 340 nm) were determined by fluorescence detection [12,26]. To obtain 
free fractions, untreated serum samples were filtered through a Centrifree filter device 
(Millipore Billerica, MA, USA) prior to heating [12]. Albumin levels in serum from CKD 
patients were assayed in a biochemistry laboratory using standard autoanalyzer techniques (the 
Modular IIP system, Roche Diagnostics, Basel, Switzerland) [5,7,23]. In HD patients, total 
protein concentration in serum was analyzed according to standard methods (Biuret reaction). 
4.2.3.3 Calculations 
Percentage protein binding (%PB) was calculated from the measured total (CT) and free (CF) 
concentrations as: 
%PB = (1 - 
CF
CT






The reduction ratio (RR) for the free and total concentration in HD patients was determined 
from the concentration at the start of the dialysis session (Cpre) and after time t = 60, 120 and 
240 min (Ct) as:  
RR = (1 - 
Ct
Cpre
)  x 100 %     (Eq. 4-2) 
4.2.3.4 Statistical Analysis 
Statistical evaluation was performed with SPSS Statistics 22 (2013, Armonk, NY, USA). Data 
were checked for normality. As most numeric data were not normally distributed, data were 
expressed as the median [25th percentile (pct); 75th pct]. To compare independent categorical 
data, Fisher’s exact test was performed. Differences between more than two groups of unpaired 
data (CKD data) were checked with a Kruskal–Wallis test (with multiple comparisons and 
Bonferroni correction). Paired comparisons (HD data) between more than two groups were 
made with a Friedman test (with multiple comparisons and Bonferroni correction). To evaluate 
the difference between two paired groups, the Wilcoxon signed-rank test was applied. Spearman’s 
rho test was performed to check correlation (all presented p- and R-values are Spearman’s rho 
values, unless stated otherwise). An univariate general linear model was used with covariates 
(CT, DM and albumin concentration) to check any improvements of the correlation between 
creatinine clearance and %PB. A linear regression procedure was used to check differences in 
regression coefficients between two groups (reduction ratio). P < 0.05 was considered 
significant, and all tests were two-tailed. 
 Results and discussion 
4.2.4.1 Patient characteristics 
Table 4-1, Table 4-2 and Table 4-3 present the demographic and clinical characteristics of the 
95 CKD patients, the 10 HD patients and the 10 healthy controls with normal renal function, 
respectively.  
Besides differences in creatinine clearance among the CKD stages, no dissimilarities were 
observed among the different CKD stages for age, gender, body mass index (BMI), diabetes 
mellitus (DM) and albumin concentration. 




Table 4-1 Demographic and clinical characteristics of the CKD patients. 
 Characteristics  CKD patients 
CKD 2 to 5 CKD 2 CKD 3 CKD 4 CKD 5 
Number, n (%) 95 (100) 11 (11.5) 37 (39) 37 (39) 10 (10.5) 
Age (years) 69 [59;76] 62 [59;71] 74 [61;77] 69 [55;74] 79 [60;83] 
Male gender, n (%) 59 (62) 9 (82) 24 (65) 22 (60) 4 (40) 
BMI (kg/m2) 29 [25;32] 27 [21;29] 29 [25;32] 29 [26;34] 25 [23;30] 
DM, n (%) 45 (47) 4 (36) 19 (51) 18 (49) 4 (40) 
Albumin (g/L) 39 [35;44] 42 [37;47] 38 [35;42] 41 [35;44] 33 [28;39] 
Creatinine clearance1 (mL/min) 32 [20;49] 67 [63;71] 45 [35;51] 22 [19;25]°,+ 11 [9;13]°,+ 
CKD: chronic kidney disease; BMI: body mass index; DM: diabetes mellitus. Median [25th percentile (pct); 
75th pct]. ° p < 0.05 versus CKD 2; + p < 0.05 versus CKD 3. 1 Creatinine clearance calculated according to the 
Cockcroft-Gault formula.  
Table 4-2 Demographic and clinical characteristics of the HD patients. 
 Characteristics  HD patients 
Age (years) 72 [61;78] 
Male gender, n (%) 8 (80) 
Ultrafiltration (mL/min) 4.8 [3.5;8.9] 
BMI (kg/m2) 28 [25;28] 
DM, n (%) 5 (50) 
Total protein (g/L) 60 [58;67] 
Creatinine clearance (mL/min) 2.6 [0.0;4.1] 
HD: hemodialysis. Median [25th pct; 75th pct]. 
Table 4-3 Demographic and clinical characteristics of the healthy controls. 
 Characteristics  Healthy controls 
Age (years) 40 [33;57] 
Male gender, n (%) 4 (40) 
BMI (kg/m2) 23 [19;27] 
Median [25th pct; 75th pct]. 
The median percentage protein binding (%PB), the free and total concentration of p-cresyl 
glucuronide (pCG), hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and 
p-cresyl sulfate (pCS) are shown in Table 4-4 for an increasing degree of kidney failure, 
i.e. consecutively for the healthy controls, the CKD patients and the HD patients. Since the 
three groups differ in origin, nutrition and hospital center, they were not statistically compared 
to each other. 
For the healthy controls, the free and total concentration of pCG were below the limit of 
quantification (LOQ), and the %PB could not be calculated. The median %PB was 34 % (HA), 
83 % (IAA), 84 % (IS) and 94 % (pCS). 
In the different stages of CKD, the free and total concentrations of the weakly-bound solutes 
pCG and HA were only increased in CKD 5 patients, and for the stronger bound solutes IAA, 












Table 4-4 Percentage protein binding (%PB), free (CF) and total (CT) concentration of protein-bound solutes in healthy controls with normal renal function, in CKD 








CKD 2 CKD 3 CKD 4 CKD 5 
pCG 
%PB  





7 [3;24]  
0.03 [0.03;0.04]  
0.03 [0.03;0.05] 
10 [6;14]  
0.03 [0.03;0.04]  
0.04 [0.03;0.04] 
9 [6;16]  
0.04 [0.03;0.07]  
0.05 [0.03;0.08] 
8 [5;20]  
0.20 [0.07;0.25]°,+  
0.25 [0.08;0.28]°,+,# 
12 [9;19]  




CF (mg/dL)  
CT (mg/dL) 
34 [22;39]  
0.13 [0.10;0.16]  
0.17 [0.11;0.25] 
38 [34;42]  
0.23 [0.18;0.38]  
0.39 [0.32;0.58] 
38 [34;43]  
0.20 [0.18;0.32]  
0.33 [0.27;0.53] 
38 [35;44]  
0.30 [0.21;0.42]  
0.51 [0.33;0.53] 
43 [36;45]  
0.54 [0.34;0.69]+  
0.93 [0.51;1.25]+ 
39 [32;54]  




CF (mg/dL)  
CT (mg/dL) 
83 [78;84]  
0.01 [0.01;0.01]  
0.04 [0.03;0.05] 
60 [56;66]  
0.02 [0.02;0.02]  
0.06 [0.05;0.07] 
67 [61;75]  
0.03 [0.02;0.03]  
0.08 [0.06;0.12] 
66 [61;72]  
0.03 [0.03;0.03]°,(+)  
0.09 [0.07;0.11]° 
68 [65;71]  
0.03 [0.03;0.04]°,+  
0.11 [0.10;0.15]° 
69 [63;80]  






84 [77;88]  
0.02 [0.01;0.02]  
0.10 [0.06;0.14] 
77 [71;83]  
0.03 [0.03;0.03]  
0.16 [0.11;0.18] 
86 [80;90]  
0.03 [0.03;0.03]  
0.23 [0.16;0.35] 
89 [87;92]°,+  
0.04 [0.03;0.04]°,+  
0.36 [0.28;0.55]°,+ 
92 [90;95]°,+  
0.06 [0.03;0.08]°,+  
0.79 [0.31;1.50]°,+ 
93 [90;95]  




CF (mg/dL)  
CT (mg/dL) 
94 [87;96]  
0.02 [0.01;0.02]  
0.31 [0.08;0.47] 
93 [89;96]  
0.05 [0.03;0.07]  
0.47 [0.38;0.70] 
97 [96;97]°  
0.04 [0.02;0.05]  
0.95 [0.59;1.37] 
96 [95;97]  
0.05 [0.03;0.12]  
1.19 [0.65;2.52]° 
94 [93;95]+  
0.21 [0.12;0.31]+,#  
3.29 [1.52;4.47]°,+ 
95 [93;97]  
0.06 [0.04;0.10]  
2.06 [1.14;2.87] 
pCG: p-cresyl glucuronide; HA: hippuric acid; IAA: indole-3-acetic acid; IS: indoxyl sulfate; pCS: p-cresyl sulfate. LOQ: limit of quantification; Median [25th pct; 75th pct]. 
° p < 0.05 versus CKD 2; + p < 0.05 versus CKD 3; # p < 0.05 versus CKD 4; (+) p = 0.061. 
 




The median percentage protein binding was in the range 7 % to 8 % (pCG), 38 % to 43 % (HA), 
60 % to 68 % (IAA), 77 % to 92 % (IS) and 93 % to 94 % (pCS). For the highly-bound IS, 
%PB was increased in CKD 4 and 5 patients with respect to CKD 2 and 3 patients, while for 
pCS, %PB showed some variation, but without a clear trend. The median %PB in the HD 
patients was 12 % (pCG), 39 % (HA), 69 % (IAA), 93 % (IS) and 95 % (pCS). 
4.2.4.2 CKD patients 
Considering the 95 CKD patients, only %PB of IS showed an (inverse) correlation with 
creatinine clearance (R = −0.64; p < 0.001) (Figure 4-5 in 4.2.7 Supplementary figures and 
Table 4-5). Normalizing %PB for total toxin concentration, however, resulted in a positive 
correlation (all p < 0.001) with creatinine clearance for all five uremic toxins (Figure 4-1). 
Figure 4-1 Percentage protein binding (%PB) normalized for total toxin concentration (CT) versus 
creatinine clearance of CKD patients for: (A) p-cresyl glucuronide; (B) hippuric acid; (C) indole-3-acetic 
acid; (D) indoxyl sulfate; and (E) p-cresyl sulfate. 
 
Table 4-5 shows the p- and R2-values of the correlation test between %PB and creatinine 
clearance in the 95 CKD patients. The influence of added covariates CT, diabetes mellitus and 
the albumin concentration was checked, as shown in Table 4-5. The total toxin concentration 
improved the model (all p < 0.05), except for pCG (Table 4-5). This result is in line with the 
correlations found in Figure 4-1. When diabetes mellitus was added to the model, only an 
improvement was found for IAA and IS (Table 4-5). However, a lower R2-value was given 
compared to CT. Including albumin concentration did not improve the correlation between %PB 
and creatinine clearance (Table 4-5), neither did it correlate with %PB (Figure 4-6 in 
(C) Indole-3-Acetic Acid (D) (E)Indoxyl Sulfate p-Cresyl Sulfate














































































































4.2.7 Supplementary figures). Therefore, the albumin concentration (in this range) did not have 
an influence on the %PB, as already published for other compounds in the literature [27,28]. 
Table 4-5  p- and R2-values of the correlations between %PB and creatinine clearance (CrCl) for pCG, 
HA, IAA, IS and pCS and the influence of added covariates total toxin concentration (CT), diabetes 
mellitus (DM) and albumin concentration in CKD patients. 
Uremic 
Toxin 
%PB versus CrCl Covariates 
CT DM Albumin 
p R2 p R2 p R2 p R2 
pCG 0.65 - 0.081 - 0.288 - 0.91 - 
HA 0.40 - 0.008 0.23 0.623 - 0.49 - 
IAA 0.18 - 0.002 0.71 0.028 0.03 0.85 - 
IS < 0.001 0.41 < 0.001 0.67 < 0.001 0.32 0.77 - 
pCS 0.12 - 0.004 0.16 0.843 - 0.62 - 
P < 0.05 is indicated in bold. R2-values only shown in the case of significant p. 
It is known that post-translational modifications of proteins increase as CKD progresses, with 
carbamylation, oxidation, glycosylation and guanidinylation as the most relevant processes 
[17,29]. Whether our result is influenced by these structural changes in the proteins or whether 
this is the result of competitive binding, leading to an enhanced free toxin concentration, 
remains unclear. Anyway, the presented results are in line with those for highly (around 90%) 
protein-bound drugs, like valproic acid or phenytoin, also showing a decreased protein binding 
in patients with renal failure [30,31]. 
4.2.4.3 HD patients 
In hemodialysis patients, median pre-dialysis %PB was 12 % (pCG), 39 % (HA), 69 % (IAA), 
93 % (IS) and 95 % (pCS). Figure 4-2 and Table 4-6 show %PB determined at the inlet of the 
dialyzer, at the start (0 min) of the hemodialysis session and after 60, 120 and 240 min. 
The total and free toxin concentrations were decreased from 120 min on for pCG, HA and pCS.  
For IAA, only the total concentration decreased from 120 min on and for IS, only the free 
concentration (Table 4-6). No differences in %PB were observed during the HD session for the 
weakly-bound pCG. For HA, %PB was increased after 120 and 240 min versus HD start, while 
for the stronger (IAA) and highly-bound (IS and pCS) solutes, this increase was only significant 
after 240 min (Figure 4-2 and Table 4-6). 
 
 




Table 4-6 Percentage protein binding, free and total concentration of protein-bound solutes in HD 





0 min 60 min 120 min 240 min 
pCG 
%PB  
CF (mg/dL)  
CT (mg/dL) 
12 [9;19]  
0.31 [0.22;0.85]  
0.35[0.25;0.99] 
13 [10;15]  
0.14 [0.11;0.44]  
0.17 [0.12;0.45] 
10 [13;20]  
0.11 [0.07;0.29]°  
0.14 [0.08;0.36]° 
11[5;19]  




CF (mg/dL)  
CT (mg/dL) 
39 [32;54]  
1.59 [0.73;3.30]  
2.41 [1.57;5.42] 
49 [43;54]  
0.91 [0.41;1.84]  
1.42 [0.99;3.52] 
50 [47;60]°  
0.70 [0.44;1.37]° 
1.37 [0.97;2.55]° 
54 [39;58]°  




CF (mg/dL)  
CT (mg/dL) 
69 [63;80]  
0.07 [0.04;0.11]  
0.19 [0.13;0.33] 
77 [72;82]  
0.04 [0.02;0.08]  
0.14 [0.10;0.26] 
80 [77;86]  
0.03 [0.02;0.06]  
0.13 [0.10;0.23]° 
83 [78;87]° 
0.03 [0.02;0.07]°  
 0.10 [0.08;0.16]°,+ 
IS 
%PB  
CF (mg/dL)  
CT (mg/dL) 
93 [90;95]  
0.08 [0.04;0.21]  
1.40 [0.69;2.18] 
94 [91;95]  
0.06 [0.04;0.16]  
1.14 [0.60;1.97] 
95 [94;95]  
0.06 [0.03;0.12]°  
1.06 [0.56;1.75] 
95 [95;96]°  









95 [92;96]  
0.13 [0.09;0.19]  
2.46 [1.45;3.70] 
96 [95;97]  
0.09 [0.07;0.14]°  
2.27 [1.32;3.41]° 
97 [97;97]°,+  
0.06 [0.04;0.10]°,+  
2.06 [1.14;2.87]°,+ 
° p < 0.05 versus 0 min; + p < 0.05 versus 60 min. Median [25th pct; 75th pct].  
Figure 4-2 Percentage protein binding at different time points during a hemodialysis (HD) session for: (A) 
p-cresyl glucuronide; (B) hippuric acid; (C) indole-3-acetic acid; (D) indoxyl sulfate;  
and (E) p-cresyl sulfate. 
 
* p < 0.05; o: outlier; x: extreme. 
Changes in percentage protein binding from the dialyzer inlet towards the outlet as measured 
at 120 min after dialysis start are depicted in Figure 4-3. For the weakly-bound pCG, passage 
through the dialyzer did not influence the percentage binding. For HA, the %PB was increased 
with a borderline significance (p = 0.066). The percentage protein binding for the stronger 
(A) p-Cresyl Glucuronide (B) Hippuric Acid
*









(IAA) and the highly-bound (IS and pCS) solutes was significantly increased from dialyzer 
inlet to outlet at 120 min. 
Figure 4-3 Percentage protein binding at the dialyzer inlet versus outlet after 120 min since dialysis start 
for: (A) p-cresyl glucuronide; (B) hippuric acid; (C) indole-3-acetic acid; (D) indoxyl sulfate;  
and (E) p-cresyl sulfate. 
 
** p < 0.05 versus the inlet; * p = 0.066 versus the inlet; o: outlier; x: extreme. 
This study is the first to demonstrate that the percentage protein binding for stronger bound 
solutes changes during dialysis, both within the dialyzer itself during a single passage and 
within a patient (i.e. during the course of the dialysis session). The influence of 
hemoconcentration on these observations was checked by a correlation test between the change 
in %PB and the change in total protein concentration at the inlet and outlet of the dialyzer, but 
no significant correlation was found (Figure 4-7 in 4.2.7 Supplementary figures). Neither can 
this be explained by changes in pH, since we only observed limited pH changes during the 
course of a dialysis session. 
A possible explanation might be found in the hypothesis that the physicochemical bond of the 
toxin with its protein is strong. As a consequence, the equilibrium reaction is too slow to restore 
the free toxin concentration within the time frame of a single passage through the dialyzer and 
even within the time frame of a dialysis session once the pool of available pre-dialysis free 
fraction has been removed. Therefore, we calculated the reduction ratio (RR) for both total and 
free toxin concentration to check this hypothesis. The RR is graphically presented in Figure 4-4 
(A) p-Cresyl Glucuronide (B) Hippuric Acid
*
(C) Indole-3-Acetic Acid (D) Indoxyl Sulfate (E) p-Cresyl Sulfate
** ** **




for pCG, HA, IAA, IS and pCS at 60, 120 and 240 min since the start of the dialysis session. 
The slopes of free and total RR are borderline significant for IS (p = 0.061) and significantly 
different for pCS (p < 0.001). 
Figure 4-4 Reduction ratio for total ( ) and free ( ) toxin concentration at different time points  
during an HD session 
 
(A) p-cresylglucuronide (free: y = 0.15x + 41; R2 = 0.96; total: y = 0.15x + 42; R2 = 0.99);  
(B) hippuric acid (free: y = 0.14x + 37; R2 = 1.00; total: y = 0.16x + 27; R2 = 1.00);  
(C) indole-3-acetic acid (free: y = 0.14x + 30; R2 = 0.96; total: y = 0.10x + 16; R2 = 0.99);  
(D) indoxyl sulfate (free: y = 0.19x + 8.7; R2 = 1.00; total: y = 0.11x + 11; R2 = 1.00); and  
(E) p-cresylsulfate (free: y = 0.21x + 6.4; R2 = 1.00; total: y = 0.10x + 6.5; R2 = 1.00). 
The difference in RR between free and total concentrations might imply that the equilibrium 
could not be formed during the course of the dialysis session. For the weakly-bound pCG, for 
example, around 90% of the total concentration is unbound and is thus easily removed by the 
dialyzer, resulting in a comparable total and free reduction ratio. The RR of the highly-bound 
pCS, on the other hand, is different for free and total concentrations, and within the four hours 
of dialysis, the RR of the total concentration cannot follow the RR of the free concentration 
(around 4%). The equilibrium between free and bound pCS is continuously disturbed because 
of the dynamic process of dialysis. Therefore, the equilibrium (as it was pre-dialysis) cannot be 
restored during the dialysis session and explains the observations in Figure 4-2 and Figure 4-3. 
Besides well-known aspects such as molecular weight, steric configuration and charge, main 
determinants for the limited removal of protein-bound solutes during dialysis may be extended 
to: (i) only the free fraction can be removed and (ii) the bound fraction is released slowly. This 
fits with the multi-pass device observations, as described by Eloot et al., where removal of 
(C) Indole-3-Acetic Acid (D) (E)Indoxyl Sulfate p-Cresyl Sulfate















































































































protein-bound solutes was limited to the first two hours of dialysis [13]. In a kinetic modelling 
study from our group [32] based on intradialytic concentrations, we found an inverse correlation 
between dialyzer clearance and the %PB. Furthermore, total distribution volumes and 
intercompartment clearances (except for pCG), which are representative for solute retardation 
inside the patients, were also inversely correlated with the %PB. Thus, the present findings are 
in full agreement with those in the kinetic analysis.  
It can be stated that during dialysis, first the free fraction will be removed and will cause a 
disequilibrium with the bound fraction, as well as with concentrations in the extra vascular 
spaces. This results in a continuous release of the bound fraction, respectively inflow from the 
extravascular space. These kinetics of protein-bound solutes were already extensively studied 
by our group showing the multi-compartmental behavior with vascular and extravascular spaces 
[33]. 
Enhancing the filtration of proteins is cumbersome, as this would result in hypoproteinemia. 
However, strategies could be developed that change the strength of the physical bond between 
the toxin and its ligand, to increase the free (dialyzable) solute concentration. 
Recent research suggested a novel approach to increase the free fraction of the protein-bound 
solutes phenyl acetic acid (PAA), indoxyl sulfate and p-cresyl sulfate during dialysis by 
infusing a hypertonic solution at the dialyzer inlet [20–22]. This increased the local ionic 
strength at the blood inlet of the dialyzer, resulting in an enhanced release of uremic toxin from 
its protein binding site, most pronounced for the middle bound PAA (%PB around 60 %). With 
this approach, the clearance during in vitro dialysis was relatively most beneficial for the 
highly-bound IS and pCS [20]. These in vitro results might be promising, but the absence of 
hemolysis due to hyperosmolarity needs to be further investigated in vivo. 
 Conclusion 
In this study, we explored the protein binding of uremic toxins in patients with different stages  
of CKD and during a hemodialysis session. The observed change in protein binding in CKD 
patients with advanced CKD stages might be due to post-translational modifications of proteins, 
characteristic for CKD progression. The observed results in HD patients explain why protein-
bound solutes are difficult to remove by dialysis: a combination of the fact that (i) only the free 
fraction can pass the filter and (ii) the equilibrium, as it was pre-dialysis, cannot be restored 
during the dialysis session, as it is continuously disturbed. This can be explained by the kinetics 




of these protein-bound uremic toxins: once the free fraction is removed, the equilibrium with 
the bound fraction and the extra vascular space is disturbed, causing a potential release of the 
bound fraction, respectively inflow from the extravascular space [33]. 
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 Supplementary figures 
Figure 4-5 Percentage protein binding (%PB) versus creatinine clearance of CKD patients for: 
(A) p-cresyl glucuronide; (B) hippuric acid; (C) indole-3-acetic acid; (D) indoxyl sulfate (with Spearman 







































































































Figure 4-6 Percentage protein binding (%PB) versus albumin concentration of CKD patients for: (A) 
p-cresyl glucuronide; (B) hippuric acid; (C) indole-3-acetic acid; (D) indoxyl sulfate; and  
(E) p-cresyl sulfate. 
 
Figure 4-7 Change (Δ) in percentage protein binding (%PB) versus change in total protein concentration 
of HD patients at the inlet and the outlet of the dialyzer, after 120 min of dialysis for: (A) p-cresyl 
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Plasma protein binding of uremic toxins and antibiotics in healthy 
subjects versus hemodialysis patients  
5.1 Introduction 
It is often hypothesized that the percentage protein binding (%PB) of different protein-bound 
uremic toxins (PBUTs) is affected by a competition between them to bind to albumin [1–3]. 
Furthermore, it is suggested that binding sites on albumin might be saturated due to the 
accumulation of PBUTs in patients with CKD, resulting in lower percentages of protein binding 
[4]. Finally, many patients with CKD take medication of which the active drug compound may 
bind to plasma proteins as well. Consequently, these drugs may compete for the same binding 
site on albumin as an uremic toxin, influencing the %PB of the drug or toxin [1,5–12].  
In this chapter, first the binding characteristics of a selected panel of PBUTs (i.e. HA, IAA, IS 
and pCS) is discussed as well as their related competition, in physiologic relevant matrices 
(i.e. serum). Second, the effect of CKD on the %PB of vancomycin and teicoplanin, i.e. two 
antibiotics which are commonly used for the treatment of infections in HD patients, as well as 





5.2 Exploring binding characteristics and the related competition of 
different protein-bound uremic toxins 
Based on: Deltombe O, de Loor H, Glorieux G, Dhondt A, Van Biesen W, Meijers B, Eloot S (2017) Exploring 
binding characteristics and the related competition of different protein-bound uremic toxins. Biochimie 139:20–
26. doi: 10.1016/j.biochi.2017.05.010 
 Abstract 
Little is known about potential differences in binding characteristics of protein-bound uremic 
toxins (PBUTs) in patients with chronic kidney disease (CKD) versus healthy controls. The 
question arises whether eventual differences are attributed to (i) the elevated levels of 
competing uremic toxins, and/or (ii) post-translational modifications of albumin.  
We evaluated the binding characteristics of hippuric acid (HA), indole-3-acetic acid (IAA), 
indoxyl sulfate (IS), and p-cresyl sulfate (pCS) by deriving a binding curve in three distinct 
conditions: (i) serum from healthy controls (healthy serum), (ii) blank serum from hemodialysis 
patients (blank HD serum; i.e. cleared from uremic toxins), and (iii) non-treated serum from 
HD patients (HD serum). Additionally, the mutual binding competition of these uremic toxins 
was studied in blank HD in pairs. In both experiments, equilibrium dialysis (37 °C, 5 h) was 
used to separate the free and bound fractions of each PBUT. Free and total PBUT concentrations 
were quantified by an ultra-high performance liquid chromatography method with tandem mass 
spectrometer detection and the percentage protein binding (%PB) of each PBUT was calculated.  
For all four compounds, the binding capacity of healthy serum was higher than blank HD serum, 
which was comparable to non-treated HD serum, except for HA. The competition experiments 
revealed that at high uremic concentrations, mutual competition was observed for the strongly 
bound PBUTs IS and pCS. The %PB of the weakly bound HA and IAA was lower (trend) only 
for the addition to blank HD serum containing the strongly bound IS or pCS. 
There is an intrinsic impact on PB in uremia, revealing a lower binding capacity, as compared 
to healthy controls. Competitive binding is only relevant for the strongly bound PBUTs at high 
uremic concentrations. In addition, at least part of the effect on binding capacity may be 
attributed to post-translational modifications of albumin. 





Chronic kidney disease (CKD) is characterized by the retention of a large number of compounds 
that, under normal conditions, are excreted by the healthy kidneys. Numerous retention solutes 
have a negative effect on many biological functions and are therefore called uremic toxins [13–
21]. Among them, the protein-bound uremic toxins (PBUTs) [22,23] mainly bind to albumin 
and this in different degrees [24,25]. The range in percentage protein binding (%PB) implies a 
differential removal of these toxins during hemodialysis, since only the free fraction can pass 
conventional dialyzer membranes [26].  
Several studies reported a decreased %PB for some of these PBUTs in uremic serum or plasma, 
compared to normal serum or plasma [4,25–28]. In these studies, it was suggested that the 
decrease in %PB was attributed to either (i) the elevated PBUT concentrations in CKD and 
hemodialysis (HD) patients, resulting in a competition among the PBUTs to bind to albumin, 
or (ii) post-translational modifications (PTMs) of albumin in CKD and HD patients by 
e.g. oxidation [29–31], glycation [32–34], carbamylation [35–37], or guanidinylation [38] of 
lysine residues. However, to date, it is not clear whether the observed decrease in %PB of 
PBUTs in CKD and HD patients is attributed to (i) the competition between them, depending 
on their degree of binding (i.e. %PB) or binding affinity, (ii) the modification of albumin, or 
(iii) the combination of both.  
In the past, a substantial number of binding studies were performed to unravel the binding 
characteristics of the studied PBUTs [1,25,28,39–44], but only few of them discussed their 
mutual competitive binding behavior in detail [25,41,43,44]. In most cases, the interaction 
between indoxyl sulfate (IS) and p-cresylsulfate (pCS) was discussed, whereas – to the best of 
our knowledge – none of these articles discussed the competition with other, less bound UTs 
such as hippuric acid (HA) or indole-3-acetic acid (IAA). Furthermore, most in vitro binding 
experiments were conducted in solutions prepared from commercially available human serum 
albumin powder (HSA) and did not take into account the PTMs affecting albumin as observed 
in CKD and HD patients [24,38,45], and their possible effect on the %PB of PBUTs [38]. 
In this work, we intended to gain more insight into the binding of HA, IAA, IS and pCS by 
evaluating their binding characteristics in three distinct conditions: (i) serum from healthy 
controls, (ii) serum from HD patients that was cleared from uremic toxins (i.e. blank HD serum) 





these uremic toxins was studied by spiking blank HD serum with two PBUTs in pairs, having 
one PBUT in a varying concentration. 
 Materials and methods 
5.2.3.1 Sample collection  
Blood samples from twelve healthy controls and pre-dialysis blood samples from sixty-seven 
stable HD patients were collected in Venosafe serum tubes (Terumo Europe, Leuven, Belgium). 
After clotting, these tubes were centrifuged [Beckman Coulter X-15R centrifuge, 3000 rpm 
(range: 784 g – 2095 g), 10 min] and aliquots were stored at -80 °C. After thawing, four different 
serum pools were prepared according to the requirements of the four experiments, i.e. the 
construction of a binding curve in (i) healthy serum, (ii) blank HD serum and (iii) non-treated 
HD serum and the competition experiments in (iv) blank HD serum. The blank HD 
sera were cleared from uremic toxins by a 24 h in vitro dialysis procedure, followed by the 
addition of activated charcoal, as recently described by de Loor et al. [46]. Each pool was stored 
at -80 °C until the experiments were performed. 
This study was performed according to the Declarations of Helsinki, was approved by the local 
Ethical Committee (2010/033 for healthy serum, 2015/0571 for non-treated HD serum and 
2015/0932 for blank HD serum), and all patients gave their written informed consent. 
5.2.3.2 Chemicals 
HA, IAA, IS and phosphate buffered saline (PBS) tablets were purchased from Sigma-Aldrich 
(St. Louis, MO, USA) and pCS from TCI Chemicals (Zwijndrecht, Belgium). Water (HPLC 
grade) was purchased from Acros Organics (Thermo Scientific, Geel, Belgium). All stock 
solutions were prepared in PBS buffer and stored at -20 °C. 
5.2.3.3 Binding characteristics and mutual competition 
Binding curves were constructed, in a single run, for the four PBUTs by spiking healthy serum, 
blank HD serum and non-treated HD serum samples (190 µL) with eight concentrations (10 µL, 
20x stock solutions of the final concentration) of either HA, IAA, IS or pCS. For each 
compound, the theoretical final concentrations were 100, 250, 500, 750, 1000, 2500, 5000 and 




10000 µmol/L, corresponding to normal physiological [23] over uremic [23] up to 
supra-physiological concentrations to ensure binding saturation. Finally, 150 µL of the spiked 
serum was used in equilibrium dialysis. 
In a second series of experiments, the mutual binding competition of all four studied PBUTs 
was investigated by spiking blank HD serum (1980 µL) with a concentration (20 µL, 100x stock 
solution of the final concentration) of one PBUT to reach a final uremic concentration of 
100 µmol/L for pCS and IS, 10 µmol/L for IAA and 400 µmol/L for HA [23], followed by an 
incubation step (37 °C, 30 min). Subsequently, the spiked blank HD serum was divided into 
aliquots of 190 µL, and the so-called competing PBUT was added to each aliquot in different 
concentrations (10 µL, 20x stock solutions of the final concentration), up to high uremic 
concentrations [23], followed by a second incubation step (37 °C, 30 min). Finally, 150 µL of 
the serum was used in equilibrium dialysis. These experiments were performed in triplicate. 
5.2.3.4 Equilibrium Dialysis 
In both series of experiments, equilibrium dialysis (ED) was used to separate the free fractions 
using a HTDialysis 96b system (HTDialysis, Connecticut, USA). The dialysis membranes, 
consisting of regenerated cellulose with a molecular weight cut-off of 3.5 kDa, were hydrated 
and used according to the manufacturer’s guidelines. The spiked serum (150 µL) was dialyzed 
against a PBS solution (150 µL, pH = 7.4, ionic strength = 0.15 mol/L) for 5 hours at 37 °C on 
a reciprocating shaker and an adhesive film was used to seal the wells. After 5 hours, 
equilibrium was reached (determined in a pilot experiment, data not shown) and samples were 
taken from both sides of the dialysis chamber and stored at -80 °C until bulk analysis.  
5.2.3.5 Analyses 
Total and free PBUT concentrations were determined by an Acquity H Class (Waters, Zellik, 
Belgium) ultra-high performance liquid chromatography system. Chromatographic separation 
was performed on an Acquity CSH Fluoro Phenyl column (50 x 2.5 mm, 1.7 µm, Waters, Zellik, 
Belgium) with an Acquity CSH Fluoro Phenyl VanGuard pre-column (10 x 2.5 mm, 1.7 µm, 
Waters, Zellik, Belgium) and PBUTs were detected using a Xevo TQS tandem mass 
spectrometer (Waters, Zellik, Belgium). The sample preparation and chromatographic analysis 





Total protein and albumin analyses were performed in the routine laboratory of Ghent 
University Hospital on a Cobas 8000 c701 (total protein) and c502 (albumin) analyzer (Roche 
Diagnostics, Mannheim, Germany) using the biuret and bromocresol green method, 
respectively.  
5.2.3.6 Calculations 
Total protein and albumin concentrations were measured in all serum pools before and after 
5 hours of ED to check possible dilution effects caused by oncotic pressure. Therefore, 3 x 
150 µL serum of each pool was dialyzed against 150 µL PBS buffer and 150 µL serum of the 
same pool. ED of serum against PBS resulted in a decrease in protein concentrations 
(i.e. 10 ± 0 % for healthy and HD serum and 6 ± 2 % for blank HD serum, all p < 0.05),  whereas 
no change in protein concentration (i.e. 0 ± 2 %) was observed when dialyzing against serum 
of the same pool. Consequently, correction for these dilution effects was performed according 
to Banker et al.[47]. 
The non-covalent binding of PBUTs with proteins results in a complex (FP) which is assumed 
to be in a dynamic equilibrium with the free fraction of uremic toxins (F) and proteins (P): 
FP ⇌ F+P     (Eq. 5-1) 




     (Eq. 5-2) 
Where CF is the free PBUT concentration, CP is the protein concentration without bound 
ligands, and CFP is the complex concentration. The dissociation constant represents the 
concentration of the free PBUT at which the binding sites on albumin are half occupied 
(i.e. CP = CFP). Consequently, the higher Kd, the weaker the affinity of the PBUT for albumin.  
The %PB was calculated from the measured free (CF) and total (CT) PBUT concentrations: 
%PB = (1- 
CF
CT
)  x 100%    (Eq. 5-3) 
To correct for differences in albumin concentrations between the serum pools, the bound 
concentrations (i.e. CT – CF) were normalized to the measured albumin concentrations (CAlb) 
and were expressed as the binding coefficient (B): 







     (Eq. 5-4) 
SigmaPlot version 13 (Systat Software, San Jose, CA, USA) was used to fit the one site 











     (Eq. 5-6) 
Where Bmax is the modeled maximal number of PBUT to a single albumin molecule (= binding 
capacity). Both models were compared with the standard error of the estimate and the Akaike 
Information Criterion (AIC) was calculated (i.e. the quality of each statistical model, relative to 
each of the other models). Models containing the lowest standard error and AIC value were 
retained. Binding curves were compared by the best-fit (Bmax) values using a t-test. P < 0.05 
was considered significant. 
5.2.3.7 Statistics 
SigmaPlot version 13 was used to perform statistical analyses. Data were checked for normality 
by a Shapiro-Wilk test. One-way repeated measures analysis of variance or Friedman tests with 
Tukey post hoc analysis were used as appropriate. P < 0.05 was considered significant. 
 Results 
Table 5-1 presents the total protein and albumin concentrations, as well as the total PBUT 
concentrations of HA, IAA, IS and pCS as determined in each pool, used for the construction 
of binding curves and for the competition experiments. Total protein and albumin 
concentrations were the highest in the pool of healthy serum, followed by those measured in 
the pool of non-treated HD serum. The effectiveness of the applied clearing procedure is shown 
by the tremendous decrease in PBUT concentration (Table 5-1). Due to serum oncotic pressure, 
a small volume shift of dialysate was observed resulting in a small (12 – 20%) decrease in total 







Table 5-1 Total protein, albumin, and total concentrations of hippuric acid (HA), indole-3-acetic acid 
(IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS) as determined in each pool, used for the construction 
of binding curves and in the competition experiments. 









Proteins (g/L)     
Total Protein 74.2 49.4 65.3 54.2 
Albumin 48.1 29.4 40.1 33.6 
Total PBUT (µmol/L)    
HA 5.00 < LODa 190.07 < LODa 
IAA 2.59 0.18 8.26 0.40 
IS 4.54 < LODb 111.35 <LOQd 
pCS 11.63 < LOQc 196.16 0.38 
HD: hemodialysis, LOD: limit of detection, LOQ: limit of quantitation, aLOD (HA) = 0.5 µmol/L,  
bLOD (IS) = 0.03 µmol/L, cLOQ (pCS) = 0.3 µmol/L, dLOQ (IS) = 0.2 µmol/L. 
The binding curves for HA, IAA, IS and pCS in healthy serum (green curve, dots), blank HD serum (blue curve, 
triangles), and non-treated HD serum (red curve, squares) are depicted in Figure 5-1 and the corresponding 
dissociation constant(s), Kd and binding capacity, Bmax obtained after nonlinear regression are summarized in B: 
binding coefficient; n = 1. 
Table 5-2. According to the standard error of the estimate and AIC comparison, a one site 
binding model was preferred for HA and pCS in healthy serum, whereas a two site binding 
model fitted the best for IAA and IS. The binding of the four studied PBUTs to albumin in 
blank HD serum and non-treated HD serum was best described by a one site binding model. 
The obtained Kd values  for HA and pCS were in the same range (10
-4) for the different types 
of serum, whereas for IAA and IS, a high affinity (10-5) site in healthy serum and a lower affinity 
site (10-4 – 10-3) in blank HD serum and non-treated HD serum were found. For all four 
compounds, binding curves constructed in healthy serum reached higher B values than those in 
blank HD serum (p < 0.05 for HA, IAA, and pCS) and non-treated HD serum (p < 0.05 for HA, 
IS, and pCS; p = 0.054 for IAA). These findings are reflected in the Bmax values, which were 
the lowest for HA (1.01 – 2.03), and where higher for IAA (3.20 – 6.05), IS (4.64 – 5.85), and 
pCS (3.69 – 5.00). This implicates that per albumin molecule, more ligands (i.e. PBUTs and 
other protein-bound solutes, such as drugs) can be bound in healthy serum than in blank HD 
and non-treated HD serum. Furthermore, the binding curve for HA in blank HD serum was 











Figure 5-1 Binding curves for hippuric acid, indole-3-acetic acid, indoxyl sulfate and p-cresyl sulfate in 
healthy serum (green curve, dots), blank HD serum (blue curve, triangles), and non-treated HD serum 








B: binding coefficient; n = 1. 
Table 5-2 Dissociation constants, binding capacities, and AIC values as determined for hippuric acid 
(HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS) in healthy serum,  
blank HD serum, and non-treated HD serum. 
  Healthy serum Blank HD Non-treated HD serum 
HA Kd (mol/L) 7.80 10-4 6.63 10-4 5.96 10-4 
 Bmax 2.03 1.56 1.01 
 AIC -31.4 -26.4 -34.4 
IAA Kd1/Kd2 (mol/L) 6.72 10-5 3.27 10-3 1.18 10-3 1.04 10-3 
 Bmax1/Bmax2 0.69 6.05 3.20 3.29 
 AIC -4.1 -14.7 -40.9 
IS Kd1/Kd2 (mol/L) 3.10 10-5 1.11 10-3 1.01 10-3 6.60 10-4 
 Bmax1/Bmax2 0.69 5.85 5.81 4.64 
 AIC -18.6 -5.1 -32.8 
pCS Kd (mol/L) 3.07 10-4 2.94 10-4 3.02 10-4 
 Bmax 5.00 3.69 3.80 
 AIC -13.6 -18.4 -30.0 
HD: hemodialysis, Kd: dissociation constant, Bmax: binding capacity, AIC: Akaike Information Criterion. 
In the competition experiments, blank HD serum was first spiked with a fixed concentration of 
one PBUT (indicated by the grey frame at the left of each graph) and subsequently spiked with 
another PBUT (indicated by ‘+ PBUT’ on the x-axis of each graph)  in a stepwise varying 
Hippuric Acid
Free concentration (µmol/L)


























































concentration and the obtained %PB of these PBUTs are shown in Figure 5-2 and Table 5-4 in 
5.2.8  Supplementary table). In the serum samples spiked with either IS or pCS, the %PB of 
HA (panel A) or IAA (panel B) when spiked to final concentrations of 400 and 10 µmol/L, 
respectively, was not affected. A decreased %PB for HA was observed when HA (500 µmol/L) 
was added to serum containing 10 µmol/L IAA (panel B). Thus, the effect seemed to be rather 
small for the weakly bound HA and IAA. The addition of a maximum concentration of 200 
µmol/L pCS and IS to serum containing 100 µmol/L IS (panel C) and pCS (panel D), 
respectively, was found to decrease the %PB of IS and pCS significantly, revealing a mutual 
competition between the strongly bound IS and pCS. 
Figure 5-2 The percentage protein binding (%PB) of hippuric acid (HA), indole-3-acetic acid (IAA), 
indoxyl sulfate (IS) and p-cresyl sulfate (pCS) as determined in blank HD serum spiked with one PBUT to 
reach a final uremic concentration (indicated by the grey frame at the left of each graph), followed by the 









o p < 0.05 versus no competitor added, + p< 0.05 versus the lowest concentration of competitor added,  
# p < 0.05 versus the middle concentration of competitor added; n = 3. 
A trend of lower %PB of HA was observed when added to 100 µmol/L pCS (51.6 – 54.1%) 
and IS (46.8 – 52.7%), as compared to serum containing 10 µmol/L IAA (for 100 and 
200 µmol/L HA; 63.3 – 65.1%). A similar trend was observed for the addition of IAA to 
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400 µmol/L HA (87.3 – 90.9%), demonstrating a possible influence of the type of PBUT that 
is present in the serum. 
 Discussion 
In this work, the binding characteristics of HA, IAA, IS and pCS are described in healthy serum, 
blank HD serum, and non-treated HD serum. Furthermore, the mutual competitive binding of 
these four PBUTs was studied in pairs, using different concentrations of individual compounds. 
The main findings of this work are: (i) for all four compounds, the binding capacity of healthy 
serum was higher than blank HD serum, which was comparable to non-treated HD serum, 
except for HA and (ii) at high uremic concentrations, mutual competitive binding was observed 
between the strongly bound PBUTs IS and pCS. The %PB of the weakly bound HA and IAA 
was lower (trend) only for the addition to blank HD serum containing the strongly bound IS or 
pCS. 
No differences in binding curves were observed for IAA, IS and pCS between blank HD and 
non-treated HD serum, despite the large amount of competing PBUTs in the latter serum pool. 
For HA, however, the binding curve constructed in blank HD serum was situated between the 
curves in healthy serum and non-treated HD serum. This blank HD serum was cleared from 
PBUTs and thus competition between the different PBUTs can in this setting be assumed as 
negligible. Thus, for HA, competition seemed to play a certain role in the binding to albumin 
in HD serum, but was only observed in the mutual competition experiments for the addition of 
500 µmol/L HA to 10 µmol/L IAA, and was performed in blank HD serum. Possibly, protein-
bound toxins, other than those studied in the present competition experiments, and protein-
bound drugs might play a role as well in this competition for HA.  
Several studies discussed the reduced binding capacity of albumin for PBUTs [4,24,26,42] and 
for drug compounds [6,10,48,49] in CKD patients. In some of these papers, the decreased 
binding capacity was attributed to the elevated concentrations of uremic toxins in CKD patients 
[4,24], while a growing number of studies describe the effect of PTMs of the albumin molecules 
on the protein binding of PBUTs in CKD patients [24,38,45]. Rueth et al. demonstrated the 
influence of guanidinylation on the binding of IS to albumin and found that Bmax values were 







Table 5-3, an overview of binding characteristics for HA, IAA, IS, and pCS as well as the 
corresponding experimental conditions to obtain these results is presented, as found in the 
literature. Most studies reported that HA, IAA, IS, and pCS bind to albumin according to a 
two-site model, while we only found this for IAA and IS in healthy serum. Additionally, the 
binding capacity of albumin was previously reported to be much lower than the Bmax values 
presented in this work. However, in the previous studies, the binding characteristics of HA, 
IAA, IS, and pCS were mostly evaluated without reaching saturation of the binding sites of 
albumin [25,28] and in most cases, the experiments were performed in a solution prepared from 
commercially available human serum albumin powder [1,3,38,39,41,42,50,51]. In our study, 
we aimed to reflect the physiologic and uremic situation the best by using healthy and HD 
serum, respectively. Moreover, a better estimate of the binding capacity of albumin could be 
obtained in these two groups by (almost) reaching binding saturation.  
To the best of our knowledge, only the mutual competitive binding of IS and pCS was reported 
previously [42,43] and our findings are in line with those discussed by Meijers  et al. as they 
showed that the mutual competition of IS and pCS in serum from both healthy controls and HD 
patients is small, but significant [43]. Watanabe et al. demonstrated a larger competitive effect 
when studying concentrations far beyond the uremic range [42]. 
Although we studied binding characteristics and binding competition in the most relevant 
matrix (i.e. serum), some issues need to be stressed. Firstly, in each experiment, the free fraction 
was obtained by equilibrium dialysis. In this method, it is known that samples are susceptible 
to pH shifts when they are in contact with the surrounding air [52]. Therefore, we used an 
adhesive film to close the system, minimizing contact with the air, and serum samples were 
dialyzed against a PBS buffer with pH = 7.4. Nevertheless, if any small shift in pH would have 
occurred, this would not have changed the %PB of the investigated PBUTs significantly, as we 
recently demonstrated [53]. Secondly, blank HD serum showed a slight decrease in protein 
concentration during the dialysis step, most likely caused by oncotic pressure. This small 
disadvantage does not outweigh the use of in vivo relevant modified human albumin present in 
blank HD serum. Furthermore, the presented binding curves and their corresponding 
characteristics were corrected for albumin concentration, and in the competition experiments, 
all tests were performed in the same pool of blank HD serum. 






Table 5-3 Summary of dissociation constants, binding capacities, and experimental conditions found in literature, as determined for hippuric acid (HA), 
indole-3-acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS). 
 Kd,1 Kd,2 Bmax,1 Bmax,2 Matrix (µmol/L) Cmax,PBUT (µmol/L) Buffer T (°C) Method Ref 
HA 6.49 10-5 7.75 10-4 n.m. 25 (HSA) 1928 20 mM SPB 37 ITC 
[51] 
 7.63 10-4 0.97 5 (HSA) 10 20 mM SPB 37 FQ 
 1.00 10-4 3.33 10-3 1.0 7.0 200 (HSA) 140 67 mM SPB 25 UF/ED [50] 
 4.00 10-5 1.50 10-3 9.2 23 336 (BSA) 300 100 mM SPB 25 POT [39] 
IAA 4.76 10-6 1.25 10-3 1.0 5.0 40 (HSA) 18 67 mM SPB 25 UF/ED [50] 
 1.16 10-2 n.m. 360 (HSA)  
67 mM 
P/SPB 
37 ED [1] 
 4.30 10-4 8.70 10-3 1.2 2.9 336 (BSA) 300 100 mM SPB 25 POT [39] 
IS 6.21 10-7 1.20 10-4 1.0 3.0 40 (HSA) 24 67 mM SPB 25 UF/ED [50] 
 8.20 10-1 0.97 900 (HSA) 30000 25 mM MES 37 ITC [3] 
 3.20 10-4 4.00 10-3 5.0 6.8 336 (BSA) 300 100 mM SPB 25 POT [39] 
 1.02 10-5 8.33 10-4 1.0 1.6 500 (HSA) n.m. PBS 25 UF [42] 
 5.04 10-6 n.m. 0.72 547 (HSA) 
1200 
PBS 
37 ED/UF [25]  1.54 10-5 n.m. 0.74 Healthy plasma 
n.a. 
 2.51 10-5 n.m. 0.65 HD plasma 
 1.34 10-5 0.54 Healthy plasma 150 n.a. RT UF [28] 
 6.10 10-6 0.72 
37.5 (Isolated 
healthy HSA) 
150 PBS RT UF [38] 
 2.71 10-6 0.23 
37.5 (Isolated 
CKD HSA) 
pCS  4.29 10-3 1.02 900 (HSA)  10 mM SPB 37 ITC [41] 
 1.00 10-5 1.96 10-4 1.0 1.2 500 (HSA) n.m. PBS 25 UF [42] 
 9.52 10-6 n.m. 1.05 547 (HSA) 
1200 
PBS 
37 ED/UF [25]  1.05 10-5 n.m. 0.78 Healthy plasma 
n.a. 
 2.83 10-5 n.m. 1.07 HD plasma 
Kd: dissociation constant in mol/L, Bmax: binding capacity, HSA: human serum albumin solution, BSA: bovine serum albumin solution, Cmax,PBUT: highest concentration of 
protein-bound uremic toxin, buffer: used to dissolve BSA or HSA, (P/)SPB: (potassium/) sodium phosphate buffer, PBS: phosphate buffered saline, MES: 
2-(N-morpholino)ethanesulfonic acid, RT: room temperature, ITC: isothermal titration calorimetry, FQ: fluorescence quenching, UF: ultrafiltration, ED: equilibrium dialysis, 






Using serum from healthy and HD patients, we adequately described the intrinsic impact on 
protein binding in uremia, revealing a lower binding capacity, as compared to healthy controls. 
Mutual competition was mainly observed for the strongly bound PBUTs and/or with high 
uremic concentrations. In addition, at least part of the effect on binding capacity may be 
attributed to PTMs of albumin in uremic patients. In the same line of the present study, it would 
be very interesting to investigate the possible competition of protein-bound drug compounds 
versus PBUTs in CKD and HD patients. 
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 Supplementary table 
Table 5-4 The percentage protein binding (%PB) of hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS) as determined in 
blank HD serum spiked with a concentration of one PBUT (indicated by the black frame at the left of each panel) to reach a final uremic concentration, followed by 
the addition of a competing PBUT, up to high uremic concentrations. 
A C 
(µmol/L) 
%PB competitor %PB HA 
 B C  
(µmol/L) 
%PB competitor %PB IAA 
     
HA 400 / 49.9 ± 1.9  IAA 10 / 86.1 ± 1.4 
+ IAA 5 89.3 ± 2.9 49.8 ± 2.2  + HA 100 65.1 ± 10.2 86.4 ± 6.8 
 10 90.9 ± 14.5 56.8 ± 0.0   200 63.3 ± 4.0 87.6 ± 3.7 
 20 87.3 ± 10.9 47.7 ± 3.3   500 31.9+,# ± 14.0 85.6 ± 6.8 
+ IS 50 95.3 ± 3.8 50.1 ± 1.7  + IS 50 95.7 ± 0.4 86.4 ± 0.4 
 100 94.7 ± 1.9 49.4 ± 1.2   100 94.9 ± 0.4 84.7 ± 1.1 
 200 92.9 ± 1.5 47.2 ± 0.8   200 94.3 ± 2.0 82.5 ± 6.2 
+ pCS 50 96.5 ± 0.6 49.9 ± 1.8  + pCS 50 96.9 ± 0.2 85.5 ± 0.3 
 100 95.5 ± 1.1 47.7 ± 2.3   100 96.5 ± 0.2 84.7 ± 0.5 
  200 94.8 ± 0.7 45.1 ± 1.5    200 95.4 ± 0.2 80.5 ± 0.6 
                         
C C 
(µmol/L) 
%PB competitor %PB IS 
 D C 
(µmol/L) 
%PB competitor %PB pCS 
     
IS 100 / 95.6 ± 1.4  pCS 100 / 95.6 ± 0.6 
+ HA 100 52.7 ± 2.9 94.9 ± 0.3  + HA 100 54.1 ± 1.3 96.2 ± 0.1 
 200 51.8 ± 1.7 93.6 ± 1.8   200 51.6 ± 1.7 96.0 ± 0.2 
 500 46.8 ± 0.9 92.9 ± 2.4   500 53.5 ± 0.9 96.4 ± 0.8 
+ IAA 5 82.3 ± 0.4 94.0 ± 1.1  + IAA 5 84.2 ± 0.4 93.7 ± 1.7 
 10 82.5 ± 1.0 95.2 ± 1.3   10 84.4 ± 1.0 95.6 ± 1.0 
 20 83.0 ± 2.3 94.6 ± 0.7   20 81.5 ± 2.3 96.1 ± 0.8 
+ pCS 50 96.0 ± 0.1 94.4 ± 0.6  + IS 50 94.4 ± 0.1 96.0 ± 0.2 
 100 94.9 ± 0.1 93.1 ± 1.3   100 93.6 ± 0.1 95.6 ± 0.2 
  200 93.7 ± 0.3 91.5o ± 1.1    200 91.7 ± 0.3 94.2o,+,# ± 0.2 
o p < 0.05 versus no competitor added, + p < 0.05 versus the lowest concentration of competitor added,  





5.3 Protein binding of vancomycin and teicoplanin and the related 
competition with protein-bound uremic toxins in plasma from healthy 
subjects and patients on hemodialysis: an in vitro study  
In preparation: Deltombe O, Stove V, Glorieux G and Eloot S, Protein binding of vancomycin and teicoplanin and 
the related competition with protein-bound uremic toxins in plasma from healthy subjects and patients on 
hemodialysis: an in vitro study. 
 Abstract 
It is often hypothesized that the protein binding of drugs might be changed in patients with 
chronic kidney disease (CKD) as compared to patients with normal renal function, as a result 
of binding competition with protein-bound uremic toxins (PBUTs).  
In the present study, the percentage protein binding (%PB) of two commonly administered 
antibiotics, i.e. vancomycin and teicoplanin, was studied in vitro by spiking a plasma pool from 
healthy subjects (only high) and from patients on hemodialysis (HD; low, medium and high) at 
different concentrations [22.5 (low), 45 (medium) and 90 (high) mg/L for vancomycin and 
35 (low), 70 (medium) and 140 (high) mg/L for teicoplanin]. Our aims were (i) to find out 
whether the %PB of the antibiotics is affected in patients treated with HD and (ii) to evaluate 
the potential protein binding competition with the following PBUTs: hippuric acid (HA), 
indole-3-acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS).  
No difference in %PB for vancomycin (%PB = 58.9 % versus 60.0 %), nor for teicoplanin 
(%PB = 94.7 % versus 94.6 %) was observed after spiking healthy and HD plasma with a high 
concentration. But, a significant increase in %PB of vancomycin was found from low over 
medium to high concentration. When the protein binding of PBUTs in the presence of 
vancomycin was studied, a minor but significant increase of %PB was found for all four 
PBUTs, high drug concentration versus low, while a similar minor increase was present for 
high concentration versus no drug for IS and pCS. For medium concentration versus reference 
there was no difference. When the highly-bound teicoplanin was added to both plasma pools, 
no relevant changes in %PB of the studied PBUTs were observed.  
Overall, it was concluded that (i) the %PB of vancomycin and teicoplanin was respectively 
slightly or not affected in plasma from HD patients and (ii) there were no relevant biological 
changes in the %PB of PBUTs, for the studied clinical concentrations, suggesting the absence 
of protein binding competition between the antibiotics versus the studied PBUTs.   
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 Introduction 
It is often hypothesized that the protein binding of drug compounds might be changed in 
patients with chronic kidney disease (CKD) as compared to patients with normal renal function 
[6, 9]. Therefore, the effect of CKD has previously been studied both in vitro and in vivo for a 
number of drugs. In general, the percentage protein binding (%PB) was found to be increased 
for basic drugs (e.g. clonidine (pKa = 8.2) and propranolol (pKa = 9.7) [6]) and decreased for 
acidic drugs (e.g. methotrexate (pKa = 3.4) [6], valproic acid (pKa = 5.1) [10, 48] and 
furosemide (pKa = 4.25) [8, 54]). Neutral drug compounds were affected in a varying way 
resulting in either an increase (e.g. cimetidine (pKa = 13
1 and 6.92) [6]) or decrease (e.g. 
phenytoin (pKa = 9.5
1 and -92) [6, 48], theophylline (pKa = 7.8
1 and -0.82) [6], diazepam 
(pKa = 2.9
2) [6, 55]) in %PB. Additionally, for some other neutral (e.g. propofol (pKa = 11.1
1 
and -52) [56]) and basic drugs (e.g. penbutolol (pKa = 9.8) [57] and gentamicin (pKa = 12.5) 
[58]), the %PB was not found to be changed in patients with CKD as compared to patients with 
normal renal function. 
Decreased drug protein binding in patients with CKD is sometimes attributed to the binding 
competition with accumulated endogenous compounds [9], also called uremic retention solutes, 
or uremic toxins when they exert toxicity [22, 23]. Not only a large fraction of drug compounds, 
but also protein-bound uremic toxins (PBUTs), such as hippuric acid (HA), indole-3-acetic acid 
(IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS), predominantly bind to albumin [25, 44]. 
Therefore, drugs and PBUTs may compete when they bind to the same binding site on albumin 
[9]. However, to the best of our knowledge, data supporting this hypothesis are only available 
for furosemide [8, 54]. A second cause of altered protein binding might be attributed to post-
translational modifications (PTMs, e.g. oxidation [29–31], glycation [32–34], carbamylation 
[35–37] and guanidinylation [38]) of albumin in patients with CKD. These PTMs may result in 
a conformational change of the binding sites, resulting in a lower or higher binding affinity. 
Vancomycin and teicoplanin are two protein-bound glycopeptide antibiotics which have a 
similar mechanism of action and can be used to treat infections caused by Gram-positive 
bacteria such as methicillin-resistant Staphylococcus aureus [59–62]. While there is a high 
variability in the reported %PB for vancomycin, i.e. from 5 to 90 % [49, 63–69], the variability 
in the reported %PB values for teicoplanin is less, i.e. ranging from 70 to 99% [65, 70–72]. Both 
antibiotics are predominantly eliminated by renal excretion [70, 73]. Therefore, dosage 





and thus %PB, in patients with CKD is scarce and has been described for vancomycin in only 
two papers [49, 63]. For teicoplanin, to the best of our knowledge, no protein binding studies 
in a CKD population were performed so far. However, knowledge on the free fraction might be 
important since only the free drug can travel through cell membranes towards the site of action 
to exert its pharmacological effect. Therefore, changes in protein binding are especially 
important when the %PB of a compound is high, such as for teicoplanin. In addition, no data 
are available on the possible protein binding competition of vancomycin and teicoplanin with 
PBUTs. 
In this in vitro study, the %PB of vancomycin, teicoplanin as well as of a selected panel of 
PBUTs (i.e. HA, IAA, IS and pCS) was compared before (PBUTs only) and after spiking a pool 
of plasma, obtained from healthy subjects and from patients on hemodialysis (HD), with either 
vancomycin or teicoplanin. 
 Materials and methods 
5.3.3.1 Sample collection 
Blood samples from 13 healthy subjects and pre-dialysis blood samples from 16 stable HD 
patients were collected in Vacutainer K2EDTA tubes (Becton Dickinson Company, New Jersey, 
USA). Subsequently, blood was centrifuged for 10 min at 2095 g at room temperature (RT) 
(Beckman Coulter X-15R centrifuge - VWR, Leuven, Belgium) and the obtained plasma was 
stored  at -80 °C. After thawing, two different plasma pools were prepared, i.e. one of healthy 
plasma and one of HD plasma, and aliquots of 975 µL were stored at -80 °C until the 
experiments were started. 
This study was conducted according to the Declarations of Helsinki, was approved by the 
Ethical Committee of Ghent University Hospital (2017/0162 and 2008/232) and all participants 
gave their written informed consent. 
5.3.3.2 Chemicals 
Vancomycin hydrochloride (500 mg) was purchased from Mylan (Hoeilaart, Belgium), 
teicoplanin (400 mg) from Sanofi-Aventis (Machelen, Belgium) and phosphate buffered saline 
(PBS) buffer pH = 7.4 from Invitrogen (Thermo Fisher Scientific, Ghent, Belgium).
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5.3.3.3 Stock solutions 
Vancomycin (500 mg, Figure 5-3) and teicoplanin (400 mg, Figure 5-4) were separately 
dissolved in 10 mL PBS to reach final theoretical concentrations of 50 g/L and 40 g/L, 
respectively. Subsequently, these solutions were further diluted to obtain a high, medium and 
low 40x stock solution of the final concentration. Theoretical concentrations of these 40x stock 
solutions were 3600 (high), 1800 (medium) and 900 (low) mg/L for vancomycin and 5600 
(high), 2800 (medium) and 1400 (low) mg/L for teicoplanin, respectively. 
Figure 5-3 Chemical structure of vancomycin hydrochloride. 
 
5.3.3.4 Vancomycin and teicoplanin spiking experiments 
Aliquots (975 µL) of healthy and HD plasma pools were thawed and mixed. Subsequently, 
25 µL of the 40x stock solution containing either a high vancomycin or teicoplanin 
concentration was added to healthy plasma (each n = 6) and 25 µL of the 40x stock solution 
containing either vancomycin or teicoplanin in high, medium or low concentration was added 
to HD plasma (each n = 6). In addition, reference samples (each n = 6) were included to study 
the baseline %PB of PBUTs in both plasma pools. Hereto, 25 µL PBS containing neither 
vancomycin nor teicoplanin was added to the reference samples. After spiking, all samples were 
mixed and incubated at RT for 30 min. Next, 500 µL plasma was transferred into Centrifree 





37 °C as previously described for vancomycin [76]. Finally, ultrafiltrate (containing free PBUT 
and either free vancomycin or teicoplanin) and corresponding plasma samples (for total PBUT 
and either total vancomycin or teicoplanin quantification) were kept at 4 °C (max 24h) until 
sample preparation or were analyzed directly (vancomycin assay only). 
Figure 5-4 Chemical structure of teicoplanin, which is composed of compounds A3-1, A2-1, A2-2, A2-3, 
A2-4 and A2-5. 
 
5.3.3.5 Analyses 
PBUTs. Plasma and ultrafiltrate samples (100 µL) were diluted by adding 260 µL HPLC grade 
water, heated for protein denaturation (30 min, 95 °C), cooled down on ice (10 min) and spun 
at 15588 g (10 min, RT, Beckman Coulter F241.5P Microfuge 18 – Analis, Ghent, Belgium). 
Subsequently, denaturated plasma samples were ultrafiltered to have all steps equal for the 
analysis of both free and total PBUTs. Next, 225 µL of each sample was transferred into an 
autosampler vial, 25 µL internal standard (fluorescein, 50 mg/L) was added and each sample 
was vortexed. Finally, all samples were placed in the autosampler at 4 °C and 18 µL was 
injected onto the column [53]. Total and free concentrations of hippuric acid (HA), 
indole-3 acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS) were determined by 
an ultra-high performance liquid chromatography (UHPLC) instrument with ultraviolet (HA) 
and fluorescence (IAA, IS and pCS) detection, as previously described in more detail [53]. The 
within-run and between-run precision for both total and free PBUTs were below 2.0 % and 
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3.3 % for HA, 2.6 % and 6.3 % for IAA, 2.6 % and 4.8 % for IS, and 2.5 % and 6.0 % for pCS, 
respectively. 
Vancomycin. Total and free vancomycin concentrations were assayed by a chemiluminescent 
microparticle immunoassay [76]. Plasma and ultrafiltrate samples were analyzed directly since 
no sample preparation was required for this assay. The within-run precision was < 6.4 % for 
both total and free vancomycin analyses [76]. 
Teicoplanin. In this method, 50 µL internal standard (trimipramine-D3) was added to 50 µL 
plasma and ultrafiltrate samples. Subsequently, 200 µL of a MeOH/ACN (1:1, both LC-MS 
grade) solution was added and samples were vortexed and cooled down at -20 °C (30 min). 
Next, all samples were mixed using a Thermomixer (5 min, 1400 rpm, 10 °C – Eppendorf, 
Hamburg, Germany) and centrifuged (5 min, 16162 g, RT – Beckman Coulter Microfuge 16, 
VWR, Leuven, Belgium). Finally, 100 µL supernatant of each sample was transferred into an 
autosampler vial and was placed in the autosampler at 10 °C and 1 µL (total teicoplanin) or 
2 µL (free teicoplanin) was injected onto the column. Total and free teicoplanin (A2-1 to A2-5 
and A3-1 compounds) concentrations were determined by an UHPLC – high resolution mass 
spectrometry method (in house developed and validated method). The within-run and 
between-run precision for both total and free teicoplanin were 12.6 % and 11.5 %, respectively. 
Total protein and albumin analyses were performed on a Cobas 8000 c701 (total protein) and 
c502 (albumin) analyzer (Roche Diagnostics, Mannheim, Germany) using the biuret and 
bromocresol green method, respectively. 
5.3.3.6 Calculations 
The %PB was calculated from the measured free (CF) and total (CT) concentration:  
%PB = (1 - 
CF
CT
)  x 100%    (Eq. 5-7) 
Statistical evaluation was performed with GraphPad Prism 4.00 for Windows (GraphPad 
Software, La Jolla, California USA). Data were checked for normality by a Shapiro-Wilk test. 
Most data are not normally distributed and are therefore expressed as median [25th percentile 
(pct); 75th pct]. Non-parametric tests, including Mann Whitney and Wilcoxon signed-rank test 







Total protein concentrations in the pool of healthy and HD plasma were 72.7 and 66.5 g/L, 
whereas albumin concentrations were 45.9 and 38.2 g/L, respectively. 
5.3.4.1 Vancomycin 
Data of the vancomycin spiking experiment are provided in Table 5-5. Addition of vancomycin 
to the HD plasma resulted in a median total vancomycin concentration of 21.9 (low); 41.8 
(medium) and 88.3 (high) mg/L and median corresponding free concentrations of 10.7 (low); 
19.3 (medium) and 35.6 (high) mg/L. No difference in %PB of vancomycin was found when 
healthy plasma was spiked with the highest concentration (%PB = 58.9 %) as compared to HD 
plasma (%PB = 60.0 %). In HD plasma, however, the median %PB of vancomycin increased 
significantly from 50.4 to 54.7 and 60.0 % when spiked with a low and median versus a high 
concentration, respectively.  
Total PBUT concentrations of HA, IAA, IS and pCS as determined in the pool of healthy 
plasma and in the pool of HD plasma are also summarized in Table 5-5. After spiking of the 
healthy plasma pool with a high concentration of vancomycin, the total concentration of HA 
was increased (+17.4 %) with a decrease (-19.4 %) in free concentration, resulting in an increase 
in %PB (+33.7  %). Spiking HD plasma with increasing concentrations of vancomycin resulted 
in a significant decrease in free HA (-7.1 %), IAA (-10.9 %), IS (-18.1 %) and pCS (-14.2 %) 
concentrations when comparing the high concentration with the low concentration of 
vancomycin. Furthermore, a decrease in free IS (-14.3 %) and pCS (-10.6 %) concentration was 
also significant as compared to the reference samples. These changes in free PBUT 
concentration resulted in a significant increase in %PB, which was +9.4 % for HA and +4.8 % 
for IAA as compared to samples spiked with a low concentration and +0.9 % and +1.1 % for 
IS and +0.6 % and +0.9 % for pCS as compared to the %PB in the reference samples and 
samples spiked with a low concentration of vancomycin, respectively (Table 5-5). 
5.3.4.2 Teicoplanin 
Data of the teicoplanin experiment are summarized in Table 5-6. Addition of teicoplanin to the 
HD plasma resulted in a median total teicoplanin concentration of 39.5 (low); 86.2 (medium) 
and 145.8 (high) mg/L and median free teicoplanin concentrations of 2.2 (low); 3.8 (medium) 
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and 7.6 (high) mg/L. After spiking of a high teicoplanin concentration to the pool of healthy 
plasma and HD plasma, a comparable %PB was obtained, i.e. 94.7 and 94.6 %, respectively 
and after spiking with a low concentration of teicoplanin, the %PB was in the same line, i.e. 
94.4 %. After spiking with a medium concentration of teicoplanin, a small increase to 95.5 % 
was observed. 
Besides a small, but significant, decrease in total concentration (-2.6 % for IAA, -2.5 % for IS 
and -2.9 % for pCS; all within the analysis variation) in HD plasma samples spiked with a low 
concentration of teicoplanin as compared to in HD reference samples, no change in total and 
free concentration was observed with increasing concentrations of teicoplanin. Consequently, 
the %PB of HA, IAA, IS and pCS remained unchanged. 
 Discussion 
In this study, the %PB of vancomycin and teicoplanin as well as of a selected panel of PBUTs 
(i.e. HA, IAA, IS and pCS) was studied before (PBUTs only) and after spiking a pool of healthy 
plasma and a pool of HD plasma with either vancomycin or teicoplanin. The main findings of 
this in vitro work are: (i) for both vancomycin and teicoplanin, there was no difference in %PB 
between healthy and HD plasma when spiked with a high concentration; (ii) for vancomycin, 
there was an increase in %PB in HD plasma when spiked with a high concentration versus a 
low concentration, whereas for teicoplanin, the %PB remained unchanged, or the change was 
very small; (iii) for all four studied PBUTs, an increase in %PB was observed when HD plasma 
was spiked with a high concentration of vancomycin as compared to low concentrations and 
for IS and pCS as compared to the reference samples as well while (iv) the %PB of all four 
PBUTs remained unchanged when healthy and HD plasma was spiked with different 
concentrations of teicoplanin.  
The %PB of vancomycin found in our study ranged between 50 and 60 % in both plasma pools. 
This is higher as compared to the findings of Sun et al. who reported a %PB of around 25 % 
after spiking to a solution of commercial human serum albumin [64]. Although the present work 
was performed in vitro, which may not completely reflect the physiologic conditions, in 






Table 5-5 Total (CT) and free (CF) concentrations as well as the percentage protein binding (%PB) of vancomycin (vanco), hippuric acid (HA), indole-3-acetic acid 
(IAA), indoxyl sulfate (IS) and p-cresyl sulfate in a pool of plasma obtained from either healthy subjects or from patients on hemodialysis (HD) before (reference 
samples) and after spiking with vancomycin. 
 Healthy plasma pool HD plasma pool 
 Reference High Vanco Reference Low Vanco Medium Vanco High Vanco 
Vanco (mg/L)       
CT  - 89.5[87.9;90.6] - 21.9[21.7;22.5] 41.8[41.4;42.2]+ 88.3[87.9;88.9]+§ 
CF - 36.3[35.4;37.4] - 10.7[10.5;10.8] 19.3[18.1;20.1]+ 35.6[35.2;35.8]+§ 
%PB - 58.9[57.5;60.6] - 50.4[49.5;51.3] 54.7[52.5;55.3] 60.0[58.8;60.4]+§ 
       
PBUTs (mg/dL)       
HA       
CT 0.16[0.16;0.16] 0.19[0.18;0.19]o 4.50[4.47;4.56] 4.47[4.40;4.49] 4.42[4.41;4.45] 4.44[4.44;4.50] 
CF 0.08[0.08;0.09] 0.07[0.07;0.07]o 2.32[2.30;2.33] 2.40[2.36;2.44] 2.22[2.21;2.23]+ 2.23[2.19;2.24]+ 
%PB 48.3[46.2;50.1] 64.6[60.7;64.8]o 48.9[47.9;49.4] 45.9[45.0;46.9] 49.7[49.4;50.3] 50.2[49.5;51.3]+ 
       
IAA       
CT 0.05[0.05;0.05] 0.04[0.04;0.04] 0.24[0.24;0.25] 0.24[0.24;0.25] 0.24[0.24;0.24] 0.24[0.24;0.24] 
CF 0.004[0.004;0.004] 0.004[0.004;0.004] 0.08[0.07;0.08] 0.08[0.08;0.08] 0.07[0.07;0.07]+ 0.07[0.07;0.07]+ 
%PB 91.6[91.4;91.7] 91.4[91.2;91.5] 69.0[68.7;69.3] 67.2[66.8;67.7] 69.5[69.3;70.3] 70.5[70.3;70.6]+ 
       
IS       
CT 0.09[0.09;0.09] 0.08[0.08;0.08] 1.93[1.91;1.94] 1.92[1.89;1.94] 1.92[1.91;1.92] 1.91[1.90;1.93] 
CF < LOQ1 < LOQ1 0.11[0.11;0.12] 0.12[0.12;0.12] 0.10[0.10;0.10] 0.10[0.10;0.10]o+ 
%PB n.a. n.a. 94.1[93.9;94.2] 93.9[93.8;93.9] 94.9[94.5;95.0] 95.0[94.9;95.0]o+ 
       
pCS       
CT 0.20[0.20;0.21] 0.19[0.19;0.19] 3.25[3.22;3.27] 3.25[3.20;3.27] 3.21[3.19;3.23] 3.19[3.18;3.22] 
CF < LOQ2 < LOQ2 0.19[0.18;0.20] 0.20[0.19;0.20] 0.17[0.17;0.18] 0.17[0.17;0.17]o+ 
%PB n.a. n.a. 94.2[94.0;94.3] 93.9[93.8;94.1] 94.5[94.3;94.8] 94.7[94.7;94.8]o 
PBUTs: protein-bound uremic toxins; LOQ: limit of quantification; n.a.: not applicable; 1 LOQ (IS) = 0.0015 mg/dL; 2 LOQ (pCS) = 0.02 mg/dL.  
Values (n = 6) are expressed as median [25th percentile (pct); 75th pct].   
o p < 0.05 versus reference sample; + p < 0.05 versus low vanco; § p < 0.05 versus medium vanco.  
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Table 5-6 Total (CT) and free (CF) concentrations as well as the percentage protein binding (%PB) of teicoplanin (teico), hippuric acid (HA), indole-3-acetic acid 
(IAA), indoxyl sulfate (IS) and p-cresyl sulfate in a pool of plasma obtained from either healthy subjects or from patients on hemodialysis (HD) before (reference 
samples) and after spiking with teicoplanin. 
 Healthy plasma pool HD plasma pool 
 Reference High Teico Reference Low Teico Medium Teico High Teico 
Teico (mg/L)       
CT  - 138.1[128.8;148.1] - 39.5[38.8;41.9] 86.2[84.2;88.1]+ 145.8[141.0;150.3]+§ 
CF - 7.5[7.1;7.7] - 2.2[2.0;2.5] 3.8[3.2;4.7]+ 7.6[6.2;8.4]+§ 
%PB - 94.7[94.0;94.9] - 94.4[93.7;95.4] 95.5[94.6;96.2]+ 94.6[94.0;95.5] 
       
PBUTs (mg/dL)       
HA       
CT 0.06[0.05;0.06] 0.06[0.06;0.06] 4.25[4.22;4.26] 4.22[4.19;4.24] 4.31[4.25;4.32] 4.21[4.20;4.26] 
CF < LOQ1 < LOQ1 2.45[2.41;2.48] 2.43[2.35;2.49] 2.40[2.38;2.41] 2.49[2.44;2.55] 
%PB n.a. n.a. 41.8[41.4;44.4] 42.7[40.7;44.6] 44.3[43.5;45.8] 41.1[39.6;42.0] 
       
IAA       
CT 0.04[0.04;0.04] 0.04[0.04;0.04] 0.23[0.23;0.24] 0.23[0.23;0.23]o 0.23[0.23;0.23] 0.23[0.23;0.23] 
CF 0.001[0.001;0.001] 0.001[0.001;0.001] 0.08[0.08;0.08] 0.08[0.08;0.08] 0.08[0.08;0.08] 0.08[0.08;0.08] 
%PB 97.5[97.3;97.8] 97.3[96.9;97.6] 65.1[64.4;66.7] 65.0[63.8;66.3] 65.9[65.2;66.6] 64.9[63.8;65.3] 
       
IS       
CT 0.08[0.08;0.08] 0.08[0.08;0.08] 1.82[1.81;1.84] 1.78[1.75;1.78]o 1.80[1.79;1.81] 1.78[1.77;1.80] 
CF 0.003[0.002;0.003] 0.003[0.003;0.003] 0.19[0.19;0.20] 0.18[0.18;0.19] 0.18[0.18;0.19] 0.19[0.18;0.19] 
%PB 96.6[96.2;96.7] 96.5[96.4;96.7] 89.4[89.0;89.9] 89.4[89.2;89.7] 89.9[89.8;90.1] 89.6[89.5;89.8] 
       
pCS       
CT 0.18[0.18;0.18] 0.18[0.18;0.19] 3.12[3.11;3.14] 3.03[2.99;3.04]o 3.07[3.04;3.08] 3.03[3.01;3.07] 
CF < LOQ2 < LOQ2 0.30[0.30;0.32] 0.30[0.29;0.30] 0.30[0.29;0.30] 0.30[0.29;0.30] 
%PB n.a. n.a. 90.2[89.9;90.6] 90.1[89.9;90.5] 90.4[90.3;90.6] 90.3[90.1;90.4] 
PBUTs: protein-bound uremic toxins; LOQ: limit of quantification; n.a.: not applicable 1 LOQ (HA) = 0.04 mg/dL; 2 LOQ (pCS) = 0.02 mg/dL.  
Values (n = 6) are expressed as median [25th percentile (pct); 75th pct].  





In vivo, the inter-patient variability in %PB is large as demonstrated by Stove et al. in patients 
from the intensive care unit (median: 25 %, range: 13 – 41 %) [76] and by Oyaert et al. in 
patients from the intensive care unit (median: 38 %, range: 12.4 – 53 %), hematology (median: 
39 %, range: 9 – 51 %), orthopedics (median: 44 %, range: 22 – 54 %) and pediatrics (median: 
19 %, range: 4 – 38%) ward [69]. Butterfield et. al. also reported a large variation in %PB of 
vancomycin (median: 41 %, range: 24 – 64 %) in patients from the intensive care unit, the 
dermatology and pneumology ward [67].  
Because of the differences in patient populations, it is not evident to compare our data to those 
mentioned above. Even the comparison with two studies in which the %PB was studied in 
patients with CKD is not obvious [63, 64]. In the first study, Rodvold et al. studied the %PB of 
vancomycin in patients with various degrees of kidney failure. Ultrafiltration was performed at 
25 °C and the %PB was found to be around 30 %, irrespective of kidney function. In the second 
study, Tan et al. reported a %PB of around 18.5 % in patients with end-stage kidney disease 
[49]. Here again, ultrafiltration was performed at 25 °C.  
Nevertheless, one of the aims of this study was to compare the %PB of vancomycin in a plasma 
pool from healthy subjects versus HD patients. We found that the %PB was not affected by 
renal failure, which is in line with the conclusion of Rodvold et al. where the %PB remained 
unchanged at different degrees of kidney failure. Our findings and those from Rodvold et al. 
are in contrast with those from Tan et al., where a decrease in %PB of vancomycin was reported 
from 46 % in pooled serum from healthy subjects with normal renal function to 18.5 % in 
patients with end-stage kidney disease. Besides vancomycin, other basic drug compounds were 
previously studied in patients with renal failure. For these drugs, the %PB was found to be 
either increased (e.g. clonidine and propranolol [6]) or unchanged (e.g. penbutolol [57] and 
gentamicin [58]). Thus, our findings are in line with those of other basic drug compounds. 
The here reported %PB of 95 % for teicoplanin is comparable to the range reported in the 
literature, i.e. 90 % – 97 % [65, 70–72]. To the best of our knowledge, this paper is the first to 
compare the %PB of teicoplanin in plasma from healthy volunteers versus HD patients. In 
accordance to our findings when spiking with a high concentration of vancomycin, also for 
teicoplanin the %PB does not seem to be affected in CKD.  
Measured PBUT concentrations are in line with those previously described in HD patients [22, 
23, 26, 46, 77]. While free PBUT concentrations and %PB were not changed after spiking with 
different concentrations of teicoplanin, changes in %PB were observed after spiking with a high 
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concentration of vancomycin. Although the decrease in free fraction concentrations was 
between 7 and 18 %, the increase in %PB was < 9.4 % for HA, < 4.8 % for IAA and < 1.1 % 
for IS and pCS. In our opinion, this degree of change might be of limited biological relevance. 
The main plasma binding protein for the four studied PBUTs is albumin and all four 
predominantly bind to the Sudlow II binding site [25, 44]. Recently, we demonstrated that the 
albumin binding sites, in the presence of uremic concentrations of HA, IAA, IS and pCS are far 
from being saturated with ligands [78]. Albumin is also the main binding protein for teicoplanin 
[79], whereas for vancomycin, both albumin and immunoglobulin A seem to be involved [64, 
69]. In our healthy and HD plasma pools, the molar albumin concentrations were about 
690 µmol/L and 574 µmol/L, respectively. This means that the median molar concentration of 
the PBUTs (HA: 250 µmol/L, IAA: 14 µmol/L, IS: 90 µmol/L and pCS: 170 µmol/L) as well 
of vancomycin (high: 60 µmol/L) and teicoplanin (high: 75 µmol/L) were all below that of 
albumin. Therefore, it was not surprising that the %PB of PBUTs, vancomycin and teicoplanin 
was not affected when all compounds were present in the same solution. In addition, 
vancomycin and teicoplanin could also bind to another site on albumin than PBUTs do. 
Information supporting this hypothesis is, to the best of our knowledge, not available. 
In a next step, the %PB of both antibiotics could be studied in patients to whom either 
vancomycin or teicoplanin was administered and compared with the %PB in patients with 
normal renal function to see whether our in vitro data could be translated to in vivo conditions. 
In this way, also the variability in %PB of vancomycin and teicoplanin could be further explored 
in these two patient populations. 
 Conclusion 
Percentage protein binding of both vancomycin and teicoplanin is not affected in plasma of HD 
patients versus healthy controls. In addition, no relevant biological changes in the percentage 
protein binding of  hippuric acid, indole-3-acetic acid, indoxyl sulfate and p-cresyl sulfate were 
observed, which may imply that both antibiotics bind at a different binding site on albumin 
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Selective transport of protein-bound uremic toxins in erythrocytes 
6.1 Introduction 
Protein-bound uremic toxin (PBUT) kinetics during hemodialysis are different as compared to 
the kinetics of small water-soluble solutes such as urea or creatinine [1–5] since only the free 
fraction can travel through the pores of a hemodialyzer membrane. Previous studies were 
conducted aiming to enhance their plasma clearance when passing the hemodialyzer [6–8]. For 
some of these PBUTs, it was previously shown that their distribution is not limited to the 
patient’s total plasma volume [5,9]. Hence, these solutes might also be distributed in the tissues. 
Therefore, besides the clearance within the hemodialyzer, the rate of equilibration across 
cellular membranes might be an important parameter to implement in dialysis kinetic models.  
In this chapter, the intracellular distribution of a selected panel of PBUTs is demonstrated in an 
easily accessible compartment, i.e. the erythrocytes. Furthermore, kinetic parameters describing 
the transport across the erythrocyte membrane were elucidated and the impact of an anion 
transport blocker was studied to better understand the transport mechanism across the 





6.2 Selective transport of protein-bound uremic toxins in erythrocytes 
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 Abstract 
To better understand the kinetics of protein-bound uremic toxins (PBUTs) during hemodialysis 
(HD), we investigated the distribution of hippuric acid (HA), indole-3-acetic acid (IAA), 
indoxyl sulfate (IS) and p-cresyl sulfate (pCS) in erythrocytes of HD patients. Their transport 
across the erythrocyte membrane was explored in absence of plasma proteins in vitro in a series 
of loading and unloading experiments of erythrocytes from healthy subjects and HD patients, 
respectively. Furthermore, the impact of an inhibitor (i.e. 4,4’ diisothiocyanato-2,2’-
stilbenedisulfonic acid; DIDS) of uptake by Band 3 proteins expressed on the erythrocyte 
membrane was studied. The four PBUTs accumulated in erythrocytes from HD patients. From 
loading and unloading experiments, it was found that (i) the rate of transport was dependent on 
the studied PBUT and increased in the following sequence: HA < IS < pCS < IAA and that 
(ii) the solute partition of intra- to extracellular concentrations was uneven at equilibrium. 
Finally, inhibiting Band 3 proteins affected the transport of HA, IS and pCS, decreasing their 
transport parameters to comparable values. By exploring erythrocyte transmembrane transport 
of PBUTs, their kinetics can be better understood, and new strategies to increase their dialysis 
removal can be developed.  
  





The group of protein-bound uremic toxins (PBUTs) include all uremic retention solutes binding 
to plasma proteins with most of them having a molecular weight < 500 Da [10,11]. The 
percentage that is bound to proteins (% protein binding, %PB) is dependent on the solute itself 
rather than on binding competition or protein saturation [12] and may reach more than 99 % 
[13,14]. In normal conditions, the free (i.e. unbound) fraction of the toxins is passively cleared 
by glomerular filtration, whereas organic anion and cation transporters present in renal proximal 
tubule cells are responsible for the active secretion of the protein-bound fraction into the urine 
[15,16].  
In patients with end-stage kidney disease treated with hemodialysis (HD), only the fraction that 
is not bound to proteins can pass the pores of the hemodialyzer membrane. Consequently, the 
dialyzer clearance of these solutes is much lower than that for comparable small non-protein-
bound solutes, especially when the %PB is high [1,2,5]. During the past decade, studies have 
been performed aiming to improve the removal of these PBUTs during hemodialysis. Amongst 
others, the removal of PBUTs was shown to be enhanced when using extended hemodialysis 
and hemodiafiltration [17,18], by changing the local ionic strength at the blood inlet of the 
dialyzer increasing the free fraction [7], and by combining dialysis with adsorption [19–22]. 
Besides the studies on extended HD, most of these papers only focused on the removal of 
PBUTs from the plasma compartment ignoring the role of erythrocytes constituting almost 
30 – 40 % of the blood volume passing the dialyzer [5,9].  
Small water-soluble solutes are known to distribute in plasma and erythrocytes [23] and the 
transport through the erythrocyte membrane has been studied before for urea, uric acid and 
creatinine [24–28]. For PBUTs, the distribution in erythrocytes is unknown, but may help to 
explain their kinetics in the patient [2,14] as well as in the hemodialyzer [14]. 
To address this question, the present study investigated the distribution of four different anionic 
PBUTs [hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl 
sulfate (pCS)] in erythrocytes as well as their transport across the erythrocyte membrane. 
Furthermore, to better understand the transport mechanism across the erythrocyte membrane, 
the impact of an inhibitor (i.e. 4,4’ diisothiocyanato-2,2’-stilbenedisulfonic acid; DIDS; 





 Materials and methods 
6.2.3.1 Sample collection 
Blood samples from 6 HD patients were collected pre-dialysis to determine the presence of 
PBUTs in erythrocytes, while blood was sampled from 8 healthy controls and another 8 HD 
patients (pre-dialysis) to be used in the loading and unloading experiments, respectively. All 
blood was sampled in K2EDTA plasma tubes (Becton Dickinson Company, New Jersey, USA).  
This study was conducted according to the Declarations of Helsinki, was approved by the Ethics 
Committee of Ghent University Hospital (2017/0162) and all participants gave their written 
informed consent. 
6.2.3.2 Chemicals 
HA, IAA and IS were purchased from Sigma-Aldrich (St. Louis, MO, USA) and pCS was 
obtained from TCI Chemicals (Zwijndrecht, Belgium). Water (HPLC grade) was purchased 
from Acros Organics (Thermo Fisher Scientific, Geel, Belgium) and the inhibitor DIDS from 
Sanbio (Cayman Chemical, MI, USA). A stock solution containing HA, IAA, IS and pCS 
(further assigned as PBUT mix) as well as a DIDS stock solution were both prepared in 
phosphate buffered saline (PBS) buffer pH = 7.4 (Invitrogen, Thermo Fischer Scientific, Ghent, 
Belgium) and stored at -20 °C. Theoretical final PBUT concentrations were based on the 
maximum uremic levels as reported by Duranton et al. [11]. Therefore, stock concentrations 
(200 times the final concentration) of 80 mmol/L (HA), 2 mmol/L (IAA) and 20 mmol/L (IS 
and pCS) were prepared. For DIDS, a theoretical final concentration of 100 µmol/L was 
achieved by preparing a stock concentration (13 times the final concentration) of 1300 µmol/L. 
6.2.3.3 In vitro protocols 
To separate erythrocytes and plasma, blood was centrifuged for 10 min at 3000 rpm, according 
to 2095 g, at room temperature (Beckman Coulter X-15R centrifuge - VWR, Leuven, Belgium). 
Proof of concept – PBUTs in erythrocytes? After blood centrifugation, plasma was removed 
and the PBUT concentrations were determined in the erythrocyte pellet. This pellet was lysed 
during the first step of the sample preparation where HPLC grade water was added, followed 
by heating up to 95 °C. 




Transport across the erythrocyte membrane. In loading (i.e. influx) and unloading (i.e. efflux) 
experiments, plasma from 13 mL blood samples was replaced by an equal volume of PBS to 
avoid the impact of plasma protein binding on the transport. Subsequently, the obtained 
erythrocyte suspension was gently mixed. Only in loading experiments, the erythrocyte 
suspension was first incubated in a water bath at 37 °C for 1 hour before the addition of 65 µL 
of PBUT mix, followed by gentle mixing. 
Impact of the anion transport inhibitor on influx. After centrifugation of 13 mL blood samples, 
plasma was removed and 1 mL DIDS solution (i.e. DIDS in PBS) was added to the pellet as 
well as PBS to obtain the original blood volume. The obtained erythrocyte suspension was 
gently mixed and samples were incubated in a water bath at 37 °C for 1 hour. Subsequently, 
65 µL of PBUT mix was added and samples were gently mixed. 
After gently mixing the erythrocyte suspension in each series of experiments, aliquots (1 mL) 
were incubated in a water bath at 37 °C while continuously shaken to avoid erythrocyte 
sedimentation. At certain time points [6 (loading only), 8, 10, 13, 16, 18, 23, 28, 38, 53, 68 min], 
an aliquot was removed from the water bath, immediately centrifuged (Beckman Coulter 
Microfuge 18 – Analis, Ghent, Belgium, 5000 rpm according to 2306 g, 5 min), and the obtained 
supernatant was stored at -80 °C until batch analysis.  
6.2.3.4 Analyses 
Total Total PBUT concentrations were determined by an ultra-high performance liquid 
chromatography instrument with ultraviolet (for HA) and fluorescence (for IAA, IS and pCS) 
detection (UHPLC-UV/FLD). Both sample preparation and chromatographic methods were 
previously described in more detail [33].  
Hematocrit (H) was determined by transferring blood into capillary tubes before centrifugation 
(Hettich centrifuge – Tuttlingen, Germany, 10000 rpm according to 9503 g, 2 min) and was 
manually read on a calibrated plate in all loading and unloading experiments, in the non-treated 
whole blood samples as well as in the corresponding erythrocyte suspensions.. 
6.2.3.5 Kinetic model 
The transport characteristics for a solute evenly equilibrating across intra- and extracellular 





needs to be adapted for solutes with non-uniform equilibration, as schematically shown in 
Figure 6-1. Differences in distribution can be quantified by the solute partition coefficient (γ) 
defined as the ratio of solute concentrations in both compartments at equilibrium [34]. In this 





     (Eq. 6-1) 
Figure 6-1 Two-compartment model. 
 
PBS: phosphate buffered saline; VPBS: PBS water volume; CPBS: solute concentration in PBS water volume; γ: 
solute partition coefficient; VRBC: erythrocyte water volume; CRBC: solute concentration in erythrocyte water 
volume; KC: intercompartment clearance. 
Assuming constant erythrocyte and PBS volumes, the two-compartment model for solute 











= - KC (
CRBC 
γ
- CPBS)             
where VPBS and VRBC (both in L) refer to the volumes of PBS water and erythrocyte water 
(i.e. the cytoplasm), CPBS and CRBC (both in mol/L) are PBUT concentrations in PBS and 
erythrocyte compartments respectively,  accounts for intracellular partition and the 
proportionality factor KC (in L/min) refers to the intercompartment clearance. 
The total mole n (in mol) of solute in the entire erythrocyte suspension is constant: 
n = VPBSCPBS+ VRBCCRBC    (Eq. 6-3) 
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The solution of this ordinary differential equation for the interval t = 0 to t = t is 
CPBS(t) = (CPBS(0) - 
b
a
) e-at - 
b
a
     (Eq. 6-5) 
where the macro parameters b (in mol/min/ L) and equilibration time constant a (in 1/min) are 




      (Eq. 6-6) 
a = KC 
γVRBC + VPBS
γVRBCVPBS
     (Eq. 6-7) 






      (Eq. 6-8) 
which is the equilibrated concentration (CPBS(eq)). These equations are comparable to those as 
derived previously, with the difference of  [27]. 
Intercompartment clearance KC is determined by erythrocyte volume (i.e. erythrocyte 
suspension volume, Vsusp, times hematocrit, Hsusp) and specific rate constant ks (1/min):  
KC= ks Hsusp Vsusp     (Eq. 6-9) 
Where ks represents the specific rate constant, which is a more general measure for the diffusion 
rate across the erythrocyte membrane. For this parameter, the hematocrit [Hsusp = VRBC / (VRBC + 
VPBS)] and water fractions for PBS (fPBS = VPBS,w / VPBS) and erythrocyte (fRBC = VRBC,w / VRBC) 











     (Eq. 6-10) 
In loading experiments without inhibitor, the model parameters ks and γ were identified by 
fitting the function in Eq. 6-5 and the macro parameters a (Eq. 6-7) and CPBS(eq) (= b/a, Eq. 6-8) 
to experimental data: CPBS(t), Hsusp, mass of the erythrocyte suspension and concentration as 
well as volume of the added PBUT mix. In loading experiments in presence of inhibitor, the 
model parameter ks was identified according to the same procedure, whereas the individual 
value for γ was assumed to be the same as in loading experiments without inhibitor and was 
therefore fixed for each healthy subject. In unloading experiments, mean values for γ as 





experimental data were used to fit the function in equation 6-5 and the macro parameters a 
(Eq. 6-7) and CPBS(eq) (= b/a, Eq. 6-8): CPBS(t), Hsusp, mass of the erythrocyte suspension and the 
measured PBUT concentration after 1 hour (i.e. CPBS(eq),m). In each series of experiments, water 
fractions in plasma and erythrocytes were assumed as fPBS = 0.99 and fRBC = 0.70 and Berkeley 
Madonna software (University of California, Berkeley, CA, USA) was used for parameter 
identification. The source codes for loading and unloading experiments are provided in 
6.2.9 Supplementary material. Two Berkeley Madonna model files including experimental 
data, for representative loading and unloading experiments, are available as supplementary 
digital material. 
6.2.3.6 Statistics 
Statistical evaluation was performed with GraphPad Prism 4.00 for Windows (GraphPad 
Software, La Jolla, CA, USA) and data were checked for normality (Shapiro-Wilk test). 
Normally distributed data are presented as mean ± standard deviation, whereas non-normal data 
are presented as median [25th percentile (pct); 75th pct]. Paired samples T-tests and Mann-
Whitney tests as well as repeated measures ANOVA tests and Friedman tests with Tukey 
(ANOVA test) or Dunns (Friedman tests) post hoc analysis were used when appropriate. 
P  < 0.05 was considered significant. 
 Results 
Presence of PBUTs in erythrocytes. In pre-dialysis blood from HD patients, it appeared that 
HA, IAA, IS and pCS are present in erythrocytes as determined by their concentration in the 
cell pellets viz. 88.1 [22.0;239.1], 2.4 [1.8;2.9], 29.7 [15.9;33.9] and 25.8 [18.4;30.6] µmol/L, 
respectively. 
Experimental data for loading and unloading experiments. For each series of experiments, we 
determined PBUT concentrations in the PBS supernatant, calculated immediately after spiking 
(CPBS(0),c) and measured at equilibrium (CPBS(eq),m) (Table 6-1). In addition, the erythrocyte 
suspension volume (Vsusp), hematocrit in native whole blood sample (Hwb) and hematocrit in 
erythrocyte suspension (Hsusp) are provided in Table 6-1. 
. 
 




Table 6-1 Experimental data for loading and unloading experiments. 










Loading   12.50 ± 0.11 47 ± 5 46 ± 5 
 HA 802.9 ± 72.3 504.3 ± 33.1 
   
 IAA 19.2 ± 1.7 9.2 ± 0.5 
 IS 227.6 ± 20.5 92.5 ± 7.0 
 pCS 209.6 ± 18.9 122.9 ± 13.1 
       
Loading + inhibitor 12.50 ± 0.11 47 ± 5 46 ± 5 
 HA 804.3 ± 76.4 518.6 ± 42.4 
   
 IAA 19.2 ± 1.8 8.3 ± 0.5 
 IS 228.0 ± 21.7 146.5 ± 14.5 
 pCS 210.0 ± 20.0 131.8 ± 12.5 
       
Unloading   12.69 ± 0.08 36 ± 3 36 ± 3 
 HA 0 39.8 [28.8;69.6]    
 IAA 0 0.8 [0.7;1.1]    
 IS 0 7.7 [5.6;9.8]    
 pCS 0 11.8 [7.0;18.2]    
HA: hippuric acid; IAA: indole-3-acetic acid; IS: indoxyl sulfate; pCS: p-cresyl sulfate; CPBS(0),c: calculated 
PBUT concentration at t = 0 min; CPBS(eq),m: measured PBUT concentration at equilibrium; Vsusp: erythrocyte 
suspension volume; Hwb: hematocrit in native whole blood sample; Hsusp: hematocrit in erythrocyte suspension.  
Values are mean ± standard deviation or median [25th pct ;75th pct]. All n = 8. 
Transport across the erythrocyte membrane - influx. The decrease in mean HA, IAA, IS and 
pCS concentration in the PBS fraction as obtained in loading experiments of erythrocytes from 
healthy subjects in absence of an anion transport inhibitor is illustrated in Figure 6-2. After 
6 min, this decrease was significant as compared to the theoretical start concentration for all 
four PBUTs and the concentrations further decreased to reach an equilibrium at 38 min for HA 
and 10 min for IAA and IS. For pCS, the concentration decreased almost immediately after 
spiking and equilibrium was already formed at the first experimental time point. 
Impact on influx of the anion transport inhibitor. The change in mean HA, IAA, IS and pCS 
concentration in the PBS fraction as obtained during loading experiments in presence of the 
inhibitor DIDS is illustrated in Figure 6-2. Here again, concentrations of the four PBUTs 
decreased over time and reached an equilibrium at 38 min for HA. For IAA, IS and pCS, 
however, no equilibrium was formed within the time course of the experiment, indicating a 
slower transport in presence of the inhibitor. 
The impact of DIDS is visible in the PBUT concentrations remaining lower (i.e. for IAA) and 
higher (i.e. for IS) in the PBS during the complete experimental time course, and for pCS at 
least up to 38 min (Figure 6-2). Overall HA transport was slightly influenced by the presence 





Figure 6-2 Concentration over time for hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) 
and p-cresyl sulfate (pCS) as measured in the PBS fraction during loading experiments in the absence 
(black dots and full line) and presence (white dots and dotted line) of the inhibitor DIDS, respectively. 
 
Within each condition, the decrease in supernatant PBUT concentration was significant up to 38 min (HA), up to 
10 min (IAA and IS in absence of the inhibitor) or 38 min (IAA, IS and pCS in presence of the inhibitor), 
respectively,  but is not indicated on the figures for clarity. 
* p < 0.05 versus absence of the inhibitor at the same time points; ** p < 0.05 versus absence of the inhibitor 
during the complete time course; *** p < 0.05 versus absence of the inhibitor up to 38 min. All n = 8. 
Figure 6-3 Concentration over time for hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) 
and p-cresyl sulfate (pCS) as measured in the PBS fraction during unloading experiments. 
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Transport across the erythrocyte membrane - efflux. Figure 6-3 shows the mean HA, IAA, IS 
and pCS concentrations measured in the PBS fraction as obtained in unloading experiments of 
erythrocytes from HD patients. Despite the large inter-patient variability, a trend in increasing 
HA concentration was observed. HA concentrations measured in the PBS were found 
significantly increased after 29 min as compared to the concentration at t = 0 and 8 min, and 
remained unchanged from 38 min on (Figure 6-3). For IAA, IS and pCS, however, this transport 
was very fast and corresponding concentrations were already in equilibrium at the first 
experimental time point.  
Kinetics. Experimental data from both series of loading experiments and from unloading 
experiments were used to fit the following kinetic parameters for HA, IAA, IS and pCS: the 
equilibration time constant (a), specific rate constant (ks), intercompartment clearance (KC) and 
solute partition coefficient (γ) (Table 6-2). 
Table 6-2 Kinetic data for loading and unloading experiments.  







Loading      
 HA 0.06 ± 0.02 0.03 ± 0.01 0.16 ± 0.04 1.24 ± 0.20 
 IAA 1.46 ± 0.02a 0.82 ± 0.10a 4.66 ± 0.23a 1.54 ± 0.13a 
 IS 0.27 ± 0.07b 0.19 ± 0.05b 1.10 ± 0.27b 2.72 ± 0.39a,b 
 pCS 0.85 ± 0.56a,b,c 0.40 ± 0.23a,b,c 2.38 ± 1.46a,b,c 1.30 ± 0.24b,c 
      
Loading + inhibitor     
 HA 0.04 ± 0.01d 0.02 ± 0.01d 0.12 ± 0.04d 1.24 ± 0.201 
 IAA 1.47 ± 0.001a 0.83 ± 0.10a 4.68 ± 0.19a 1.54 ± 0.131,a 
 IS 0.03 ± 0.004a,d 0.02 ± 0.003b,d 0.10 ± 0.01b,d 2.72 ± 0.391,a,b 
 pCS 0.05 ± 0.007b,c,d 0.02 ± 0.004b,d 0.13 ± 0.02b,d 1.30 ± 0.241,b,c 
      
Unloading      
 HA 0.07 ± 0.01 0.04 ± 0.01d 0.18 ± 0.02 1.242 
 IAA 2.24 [0.39;2.35]a 1.47 [0.27;1.54]a 6.83 [1.19;7.21]a 1.542 
 IS 0.31 [0.27;0.45] 0.28 [0.25;0.38]d 1.27 [1.10;1.91] 2.722 
 pCS 0.54 [0.40;2.32]a 0.32 [0.25;1.35]a 1.51 [1.02;6.34]a 1.302 
HA: hippuric acid; IAA: indole-3-acetic acid; IS: indoxyl sulfate; pCS: p-cresyl sulfate;  
a: equilibration time constant; ks: specific rate constant; KC: intercompartment clearance;  
γ: solute partition coefficient. Values are mean ± standard deviation or median [25th pct;75th pct].  
a, b or c p < 0.05 versus HA, IAA or IS, respectively as obtained within the same series of experiments.  
d p < 0.05 versus loading experiments without the inhibitor, respectively. 
1 or 2 Individual respectively mean values for γ as obtained in loading experiments without the 
inhibitor were used to fit parameters. All n = 8. 
In loading experiments without inhibitor, values for the solute partition coefficient ranged 
between 1.24 and 2.72, suggesting an asymmetrical distribution of solute in erythrocytes and 
PBS for each of the PBUTs. Parameters a, ks and KC were found to be the lowest for HA, 





In loading experiments in the presence of an inhibitor, the transport parameters a, ks, and KC 
reached comparable low values for HA, IS and pCS, whereas those for IAA were not affected 
(Table 6-2).  
In unloading experiments, a, ks and KC were significantly higher for IAA and pCS as compared 
to those for HA, whereas those for IS, showed a trend to be higher than those for HA but lower 
than those for IAA and pCS.  
When comparing kinetic parameters a, ks and KC as obtained in loading experiments with those 
obtained in unloading experiments, only ks was significantly different for HA and IS. 
 Discussion 
In this work, the intracellular concentration of PBUTs in erythrocytes of HD patients was 
measured and the transport of these solutes across the erythrocyte membrane was studied in 
vitro in blood from healthy controls as well as in blood from HD patients. Furthermore, a first 
attempt was undertaken to determine the transport mechanism of these PBUTs across the 
erythrocyte membrane by using an erythrocyte Band 3 anion transport inhibitor, DIDS. The 
main findings are: (i) HA, IAA, IS and pCS are distributed in erythrocytes; (ii) the rate of 
transport (i.e. both influx and efflux) is dependent on the studied PBUT and increases in the 
following sequence: HA < IS < pCS < IAA and (iii) the presence of DIDS, which inhibits anion 
transport via Band 3 protein across the erythrocyte membrane, slows down the transport of HA, 
IS and pCS 
The studied PBUTs distribute within the erythrocytes, which was confirmed by spiking an 
erythrocyte suspension with a high uremic concentration of PBUTs and measuring their uptake 
over time. After PBUT addition to the extracellular (PBS) compartment, concentrations in PBS 
decreased either slowly (i.e. for HA), at intermediate speed (i.e. for IS), or very fast (i.e. for 
pCS and IAA) so that an apparent equilibrium between the PBS and erythrocyte compartments 
was established after, respectively, 38 min, 10 min or almost immediately. Obtained transport 
parameters [i.e. equilibration time constant (a), specific rate constant (ks) and intercompartment 
clearance (KC)] demonstrated that HA is more slowly transported into erythrocytes as compared 
to IS (trend), pCS and IAA. When unloading erythrocytes from HD patients suspended in PBS, 
it was found that the rate of solute efflux was comparable to the rate of solute influx, based on 
comparable kinetic parameters between unloading and loading experiments, despite the larger 
inter-patient variability on both the PBUT concentrations and the kinetic parameters (not for 




HA). Consequently, it seemed that the influx and efflux transport of PBUTs across the 
erythrocyte membrane was symmetrical, suggesting a facilitated diffusion mechanism driven 
by a concentration gradient. 
In loading experiments in absence of an inhibitor, the solute partition coefficient (γ) for each of 
the studied PBUTs exceeded 1, implying an apparent equilibrium with higher concentrations in 
the erythrocytes as compared to in PBS. This might be due to interaction with membrane 
structures and/or cytoplasmic components. For the latter, we may however exclude hemoglobin 
since interaction with hemoglobin was found negligible in an in vitro experiment (n = 3) 
studying possible binding of these PBUTs to hemoglobin (data not shown). 
It appeared that the influx and efflux of IAA across the erythrocyte cell membrane is much 
faster than for the other three PBUTs, which is reflected by its high values for a, ks and KC. 
Concentrations of indole, the in vivo precursor of IAA, were determined in some of the loading 
experiment samples to check whether the fast decrease in IAA concentrations was due to a fast 
back transformation of IAA into indole. However, indole concentrations were negligible in the 
PBS fraction (data not shown). Alternatively, (part of) IAA could bind to the erythrocyte 
membrane surface or to proteins present in the cell membrane or in the cytoplasm immediately 
after addition of the PBUT mix, resulting in an apparent fast removal from the PBS 
compartment [35]. However, to the best of our knowledge, no data of IAA binding to 
erythrocyte membranes is available in literature to support this hypothesis. 
We also studied the impact of an inhibitor (i.e. DIDS) for anion transport. This compound is 
known to reversibly bind to Band 3 proteins, anion exchangers located on erythrocyte 
membranes, mediating transmembrane transport [29–32]. Because these Band 3 proteins can 
only influence solute transport, the distribution of PBUTs will not be changed. Hence, in the 
kinetic model of the loading experiments with DIDS, solute partition coefficients can be taken 
equal to those as found in the loading experiments without DIDS. By doing this, we observed 
that the transport parameters a, ks, and KC decreased to comparable low values for HA, IS and 
pCS. For this reason, the transport of HA, IS and pCS is at least in part facilitated by Band 3 
proteins (i.e. carrier-mediated facilitated diffusion).  
Notwithstanding the similar equilibration time constants for HA, i.e. 0.06 ± 0.02 1/min, as found 
in the present work and those for creatinine, i.e. 0.05 ± 0.01 1/min, as previously reported by 
Schneditz et al. [27], the transport mechanism of both compounds (and partly for IS and pCS 





compounds at pH 7.4 (i.e. positive for creatinine and negative for HA, IS and pCS). Apart from 
the anion exchanger Band 3, other anion transporters may be involved in transport of the studied 
PBUTs as well. Amongst others, it has been shown that the multidrug resistance protein 1 
(MRP 1) was present in erythrocyte membranes [36,37]. This transporter is known to efflux 
several sulfate conjugates of endogenous as well as of xenobiotic compounds from diverse 
tissues [38,39] and might thus potentially be involved in the transmembrane transport of IS and 
pCS as well. More recently, a database (http://rbcc.hegelab.org/) was created containing 
information on different other transport proteins present in the erythrocyte membrane [40].  
The distribution of solutes within erythrocytes and the slow transport from erythrocytes to 
plasma has important consequences for their removal during hemodialysis. For example, for 
solutes slowly equilibrating across the erythrocyte membrane, the true concentration in plasma 
leaving the hemodialyzer is much lower than what is measured when solutes are primarily 
removed from plasma, and intracellular solutes remain sequestered in erythrocytes. The 
concentration measured in a plasma sample, however, depends on the time the blood sample is 
allowed to equilibrate (i.e. the time erythrocytes are allowed to “unload” their solutes) and on 
the rate of solute equilibration between plasma and erythrocytes before the blood components 
are separated by centrifugation. If blood is collected at the dialyzer outlet line, there is a 
disequilibrium between the intra- and extracellular concentrations. For solutes equilibrating fast 
across the erythrocyte membrane, the solute concentration as measured in the plasma could be 
overestimated at the time of measurement. This results in a false underestimation of the 
extracorporeal solute clearance, as previously demonstrated for creatinine [41]. For the present 
PBUTs, we also found that the time between blood sampling and centrifugation affects the 
serum/plasma concentration in samples collected at the dialyzer outlet line (data provided in 
6.2.8 Supplementary data). 
Besides the %PB, also the magnitude and rate of accumulation of PBUTs in erythrocytes may 
have an impact on the amount of solute removed by the dialyzer. For solutes rapidly 
equilibrating across the erythrocyte membrane, solute is not only cleared from the plasma 
compartment but also from the erythrocyte compartment and plasma and erythrocyte 
concentrations will be close to equilibrium at the dialyzer inlet as well as at the outlet. On the 
contrary, for solutes slowly equilibrating across the erythrocyte membrane, such as creatinine, 
the transport across the membrane should be taken into account, as described elsewhere [42]. 
The exact fraction of extracorporeal blood flow cleared in the dialyzer can be estimated from 




dialyzer transit time, hematocrit, and specific rate constant [27] but should be adjusted by a 
solute partition coefficient for the studied PBUTs. 
 Conclusion 
This is the first study to identify and quantify intracellular distribution of PBUTs in 
erythrocytes. The rate of transport (i.e. influx and efflux) across the erythrocyte membrane 
increased according to HA < IS < pCS < IAA. In addition, at least part of the HA, IS and pCS 
uptake by erythrocytes is attributed to the anion transporter Band 3. 
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 Supplementary data 
6.2.8.1 Effect of time between sampling and blood centrifugation on the serum/plasma 
concentration of different protein-bound uremic toxins 
Extra blood samples from 10 stable HD patients were collected at the dialyzer outlet line after 
120 min of dialysis (performed according to the Declarations of Helsinki, approved by the 
Ethics Committee of Ghent University Hospital (2017/0162) and all participants gave their 
written informed consent). Blood was collected in two different K2EDTA plasma tubes and in 
serum separating tubes (all Becton Dickinson Company, New Jersey, USA). Plasma tubes were 
centrifuged either immediately after sampling or after a period of 30 min on ice whereas serum 
tubes were left at room temperature for 30 min to allow for clotting. Total serum and plasma 
PBUT concentrations were determined by UHPLC-UV/FLD [36]. Statistical analysis was 
performed with GraphPad Prism 4.00 for Windows (GraphPad Software, La Jolla, CA, USA) 
and data were checked for normality (Shapiro-Wilk test). Repeated measures ANOVA and 
Friedman tests with, respectively Tukey and Dunns post hoc analysis, were used when 
appropriate. P < 0.05 was considered significant. 
Figure 6-4 Effect of time between sampling and blood centrifugation on the serum and plasma 
concentrations of hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate 
(pCS) as determined in blood samples collected at the dialyzer outlet. 
 
Blood tubes were centrifuged either immediately [plasma (0 min)], after 30 min on ice [plasma (30 min, ice)] or 
after 30 min at room temperature [(serum 30 min, RT)]. * p < 0.05. 
Serum concentrations were significantly increased for IAA and pCS (Figure 6-4), while only a 
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room temperature as compared to plasma samples immediately separated after collection. 
Placing blood samples on ice for 30 min attenuated the equilibration process resulting in only 
a small increase in extracellular concentration (visual trend only). 
These results indicate that when blood samples are collected the moment there is a 
disequilibrium between intra- and extracellular concentrations (e.g. in samples taken at the 
dialyzer outlet line or in samples taken at a later stage during dialysis), plasma concentrations 
will depend on the time between sampling and centrifugation as well as on the solute 
equilibration rate. Because immediate centrifugation after collection is not always achievable 
in clinical practice, this process of solute equilibration can be attenuated by placing blood 
samples immediately on ice prior to centrifugation. 
 Supplementary material 
6.2.9.1 Berkeley Madonna source code for loading experiments for hippuric acid (HA) 
without inhibitor 
{------------------------------------------} 
{Identification of model parameters ks and gamma from equilibration in solute loading tests 
using HA data from "HA_HealthyControl1(MV).txt" file using the exact analytical solution 
and Berkeley-Madonna vs. 8.3. software. 
 
Open a new file from the "File" dropdown menu and delete any default information from the 
opening window. 
Copy and paste the source code (from the first "{" to the last "}" of this text as plain TEXT into 
that window. 
Load the experimental sample data from the "Model" drop-down menu using the "Datasets" 
command. 
Import the "HA_HealthyControl1(MV).txt" data as 1D vector. 
Run (click the "RUN" icon) this model and plot the "ct" and "#HA_HealthyControl1MVLtxt" 
data vs time. 
Double-click the figure and select the "#HA_HealthyControl1MVLtxt" variable for dislplay. 
Then use "Curve fit" in the "Parameter" drop-down menu, select the parameters "a" and 
"gamma" , and press "o.k." 
The model "ct" is fit to experimental "#HA_HealthyControl1MVLtxt" data. 
The parameters identified form the optimal fit can be read in the "parameter" window or by 
clicking the "P" icon in the plot. 
The numerical values for "ks" and Kc" and selected variables can be displayed by switching 
from "plot-view" to "table view"} 
 
STARTTIME = 0 
STOPTIME = 70 






Hsusp=0.425; hematocrit of erythrocyte suspension 
Msusp=13.05; mass of erythrocyte suspension in g 
cs=82603; concentration of HA in PBUT mix in µmol/L 
Vs=0.000065; volume of spiking solution in L 
fPBS=0.99; water fraction in PBS  
fRBC=0.70; water fraction in erythrocytes 
rhosusp=1050; erythrocyte suspension density in g/L 
 
a=0.06; exponent, slope of the experimental decrease 
gamma=1; solute partition coefficient 
 
DISPLAY ct, a, ks, Kc, gamma 
 
ct=(c0-ceq)*exp(-a*TIME)+ceq ; PBS concentration at time t in µmol/L 
c0=ntot/(Vsusp*(1-Hsusp)*fPBS+Vs); initial PBS concentration in µmol/L 
ceq=ntot/(Vsusp*(1-Hsusp)*fPBS+Vsusp*Hsusp*fRBC*gamma+Vs) 
{PBS concentration at equilibrium in µmol/L} 
ks=a/(Hsusp/(1-Hsusp)/fPBS+1/(gamma*fRBC)); specific rate constant in 1/min 
Kc=ks*Hsusp*Vsusp*1000; intercompartment clearance in mL/min 
 
Vsusp=Msusp/rhosusp; volume of erythrocyte sample in L 
ntot=cs*Vs; total mole of solute in erythrocyte suspension in µmol 
{---------------------------------------------} 
6.2.9.2 Berkeley Madonna source code for unloading experiments for hippuric acid (HA) 
{------------------------------------------} 
{Identification of model parameter "ks" from equilibration in solute unloading tests with 
experimental HA data from "HA_ HDPatient1(AM).txt" data file using the exact analytical 
solution and Berkeley-Madonna vs. 8.3. software. 
 
Open a new file from the "File" drop-down menu and delete any default information from the 
opening window. 
Copy and paste the source code (from the first "{" to the last "}" of this text as plain TEXT into 
that window. 
Load the experimental sample data from the "Model" drop-down menu using the "Datasets" 
command. 
Import the "HA_ HDPatient1(AM).txt" data as 1D vector. 
Run (click the "RUN" icon) this model and plot the "ct" and "#HA_ HDPatient1AMtxt" data 
vs. time. 
Double-click the figure and select the "#HA_ HDPatient1AMtxt" variable for dislplay. 
Then use "Curve fit" in the "Parameter" drop-down menu, select parameters "a" and "ceq" and 
press "o.k.". 
The model "ct" is fit to experimental "#HA_ HDPatient1AMtxt" data. 
The parameters identified form the optimal fit can be read in the "Parameter" window or by 
clicking the "P" icon in the plot. 
The numerical values for "ks" and Kc" and selected variables can be displayed by switching 
from "plot-view" to "table view"} 





STARTTIME = 0 
STOPTIME = 70 
DT = 0.02 
 
Hsusp=0.32; hematocrit of erythrocyte suspension 
Msusp=13.27; mass of erythrocyte suspension in g 
ceq=70.24; measured PBS concentration at equilibrium after 1 hour in µmol/L 
c0=0; solute concentration in PBS at t=0 in µmol/L 
fPBS=0.99; water fraction in PBS  
fRBC=0.70; water fraction in erythrocytes 
rhosusp=1050; erythrocyte suspension density in g/L 
 
a=0.06; exponent, slope of the experimental decrease 
gamma=1.24; solute partition coefficient from loading experiments 
 
DISPLAY ct, ceq, a, ks, Kc, gamma 
 
ct=(c0-ceq)*exp(-a*TIME)+ceq; PBS concentration at time t in µmol/L 
ks=a/(Hsusp/(1-Hsusp)/fPBS+1/(gamma*fRBC)); specific rate constant in 1/min 
Kc=ks*Hsusp*Vsusp*1000; intercompartment clearance in mL/min 
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General summary, critical interpretation, relevance of the work and 
future perspectives 
7.1 General summary and critical interpretation 
Chronic kidney disease (CKD) is defined as either kidney damage or a glomerular filtration rate 
(GFR) < 60 mL/min/1.73 m² over a period of at least three months [1] (Chapter 1). At end-stage 
kidney disease (i.e. GFR < 15 mL/min/1.73 m²), a renal replacement therapy is often started 
and, besides kidney transplantation and peritoneal dialysis, hemodialysis can be initiated. In 
this extracorporeal technique, blood flows through the lumen of hollow fibers in an artificial 
kidney (i.e. the hemodialyzer). The semi-permeable membrane of these fibers allows the 
transport of solutes from the blood into a water-electrolyte fluid (i.e. dialysis fluid), which flows 
around the fibers in an opposite direction. 
A myriad of waste products are accumulated in patients with CKD, as a result of their decreased 
renal function. These uremic retention solutes may exert toxicity [2–10] and many of them have 
an impact on the cardiovascular system and contribute thus to the increased propensity for 
cardiovascular events and mortality in CKD [11,12]. Based on their physico-chemical 
properties, the so-called uremic toxins have been categorized into three groups: (i) the small 
water-soluble solutes (MW < 500 Da), (ii) the middle molecules (MW > 500 Da) and (iii) the 





Unlike water-soluble solutes, the removal of PBUTs is hampered during dialysis since only the 
free (i.e. unbound) fraction can pass the pores of the hemodialyzer membrane. Consequently, 
the removal efficiency of these PBUTs is much lower than of small water-soluble solutes, such 
as urea, especially for those with a high percentage protein binding (%PB) [15–17]. During the 
past decade, studies have been performed aiming to improve the clearance of these PBUTs 
during hemodialysis. Except for the studies on extended HD, most of them only focused on the 
removal of PBUTs from the serum/plasma compartment [18–21] ignoring the role of extra-
plasmatic distribution [17,22]. 
To date, the kinetics (e.g. protein binding, distribution in the patient, clearance during 
hemodialysis) of PBUTs are not well understood (Figure 7-1). It is often hypothesized that the 
%PB of uremic toxins might be decreased in patients with CKD as compared to healthy 
subjects, because of the possible saturation of plasma proteins as a consequence of the elevated 
uremic toxin concentrations in these patients [23]. Additionally, it has been suggested that the 
%PB might be influenced by competition between different PBUTs bound to the same binding 
site on albumin [24–26], as well as between PBUTs and drug compounds [24,27–34]. Also, the 
distribution of PBUTs in the body is not yet completely characterized. So far, it has been found 
that PBUT transport in the patient is hampered during hemodialysis, suggesting the presence of 
these PBUTs not only in the patient’s plasma volume, the only volume that is easily accessible 
during hemodialysis [17,22], but also in e.g. intracellular compartments. Consequently, the rate 
of transport across biological membranes could play an important role in the removal of these 
PBUTs during HD and with it, the removal efficiency. Assessing intracellular distribution by 
direct measurements is, however, limited to erythrocytes and leukocytes. Finally, the effects of 
laboratory and sample parameters on the free concentration of PBUTs (e.g. matrix, temperature, 
pH) are not clear but should be known since the %PB is usually calculated from the total and 
free PBUT concentration. 
Therefore, the presented work was performed aiming to better understand the kinetics of PBUTs 
in CKD. Different processes which may play a role either in the determination of free PBUT 
concentrations (i.e. the matrix, temperature and pH) or in the kinetics (i.e. altered protein 
binding in CKD, protein binding competition between the different PBUTs and/or between drug 
compounds, the distribution in erythrocytes and the corresponding transport across the 
erythrocyte membrane) of these PBUTs were studied and are schematically presented in Figure 
7-1. Studied PBUTs included p-cresyl glucuronide (pCG), hippuric acid (HA), indole-3-acetic 
acid (IAA), indoxyl sulfate (IS) and p-cresyl sulfate (pCS). 




Figure 7-1 Research questions about the different processes impacting protein binding and kinetics of 
PBUTs. 
 
HA: hippuric acid; IAA: indole-3-acetic acid; IS: indoxyl sulfate; pCS: p-cresyl sulfate;  
CKD: chronic kidney disease; drug: vancomycin and teicoplanin. 
The basic principles of the analytical methods which were used in this thesis are described in 
Chapter 2. In the presented work, PBUTs were quantified in serum or plasma samples using 
(ultra-)high performance liquid chromatography (UHPLC) methods where PBUTs were 
detected by ultraviolet and fluorescence detection (UHPLC-UV/FLD) or tandem mass 
spectrometry (UHPLC-MS/MS). The antibiotics vancomycin and teicoplanin were assayed by 
a chemiluminescent microparticle immunoassay (CMIA) and an UHPLC – high resolution 
mass spectrometry (UHPLC-HRMS) method, respectively. Furthermore, the importance of 
sample preparation in (bio)analytical chemistry was highlighted as well as the theory of the two 
most commonly used methods to obtain free concentrations, i.e. equilibrium dialysis and 
ultrafiltration.  
In Chapter 3, the development and optimization of analytical methods which were used in this 
thesis are discussed. In general, the percentage protein binding (%PB) of a compound is 
indirectly determined by measuring the free and total concentration of that compound. Both 
equilibrium dialysis and ultrafiltration (Centrifree and Amicon filters) were used in this thesis 
and for this reason, we tested whether PBUTs were susceptible to non-specific adsorption to 
the membranes and/or devices. Only HA showed a small non-specific adsorption (sample loss 
of 11.5 %) to the equilibrium dialysis membrane and/or device but was not taken into account 
in further experiments, because it was supposed that the extent of non-specific adsorption is 






















adsorption is eliminated when measuring the concentrations at both sides to calculate the free 
fraction, which was the case for each study where equilibrium dialysis was used. We also 
compared the free PBUT concentrations as obtained by equilibrium dialysis and ultrafiltration 
(Amicon filters only) because this analysis was previously not performed, except for IS and 
pCS where Centrifree filters were used [35]. At the tested settings, we found comparable free 
concentrations, and thus %PB, for all four PBUTs when using equilibrium dialysis and 
ultrafiltration. Hence, both tested settings were used in the studies in this thesis.  
Different methods have previously been developed to determine the %PB of PBUTs [35–37] 
but none of these described the impact on their %PB of different measurement conditions, 
except for temperature for IS and pCS in Viaene et al. (room temperature versus 37 °C) [35]. 
We demonstrated that the %PB of PBUTs could be assessed in both serum and K2EDTA plasma 
when analyzed by UHPLC-UV/FLD and that the observed small difference in pH between 
serum and plasma samples had no influence on %PB. In addition, our results revealed the 
importance of ultrafiltration temperature when separating the free PBUT fraction. In addition, 
at 4 °C, %PB is significantly higher as compared to 37 °C or room temperature and is in line 
with data for drug compounds [38–40]. In order to reflect the physiologic situation, we 
recommend to perform ultrafiltration at 37 °C. This temperature-dependent relationship for 
%PB of PBUTs was previously only reported for IS and pCS, in which other ultrafiltration 
filters were used, but the same conclusions were made as in our work [35]. 
In the last part of Chapter 3, the development of a novel method for the quantification of total 
and free teicoplanin in K2EDTA plasma samples by UHPLC-HRMS is provided. Also here, 
both equilibrium dialysis and ultrafiltration were tested for non-specific adsorption and 
obtained %PB values were compared. Non-specific adsorption was observed in two different 
ultrafiltration filters resulting in a mean sample loss of 77 and 21 % for Amicon and Centrifree 
UF filters, respectively. Despite the frequent use of ultrafiltration filters to obtain free 
teicoplanin concentrations [41–43], only one study previously reported a significant 
non-specific adsorption to ultrafiltration membranes and the authors introduced a correction 
factor for this [41]. Because of the lowest sample loss, we decided to retain Centrifree filters 
only and to filter calibration standards as well. We were the first to describe the good agreement 
in %PB of teicoplanin in spiked plasma between equilibrium dialysis and ultrafiltration at the 
used settings. Also here, the %PB assessed at 37 °C was compared to room temperature and we 
decided to use the 37 °C setting, as in Roberts et al. [43]. The apparent higher %PB of 
teicoplanin (around 97 %) reported in Dykhuizen et al. [41] might be caused by the UF 




temperature of 4 °C. This temperature was not compared in the thesis, but in analogy to PBUTs 
and other protein-bound drugs, this low temperature may result in a higher %PB. In patient 
samples, a mean %PB of 87.7 % was demonstrated (range: 79.6 – 95.4 %) when assessed at 
37 °C. This large inter-patient variability was previously reported by others as well [42,43]. 
Therefore, target attainment by monitoring the free (i.e. biologically active) concentration might 
be more suitable as compared to estimating free concentrations using a mean fraction of 
e.g. 10 %.  
It should be noted that our developed and validated UHPLC-HRMS method is not the only one 
to quantify both total and free teicoplanin concentrations [41–43], but our approach is different 
from others by (i) the small plasma volume required for total and free teicoplanin quantification 
(i.e. 200 µL versus 700 µL in [43] and > 1 mL in [41]), (ii) the short analysis run time 
(i.e. 4.5 min versus 17 min in [43]), and (iii) the high specificity which was achieved by the 
high mass resolution of 70 000. Method comparison between the QMS® teicoplanin assay, 
which is used in routine laboratories for the quantification of total teicoplanin only, and our 
UHPLC-HRMS method revealed a moderate agreement with a correlation coefficient r = 0.82, 
which is in line with the correlation found for total teicoplanin by Mueller et al. [44]. The 
developed UHPLC-HRMS method can be useful in future therapeutic drug monitoring of 
teicoplanin, especially when the free concentration needs to be known. In this thesis, the newly 
developed method was used to compare the %PB of teicoplanin in a plasma pool of healthy 
subjects versus HD patients and to evaluate the potential competition with PBUTs (Chapter 6). 
In Chapter 4, we reported the %PB of PBUTs in patients at different stages of CKD (i.e. stages 
2 to 5) as well as in HD patients during a dialysis session in which the %PB was determined in 
samples taken at different time points. We attributed the observed decrease in %PB when 
normalized to the total concentration with decreasing creatinine clearance to protein binding 
competition amongst the different PBUTs; by the saturation of plasma proteins with PBUTs or 
protein-bound drugs; or by structural changes of albumin, caused by post-translational 
modifications. During an HD session, we observed an increase in %PB of PBUTs at the end of 
the session as well as after one passage through the hemodialyzer. A possible explanation for 
this could be the slow re-equilibration of the free fraction in the plasma and/or the slow input 
from the extra-plasmatic compartment [45], resulting in a continuously disturbed equilibrium 





These in vivo observations were difficult to explain and only hypotheses could be made because 
of the limited information on the kinetics of PBUTs available in literature. Therefore, 
subsequent studies in this thesis were performed to better understand the kinetics of PBUTs in 
CKD. 
In Chapter 5, the lower binding capacity of albumin in HD patients was demonstrated by 
deriving a binding curve for each of the studied PBUTs in a serum pool from healthy subjects 
as well as in a serum pool from HD patients (cleared and untreated). No difference in binding 
capacity of albumin was found between the serum pool of HD patients which was cleared from 
possible binding competitors as compared to untreated serum, except for HA. This was a first 
indication that competition for protein binding might be of minor importance for the studied 
PBUTs and was confirmed in the binding competition experiments where competition was only 
relevant at high uremic concentrations. The binding curves also demonstrated that albumin is 
not saturated with the studied PBUTs, even not at high uremic concentrations. Therefore, we 
proposed that the difference in protein binding between healthy and HD serum could at least in 
part be attributed to post-translational modifications of albumin, resulting in conformational 
changes and subsequent alterations in binding capacity. So far, only one paper demonstrated 
the direct impact of such a post-translational modification (i.e. guanidinylation) on the binding 
capacity of albumin for IS and tryptophan [46]. Thus, this field should be further explored in 
order to improve the knowledge of the impact of post-translational modifications on the binding 
capacity of albumin, as for example in the field of protein-bound drugs.   
In the second part of Chapter 5, the %PB of two commonly used antibiotics in HD patients, 
i.e. vancomycin (%PB ~ 55 %) and teicoplanin (%PB ~ 95 %), was compared in a plasma pool 
from healthy subjects and in a plasma pool from HD patients. No difference in %PB of neither 
vancomycin nor teicoplanin was found between both pools, which may imply that at clinically 
relevant concentrations the albumin binding sites are not saturated in HD plasma.  
For vancomycin, an in vitro %PB of around 60% was observed when both pools were spiked 
with a high concentration and this value was higher than previously reported in vivo [40,47,48]. 
It should be noted that the variability in reported %PB values for vancomycin is large within 
the same patient population but also between different patient populations [40,47,48]. In 
addition, differences in sample handling to obtain free vancomycin can also affect the observed 
%PB [39,40]. Because our aim was only to compare the %PB in plasma of healthy subjects and 




HD patients, we did not take into account the potential inter-patient variability and used only 
two distinct plasma pools. 
While no comparable studies were performed for teicoplanin, two independent studies were 
conducted for vancomycin [49,50]. In one of these studies, the %PB of vancomycin was 
compared between patients with normal renal function and patients with different renal 
functions [49], while for the other study, patients with end-stage kidney disease [50] were 
included. Both studies reported a lower mean %PB of vancomycin as compared to our study, 
i.e. 30 % and 18.5 % in [49] and [50], respectively. This discrepancy in %PB may potentially 
be explained by a difference between in vivo and in vitro experiments and/or by the large 
inter-patient variability [40,47,48]. Although a decreased %PB of vancomycin in patients with 
end-stage kidney disease as compared to patients with normal renal function was reported by 
Tan et al., we could not confirm this in our in vitro experiment. However, our findings are more 
in line with other basic drug compounds which were previously studied in patients with renal 
failure. For these drugs, the %PB was found to be either increased (e.g. clonidine and 
propranolol [28]) or unchanged (e.g. penbutolol [51] and gentamicin [52]). 
For teicoplanin, we observed no protein binding competition with PBUTs, while for 
vancomycin a small increase in %PB was registered. Changes in %PB of PBUTs might be of 
limited biological relevance so that it can be postulated that protein binding competition is 
absent. Possibly, these results may imply that vancomycin and teicoplanin bind to different 
binding sites on albumin than PBUTs and/or the number of binding sites on albumin are not 
saturated in the studied clinically relevant concentration ranges. 
To address the possibility of extra-plasmatic distribution of PBUTs, we demonstrated in 
Chapter 6 their presence in erythrocytes from HD patients and derived parameters describing 
the transport across the erythrocyte membrane. This was performed in vitro in a series of 
loading and unloading experiments of erythrocytes (in absence of plasma proteins) from healthy 
subjects and HD patients, respectively. For each PBUT, the intracellular partition was 
determined and was found to be higher than 1, which implies a higher concentration in the 
erythrocytes as compared to the plasma. This resulted in an apparent equilibrium and might be 
explained by the interaction of these toxins with membrane structures and/or cytoplasmic 
proteins. However, when we studied the possible binding of these PBUTs to hemoglobin in a 
small in vitro experiment, the PBUT-hemoglobin interaction seemed negligible. For each 





different PBUTs, however, the rate of transport across the erythrocyte membrane increased 
according to the sequence HA < IS < pCS < IAA.  
We also studied the impact of an inhibitor (i.e. 4,4’-diisothiocyanato-2,2’-stilbenedisulfonic 
acid,  DIDS) for anionic transport. This compound is known to bind reversibly to Band 3 
proteins, the anion exchangers located on erythrocyte membranes [53–56]. For HA, IS and pCS, 
inhibiting Band 3 proteins resulted in a decrease  in transport across the erythrocyte membrane, 
but did not stop it. For this reason, the transport of HA, IS and pCS may, at least partly, be 
attributed to the Band 3 protein and a second transport mechanism. From our experiments, 
however, we were not able to elucidate the exact transport mechanism for IAA nor for HA, IS 
and pCS, besides Band 3 transport. 
Figure 7-2 Answers to the research questions about the different processes impacting protein binding and 
kinetics of PBUTs. 
 
HA: hippuric acid; IAA: indole-3-acetic acid; IS: indoxyl sulfate; pCS: p-cresyl sulfate;  
CKD: chronic kidney disease; drug: vancomycin and teicoplanin. 
7.2 Conclusion 
In conclusion (Figure 7-2), to determine the %PB of PBUTs, a first step is to separate the free 
and bound fraction by either equilibrium dialysis or ultrafiltration and it is recommended to 
perform this at 37 °C. The free fraction, and thus the calculation of %PB, is independent (when 
measured by UHPLC-UV/FLD) of the sample matrix (i.e. serum or plasma), not influenced by 
a single freeze/thaw step, and is constant for a pH in the range 7.4 to 8.0. As compared to 
healthy subjects, %PB in uremia is lower for PBUTs (in vivo and in vitro) but unchanged for 






























bound PBUTs is influenced by the presence of other highly bound PBUTs at high uremic 
concentrations, and not by the presence of lower bound PBUTs and/or vancomycin and 
teicoplanin, at least not in vitro. Hence, since competition cannot fully explain differences in 
%PB in uremic and healthy blood and since albumin binding sites are not saturated in uremic 
blood, it seems more obvious to attribute this difference in %PB to post-translational 
modifications of albumin. Finally, PBUT removal during dialysis seems also hampered by the 
uneven partition of PBUTs in the erythrocytes as well as by the different but still incompletely 







7.3 Relevance of the work and future perspectives 
Because of their protein binding, the removal of protein-bound uremic toxins (PBUTs) during 
hemodialysis (HD) is much lower as compared to small water-soluble solutes, especially for 
those with a high percentage protein binding (%PB). Since many of the PBUTs have been 
associated with, amongst others, inflammation and cardiovascular disease, it is of great interest 
to improve their removal during HD. To achieve this, the full picture of PBUT kinetics in the 
patient and the extracorporeal circuit needs to be understood. 
To address this, the kinetics of PBUTs and two frequently administered protein-bound 
antibiotics were explored either in vivo and/or in different in vitro settings. 
First, analytical techniques to determine the total and free concentrations of PBUTs as well as 
of the antibiotic teicoplanin were either optimized or developed, respectively. The pre-
analytical step, i.e. the sample preparation, for total and free PBUT determination was further 
fine-tuned because of either inconsistencies or a lack of information in literature. The role of 
this sample preparation may not be underestimated because this may result in an under- or 
overestimation of the true in vivo values %PB. Because of the interest to measure free, i.e. 
biologically active and thus therapeutically relevant, concentrations of teicoplanin, and the large 
inter-patient (and even intra-patient) variability in the free fraction, no general rule-of-thumb 
can be introduced to estimate the free teicoplanin concentration. For this reason, a novel 
ultra-high performance liquid chromatography method with high resolution mass spectrometry 
was developed and validated. A drawback of our new method is, however, that individual 
measurements of total concentrations deviated up to 50 % between our method and the QMS 
teicoplanin method, which is used for routine analyses. This is clinically not acceptable, and 
further research would be recommended to unravel this discrepancy. In addition, it could be 
interesting to investigate the origin of the interfering compound for teicoplanin A2-4 & A2-5. 
Second, we demonstrated that the findings of our in vivo study, in which the %PB of PBUTs 
decreased with decreasing renal function, were not attributed to protein binding competition 
amongst different PBUTs, nor by protein binding competition with two antibiotics (i.e. 
vancomycin and teicoplanin), at least not in vitro. In addition, this decrease in %PB could not 
be attributed to the saturation of albumin either. These novel insights in the binding 
characteristics of PBUTs may implicate that the difference in %PB of PBUTs (and probably 
for some drug compounds as well) in uremic and healthy blood is more likely to be caused by 




post-translational modifications of albumin. With this new information, it became clear that 
albumin has a high binding capacity, which is decreased in HD patients, but at uremic levels, 
albumin is still capable to bind many ligands. Future studies can be performed to further unravel 
the magnitude and effect of post-translational modifications on the %PB of PBUTs and of 
different drug molecules. 
Since the two antibiotics vancomycin and teicoplanin are mainly excreted by the kidneys and 
most patients on HD have no or only a small residual renal function, their elimination in HD 
patients is largely dependent on the clearance of the dialyzer. In addition, it is often 
hypothesized that the free fraction of drugs is changed in uremia as compared to healthy blood, 
as a result of binding competition with PBUTs and/or of albumin saturation, but without (much) 
data supporting this. The dosage regimen of vancomycin and teicoplanin, as well as of other 
antibiotics, in HD patients is often estimated based on the residual renal function, but not on 
the possible higher or lower free fraction, while it is the free concentrations that is responsible 
for the therapeutic action. When the free fraction, and thus %PB, is changed in uremia as 
compared to patients with normal renal function and the dosage is not adapted to this change, 
this could result in under- or overdoses and thus a higher risk for resistance against the antibiotic 
or a higher risk for toxicity, respectively. Therefore, we compared the %PB of vancomycin and 
teicoplanin between healthy and uremic blood, in an in vitro setting and found no difference, 
neither relevant competition with PBUTs. In a next step, the %PB of these (and other) 
antibiotics should be compared in vivo to incorporate intra- and inter-patient variability and to 
see if our in vitro findings can be translated to in vivo data. Furthermore, including more 
protein-bound drugs could potentially help to interpolate for other drugs from the same 
category. Ultimately, the improved knowledge on the kinetics of antibiotics in HD patients 
could help to fine tune dosing recommendations. 
Third, as already mentioned in the general discussion, several studies have previously been 
performed aiming to improve the clearance of PBUTs during hemodialysis, but only focused 
on the removal from the serum/plasma compartment by e.g. increasing the free fraction or by 
combining dialysis with adsorption, ignoring their possible extra-plasmatic distribution. In this 
thesis, we demonstrated the presence of PBUTs in an easily accessible compartment, i.e. the 
erythrocytes. Their transport across erythrocyte membranes was studied and kinetic parameters 
were derived to further fine tune kinetic modeling of these PBUTs during dialysis. For this 
purpose, diffusion-adjusted regional blood flow models offer a higher physiologic relevance as 





systems with a low (e.g. muscle and skin) and a high (e.g. liver and kidney) blood flow and take 
into account the transport across intra- and extracellular compartments. Future experiments, 
e.g. adding albumin to test samples, adding DIDS when loading erythrocytes from HD patients 
etc. should be conducted to describe the transport of PBUTs in more physiologically relevant 
conditions. Eventually, this may help to further improve the removal of PBUTs in patients 
treated with HD, possibly by adapting removal strategies, and finally to result in a better patient 
outcome and survival.   
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Background. As a result of decreased renal function, numerous solutes are accumulated in 
patients with chronic kidney disease (CKD). Many of these uremic retention solutes exert 
toxicity and have been classified into three groups, including small water soluble solutes, 
middle molecules and protein-bound uremic toxins (PBUTs). The percentage of solute bound 
to plasma proteins (percentage protein binding, %PB) varies amongst the different PBUTs and 
comprises the full range from almost 0 up to 100%. Because of this protein binding, removal 
efficiency of PBUTs during hemodialysis (HD) is much lower as compared to small 
water-soluble solutes, especially for those with a high %PB. Since many of the PBUTs have an 
impact on the cardiovascular system and contribute to the increased propensity for 
cardiovascular events and mortality in patients with CKD, it is of great interest to improve their 
removal during HD. For this, we need to understand the full picture of PBUT kinetics in the 
patient and the extracorporeal circuit.   
Aims. The kinetics of PBUTs and protein-bound antibiotics were explored either in vivo and/or 
in different in vitro settings after development and/or optimization of analytical techniques. 
Methods. Studied protein-bound solutes included (i) the uremic toxins p-cresyl glucuronide 
(pCG; only in the in vivo study), hippuric acid (HA), indole-3-acetic acid (IAA), indoxyl sulfate 
(IS) and p-cresyl sulfate (pCS), as ranked here for increasing %PB, and (ii) the frequently 
administered antibiotics vancomycin and teicoplanin. 
The in house developed method for PBUT quantification was fine-tuned by checking the effect 
of sample temperature (i.e. 37 °C, room temperature and 4 °C), pH, matrix (i.e. serum and 
plasma) and a single freeze/thaw cycle on the %PB using blood samples from 10 HD patients. 
For the quantification of the antibiotic teicoplanin, a novel ultra-high performance liquid 
chromatography – high resolution mass spectrometry (UHPLC-HRMS) assay was developed 
and validated. 
In an in vivo study, PBUT %PB data were collected in 95 patients with different stages of CKD 
and in 10 patients on HD. In these HD patients, kinetics with %PB changes were evaluated by 
blood sampling at different time points during an HD session from the arterial as well as venous 






To better explain the in vivo results, binding characteristics of PBUTs and binding competition 
amongst them were explored in vitro. This was performed in a serum pool from healthy subjects 
as well as from HD patients (cleared and untreated) to include the possible impact of changes 
in albumin. In addition, %PB of the antibiotics was compared in vitro in a plasma pool from 
healthy subjects as well as from HD patients, and the possible binding competition with PBUTs 
was checked.  
Finally, to better understand PBUT kinetics, their distribution in a direct accessible 
extra-plasmatic compartment, i.e. the erythrocytes, was assessed in blood from 6 HD patients 
and transport parameters were derived by loading erythrocytes of 8 healthy subjects with a 
mixture of PBUTs and by unloading erythrocytes of 8 HD patients. 
Results. PBUT %PB was not influenced by the choice of matrix, sample pH and a single 
freeze/thaw cycle, while it increased with decreasing temperatures, such that the assessment of 
%PB should preferably be performed at 37 °C to mimic clinical conditions.  
The novel highly sensitive UHPLC-HRMS method allowed accurate and precise quantification 
of free and total teicoplanin, and thus the %PB, in a total analysis run time of 4.5 min and 
required only 200 µL of plasma volume.  
In CKD patients, the in vivo study revealed a decrease in PBUT %PB with creatinine clearance, 
when normalized to total PBUT concentration. During an HD session, %PB was increased at 
the dialysis end for the stronger (IAA) and the highly-bound (IS and pCS) PBUTs. In addition, 
%PB of these stronger and highly-bound PBUTs was found to increase when blood is passing 
through the hemodialyzer at 120 min after dialysis start.  
We found that albumin has a higher binding capacity for PBUTs in healthy serum as compared 
to blank and non-treated HD serum. It was also observed that the number of bound PBUTs per 
albumin molecule increases linearly with free PBUT concentration even beyond high uremic 
levels. Binding competition was found between the two highly-bound PBUTs IS and pCS at 
high uremic concentrations. For the studied antibiotics, %PB was not different in healthy and 
uremic plasma as measured in vitro, and no biologically relevant changes in the %PB of PBUTs 
were observed in the presence of antibiotics. 
PBUTs were found being distributed in erythrocytes, with an uneven partition between the 





erythrocyte membrane was comparable for each PBUT, but increased according to the trend 
HA < IS < pCS < IAA. 
Conclusion. The %PB of PBUTs should be determined at 37 °C, is independent of the sample 
matrix, not influenced by a single freeze/thaw step, and is constant for a pH in the range 7.4 to 
8.0. As compared to healthy subjects, %PB in uremia is lower for PBUTs (in vivo and in vitro) 
but unchanged for the studied antibiotics vancomycin and teicoplanin (in vitro). Neither binding 
competition, nor albumin saturation can completely explain differences in %PB in uremic and 
healthy blood. It is more obvious to attribute this difference in %PB at least in part to 
post-translational modifications of albumin. Finally, PBUT removal during dialysis seems also 
hampered by the uneven partition of PBUTs in the erythrocytes as well as by the different but 
still incompletely elucidated transport through the cell membrane according to the trend 













Achtergrond. Patiënten met chronisch nierlijden stapelen een groot aantal componenten op in 
hun lichaam ten gevolge van de verlaagde nierfunctie. Veel van deze opgestapelde 
componenten, ook wel uremische retentiestoffen genoemd, hebben een toxisch effect en 
worden dan verdeeld in drie groepen, zijnde de kleine water oplosbare componenten, de 
middelgrote moleculen en de eiwitgebonden uremische toxines (protein-bound uremic toxins, 
PBUTs). Het percentage van een bepaalde uremische toxine dat aan plasma eiwitten gebonden 
is (percentage proteïne binding, %PB) is verschillend tussen de PBUTs en kan variëren van 
bijna 0 tot 100 %. Vanwege hun eiwitbinding worden PBUTs tijdens hemodialyse minder 
efficiënt verwijderd dan kleine water oplosbare componenten, voornamelijk als hun %PB hoog 
is. Veel van de PBUTs hebben een invloed op het cardiovasculair systeem en verhogen dus de 
kans op cardiovasculaire aandoeningen en mortaliteit in patiënten met chronisch nierlijden. Het 
is dus van groot belang om de verwijdering van deze PBUTs tijdens hemodialyse (HD) te 
verbeteren. Hiervoor moeten we echter de volledige kinetiek van de PBUTs begrijpen zowel in 
de patiënt zelf als in het extracorporale circuit. 
Doel. De kinetiek van eiwitgebonden uremische toxines en eiwitgebonden antibiotica werd 
bestudeerd in vivo en/of in verschillende in vitro opstellingen na het ontwikkelen en/of 
optimaliseren van analytische technieken. 
Methodes. Volgende eiwitgebonden componenten werden bestudeerd: (i) de PBUTs p-cresyl 
glucuronide (pCG; enkel in de in vivo studie), hippuurzuur (HA), indool-3-azijnzuur (IAA), 
indoxyl sulfaat (IS) en p-cresyl sulfaat (pCS), dewelke hier gerangschikt staan volgens een 
toenemende %PB en (ii) de regelmatig toegediende antibiotica vancomycine en teicoplanine. 
De in huis ontwikkelde analyse methode voor de bepaling van PBUTs werd verfijnd door het 
effect van staaltemperatuur (d.i. 37 °C, kamertemperatuur en 4 °C), pH, matrix (d.i. serum of 
plasma) en één vries/dooi cyclus op het %PB na te gaan, door gebruik te maken van bloedstalen 
van 10 HD patiënten. Voor de bepaling van het antibioticum teicoplanine werd er een nieuwe 
ultra-hoge performante vloeistofchromatografie – hoge resolutie massaspectrometrie 
(UHPLC-HRMS) methode ontwikkeld en gevalideerd. 
Het %PB van PBUTs werd berekend in een in vivo studie bij 95 patiënten met verschillende 





in %PB van PBUTs werd geëvalueerd in HD patiënten door bloedstalen te verzamelen van de 
arteriële en veneuze bloedlijnen op verschillende tijdspunten tijdens een dialysesessie. 
Om de resultaten van de in vivo studie beter te kunnen begrijpen werden de 
bindingskarakteristieken en de onderlinge bindingscompetitie van PBUTs verkend. Dit werd 
nagegaan in vitro in een serummengsel van gezonde vrijwilligers enerzijds en van HD patiënten 
(blanco en onbehandeld) anderzijds om mogelijke verschillen in albumine in rekening te 
brengen. Ook het %PB van twee antibiotica, vancomycine en teicoplanine, werd vergeleken 
in vitro in een plasmamengsel van gezonde vrijwilligers enerzijds en van HD patiënten 
anderzijds en de mogelijke bindingscompetitie met PBUTs werd bekeken.  
Verder werd ook de verdeling van PBUTs bestudeerd in een eenvoudig toegankelijk 
extra-plasmatisch compartiment, d.i. de erythrocyten, in bloed van 6 HD patiënten. Transport 
parameters werden afgeleid via het laden van erythrocyten van 8 gezonde vrijwilligers met een 
mengsel van de toxines, alsook via het ontladen van erythrocyten van 8 HD patiënten. 
Resultaten. Het %PB van PBUTs was onafhankelijk van de matrix, de pH van het staal en één 
vries/dooi cyclus, terwijl het wel steeg bij afnemende temperaturen. Hierdoor is het aangeraden 
het %PB te bepalen bij 37 °C om de klinische condities na te bootsen. 
De nieuwe UHPLC-HRMS methode maakte het mogelijk om totaal en vrij teicoplanine, en dus 
het %PB, te kwantificeren op een zeer gevoelige, accurate en precieze manier, in een totale 
analysetijd van 4.5 min en het benodigd plasma volume bedroeg slechts 200 µL. 
De in vivo studie toonde aan dat het %PB van eiwitgebonden uremische toxines, genormaliseerd 
voor de totale concentratie, daalde met afnemende renale functie in patiënten met chronisch 
nierlijden. Tijdens een dialysesessie steeg het %PB naar het einde toe voor de hoger gebonden 
(IAA) en de nog hoger gebonden (IS en pCS) toxines. Bovendien was het %PB van IAA, IS en 
pCS toegenomen als bloed doorheen de kunstnier stroomde, op 120 min na de start van de 
dialyse. 
Het bleek dat albumine een hogere bindingscapaciteit heeft voor eiwitgebonden uremische 
toxines in gezond serum dan in HD serum (blanco en onbehandeld). Daarnaast steeg het 
absolute aantal toxines die gebonden is per albumine molecule lineair met de vrije toxine 
concentratie, tot voorbij hoge uremische concentraties. Bindingscompetitie tussen de 
verschillende PBUTs werd enkel vastgesteld bij hoge uremische concentraties van de hoog 





significant verschil in %PB waargenomen tussen gezond en uremisch plasma, net zoals er geen 
biologisch relevante verandering in %PB van PBUTs in de aanwezigheid van de antibiotica 
werd vastgesteld. 
Als laatste werd er gevonden dat PBUTs zich in erythrocyten verdelen, maar ook dat er een 
oneven verdeling is tussen het intra- en extracellulair compartiment. De influx en efflux 
snelheid voor transport doorheen de erythrocyt membraan was vergelijkbaar per PBUT, maar 
nam toe volgens de trend HA < IS < pCS < IAA. 
Conclusie. De %PB van PBUTs wordt best bepaald op 37 °C, is onafhankelijk van de matrix, 
niet beïnvloed door één vries/dooi cyclus en is constant in een pH gebied van 7.4 tot 8.0. De 
%PB in uremie is lager voor de PBUTs (in vivo en in vitro) in vergelijking met gezonde 
personen, maar lijkt ongewijzigd voor de bestudeerde antibiotica vancomycine en teicoplanine 
(in vitro). Noch bindingscompetitie, noch albumine verzadiging kunnen de verschillen in %PB 
tussen uremisch en gezond blood volledig verklaren. Het is meer aannemelijk dat dit verschil 
in %PB, of toch gedeeltelijk, toegeschreven wordt aan posttranslationele modificaties van 
albumine. Als laatste kan gesteld worden dat de moeilijke verwijdering van PBUTs tijdens 
dialyse deels beïnvloed wordt door hun verdeling in extra-plasmatische compartimenten zoals 
de erythrocyten en daarbij hun verschillend, maar nog steeds onvolledig uitgeklaarde, transport 
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